DIAGNOSIS OF MYCOPLASMA MASTITIS: VALIDATION AND DEVELOPMENT
By
SUKOLRAT BOONYAYATRA
A dissertation submitted in partial fulfillment of the requirements for the degree of
DOCTOR OF PHILOSOPHY
WASHINGTON STATE UNIVERSITY College of Veterinary Medicine
DECEMBER 2010
To the Faculty of Washington State University:
The members of the Committee appointed to examine the dissertation of
SUKOLRAT BOONYAYATRA find it satisfactory and recommend that it be accepted.
______Lawrence K. Fox, Ph.D., Chair
______Thomas E. Besser, Ph.D.
______Ashish Sawant, Ph.D.
______John M. Gay, Ph.D.
ii
ACKNOWLEDGMENTS
I would like to thank Dr. Larry Fox, committee chair, for his guidance, support and encouragement of working with mycoplasma mastitis. Additionally, I am very grateful for his acceptance when I transferred from Tennessee. I thank my other committee members, Dr. John
Gay, Dr. Ashish Sawant, and Dr. Tom Besser for their guidance and suggestions on the various aspects and helping me solve many problems with my work.
This thesis dissertation would not have been possible without many people who provided technical assistance in the laboratory. I am very thankful to Dorothy Newkirk for her expert assistance. I also thank to other FDIU staffs for their suggestion and helping me go through all lab work smoothly. I want to thank Dr. Ziv Raviv and Dr. Amy Wetzel for their kindness of teaching me everything about real-time PCR when I was in the Ohio State University.
I am grateful to Dr. Stephen Oliver, other professers and staffs in the University of
Tennessee in Knoxville for providing me a wonderful time in my life when I was in this volunteer state. I want to sincerely thank to the Royal Thai government for the scholarship which allowed me to have this great experience in the United States.
I thank my husband, Veerasak Punyapornwithaya, for helping me solve many problems and being such a good husband and friend. I want to thank my daughter, Minnie, for being my biggest motivation of finishing the research. I am deeply grateful to my parents and sisters for their encouragement and understanding for everything I have done.
Finally, I would like to thank all people who contributed to the successful of all the work in this thesis dissertation.
iii
DIAGNOSIS OF MYCOPLASMA MASTITIS: VALIDATION AND DEVELOPMENT
Abstract
by Sukolrat Boonyayatra, Ph.D.
Washington State University
December 2010
Chair: Lawrence K. Fox
Microbiological culture of milk samples has been used as a standard diagnosis for
mycoplasma mastitis. It is suggested to perform with fresh samples for optimum diagnosis.
Submission of fresh samples is often difficult given the logistics of collection and shipping of
milk samples from farm to laboratory. Therefore , milk samples are usually chilled or frozen
before culture. A study of the effects of storage methods on the recovery of Mycoplasma species
from milk samples was performed. The results indicated that holding milk at refrigerated
temperatures (5°C) for 5 days and freezing milk samples (-20°C) lowers the number of recovered
Mycoplasma species . Moreover the addition of glycerol prior freezing to achieve 10% and 30%
(v/v) solutions was found to improve the recovery of Mycoplasma species from frozen milk samples.
Even though a Mycoplasma -like-colony is observed by a standard culture method, the diagnosis can be misinterpreted as Acholeplasma species which is indistinguishable by culture.
To validate and suggest techniques used to discriminate between these two genera, a study on the discrimination between Mycoplasma and Acholeplasma using digitonin and nisin disc diffusion assays, and PCR was performed. Findings revealed a high and comparable efficiency of using
iv
nisin and digitonin disc diffusion assays and PCR to distinguish Mycoplasma and Acholeplasma species.
Given the fastidious nature of Mycoplasma species, and the time-consuming nature of the standard culture method, a diagnostic test of mycoplasma mastitis that is more sensitive, less time consuming, and can speciate mycoplasma mastitis pathogens would be valuable. The development of real-time PCR assays to detect 3 major mycoplasma mastitis pathogens: M. bovis, M. californicum and M. bovigenitalium was investigated to provide an alternative diagnostic tool for mycoplasma mastitis. The results given by the novel real-time PCR assays showed a perfect agreement with the gold standard, and the results were obtained within 4-5 hours.
The overall goal of studies reported herein was to investigate improvements in the efficiency of the diagnosis of mycoplasma mastitis in dairy cows. Findings indicate that both phenotypic and genotypic diagnostic techniques can be applied, and in conjunction with current standard techniques, will better identify cows with mycoplasma mastitis.
v
TABLE OF CONTENTS
Page
ACKNOWLEDGMENT...... iii
ABSTRACT ...... iv
LIST OF TABLES ...... ix
LIST OF FIGURES ...... x
CHAPTER 1
1.1. INTRODUCTION ...... 1
1.2. REFERENCES ...... 4
CHAPTER 2 (LITERATURE REVIEW)
2.1. MYCOPLASMA SPECIES ...... 7
2.2. MYCOPLASMA MASTITIS IN DAIRY CATTLE ...... 8
2.3. EFFECT OF STORAGE METHODS ON SURVIVAL OF MYCOPLASMA 10
2.4. DISCRIMINATION BETWEEN MYCOPLASMA AND ACHOLEPLASMA 12
2.5. DIGITONIN ...... 13
2.6. NISIN ...... 14
2.7. NESTED PCR TECHNIQUE ...... 16
2.8. SPECIATION OF MYCOPLASMA SPECIES ...... 17
2.9. REAL-TIME PCR ...... 19
2.10. CONCLUSION AND HYPOTHESIS ...... 23
vi
CHAPTER 3
3.1. INTRODUCTION ...... 44
3.2. MATERIALS AND METHODS ...... 46
3.3. RESULTS ...... 47
3.4. DISCUSSION ...... 48
3.5. ACKNOWLEDGMENT...... 51
3.6. REFERENCES ...... 52
CHAPTER 4
4.1. INTRODUCTION ...... 56
4.2. MATERIALS AND METHODS ...... 58
4.3. RESULTS ...... 62
4.4. DISCUSSION ...... 65
4.5. ACKNOWLEDGMENT...... 68
4.6. REFERENCES ...... 68
CHAPTER 5
5.1. INTRODUCTION ...... 80
5.2. MATERIALS AND METHODS ...... 81
5.3. RESULTS ...... 87
5.4. DISCUSSION ...... 89
5.5. ACKNOWLEDGMENT...... 92
5.6. REFERENCES ...... 93
CHAPTER 6
CONCLUSIONS...... 106
vii
APPENDIX
A. RAW DATA
A.1: Chapter 3 (Refrigeration experiment) ...... 108
A.2: Chapter3 (Freezing experiment) ...... 118
A.3: Chapter 4 and 5 ...... 131
B. METHODS
B.1: Cloning and filtration techniques for Mycoplasmas ...... 143
B.2: DNA extraction and purification using Purelink Genomic DNA kit 144
B.3: PCR to amplify 16S-23S rRNA intergenic spacer region of Mycoplasma species
and Acholeplasma species ...... 146
B.4: Restricted fragment length polymorphism (RFLP) ...... 147
B.5: PCR to amplify 16S rRNA genes using universal primers ...... 147
B.6: Gel electrophoresis ...... 148
B.7: Real-time PCR using Quantitect Probe PCR reaction kit for Applied
Biosystem StepOne Plus real-time PCR machine...... 149
B.8: Digitonin disc diffusion assay ...... 150
B.9: Nisin disc diffusion assay ...... 151
C. COPY RIGHT RELEASES ...... 152
viii
LIST OF TABLES
CHAPTER 2
1. Taxonomy of the class of Mollicutes ...... 38
CHAPTER 3
1. Mycoplasma counts from fresh and refrigerated milk samples ...... 54
2. Mycoplasma counts from fresh and frozen milk samples with various concentrations of glycerol addition ...... 55
CHAPTER 4
1. Sources of reference strains of Mycoplasma species and Acholeplasma species ...... 72
2. Sequences of primers and targeted regions ...... 73
3. Distribution of isolates of Mycoplasma species and Acholeplasma species as identified by 16S
rRNA partial sequencing...... 74
4. Descriptive statistics of zone of growth inhibition (mm) observed with the digitonin disc
diffusion assay ...... 75
5. Agreement of genera determination by digitonin disc diffusion assay with 16S rRNA partial
sequencing...... 76
CHAPTER 5
1. Mycoplasma species and other bacterial species tested for specificity of the novel real-time
PCR assays ...... 96
2. Sequences of primers and probes used in the study and their targeted regions ...... 98
ix
3. Distribution of isolates of Mycoplasma species and Acholeplasma species as identified by
16S rRNA partial sequencing ...... 99
4. Identification of Mycoplasma species and Acholeplasma species isolates using PCR-RFLP
and real-time PCR ...... 100
x
LIST OF FIGURES
CHAPTER 2
1. Chemical structure of digitonin ...... 39
2. Structure of nisin A ...... 40
3. General model of the ‘barrel stave’ mechanism of pore formation by peptides ...... 41
4. Models of pore formation by nisin...... 42
5. Step-wise reaction of real-time PCR using a fluorogenic probe...... 43
CHAPTER 4
1. Example plate of Mycoplasma species with a zone of inhibition only presented around
digitonin disc ...... 77
2. Example plate of Acholeplasma species with a zone of inhibition only presented around nisin
discs with both 103.2 µg (N0) and 10.32 µg (N-1) ...... 78
3. Electrophoretic gel of amplicons of some reference strains of Mycoplasma species and
Acholeplasma species ...... 79
CHAPTER 5
1. Electrophoretic gel of amplicons before digestion and after digestion by ASE1 ...... 101
2. Digested amplicons obtained from 6 M. bovigenitalium isolates ...... 102
3. Standard curve of M. bovis real-time PCR assay using pIDTSMART-AMP plasmids cloned
with the target sequence in fusA gene of M. bovis ...... 103
xi
4. Standard curve of M. bovigenitalium real-time PCR assay using pIDTSMART-AMP
plasmids cloned with the target sequence in 16S-23S intergenic spacer region of M.
bovigenitalium ...... 104
5. Standard curve of M. californicum real-time PCR assay using pIDTSMART-AMP plasmids
cloned with the target sequence in rpoB gene of M. californicum ...... 105
xii
Dedication
This dissertation is dedicated to my father, Surachart Boonyayatra, my mother, Urai
Kwinram and my sisters, Aree and Kanyarpak Boonyayatra, for their support since I came to the
United States. I would also like to dedicate this dissertation to my husband, Veerasak
Punyapornwithaya, and my lovely daughter, Ruangkhao (Minnie) Punyapornwithaya, for their encouragement and support as a family for the past three years in Pullman.
xiii
CHAPTER 1
INTRODUCTION
Mycoplasm a species are Mollicutes known to be able to cause clinical and subclinical mastitis in dairy cattle. Mastitis associated with Mycoplasma has been reported worldwide (Fox
et al., 2005). Numerous species of Mycoplasma have been reported to be associated with mastitis
in dairy cattle. Among all reported cases, Mycoplasma bovis, M. californicum, M. alkalescens,
M. bovigenitalium and M. canadense are the species most commonly associated with bovine
mastitis (Gonzalez and Wilson, 2003). Mycoplasma is considered a contagious pathogen, capable
of transmitting easily from cow-to-cow (Gonzalez and Wilson, 2003) and treatment is usually
unsuccessful (Bushnell, 1984). Therefore, control of mycoplasma mastitis may be best achieved through the identification and segregation or culling of infected cows, which are the infection reservoirs (Fox et al., 2005). Mycoplasma species are difficult to isolate which makes diagnosis of infection challenging. Because specialized media, Modified Hayflicks, and incubation for several days in 10% CO 2 are required (Hogan, 1999), many laboratories may not routinely culture milk for mycoplasma organisms. Additionally, cows with mycoplasma mastitis may shed the pathogen intermittently and shedding of Mycoplasma species into milk of infected cows may be as low as <100 colony forming unit (CFU)/ml, below the threshold of detection by standard culture methods (Biddle et al., 2003). These difficulties increase the importance of proper milk sample handling before culture in an effort to avoid false negative results. Most milk samples are either stored in a refrigerator with the temperature approximately 4 to 7 °C or kept frozen with the temperature approximately -18 to -20 °C before culturing in the laboratory. A study has shown that freezing milk cultures can be detrimental to the recovery of mycoplasma mastitis
1
pathogens (Biddle et al., 2004), resulting in false negative reporting of Mycoplasma species
positive milk samples. However, the effect of storing milk samples at refrigeration temperature
on survival of Mycoplasma species has never been reported. Moreover, application of a
cryopreservative such as glycerol may be able to improve the recovery of Mycoplasma species
from frozen milk samples. Therefore, effects of storing milk samples at a refrigeration
temperature (5 °C) and effects of adding glycerol to milk samples prior freezing (-20 °C) should
be determined.
Even with cultivable samples, identification of Mycoplasma species can still be confused
with other Mollicutes especially Acholeplasma species. Although Acholeplasma species can
cause mastitis (Pan and Ogata, 1969; Counter, 1978), prevalence of clinical mastitis with this
microbe is very rare and thus its appearance is generally regarded as a contaminant. The
digitonin disc diffusion technique is the standard method to discriminate Mycoplasma from
Acholeplasma when culture is used (Gardella et al., 1983). The principle of this technique is
based on the requirement of sterol for growth by Mycoplasma species. Digitonin can interact with cholesterol to increase membrane permeability and consequently kill Mycoplasma .
Acholeplasma species are less fastidious with respect to their sterol requirement and are more resistant to digitonin. Thus digitonin can be used to distinguish Acholeplasma species from
Mycoplasma species by measuring differences in resistance to the same concentration. In addition to the digitonin disc diffusion assay, utilization of an antimicrobial peptide, nisin can also be used to differentiate between Acholeplasma species from Mycoplasma species when culture techniques are applied. Nisin is an antimicrobial peptide produced by Lactococcus lactis .
Mycoplasma species and Acholeplasma species have different sensitivities to the peptide (Abu-
2
Amero et al., 1996). Nisin can inhibit growth of Acholeplasma species whereas no growth
inhibition is observed for Mycoplasma species.
Mycoplasma species and Acholeplasma species can be distinguished using genomic
analysis, specifically a duplex-nested polymerase chain reaction (PCR) method for detection has
been reported (Tang et al., 2000). Based on the presence of >1 operon of tRNA genes in the
targeted 16S-23S rRNA intergenic spacer region of A. laidlawii , they were able to discriminate
A. laidlawii from other Mycoplasma species. Even though all these 3 techniques; digitonin disc diffusion assay, nisin disc diffusion assay, and duplex-nested PCR, have been used to distinguish between cultures of these species, no study has been completed to demonstrate a side by side comparison to demonstrate assay differences in sensitivities and specificities of detection. A validation of techniques used to discriminate Mycoplasma species from other Mollicutes is
needed to avoid false positive results for mycoplasma mastitis.
To overcome problems with the standard culture techniques, such as length of culture
time and loss of viable organisms with storage, many PCR-based strategies have been developed
for mycoplasma mastitis diagnosis. Most of these studies have focused only on the identification
of M. bovis in milk samples (Ghadersohi et al., 1997; Hayman and Hirst, 2003; Hotzel et al.,
1999; Hotzel et al., 1996; Pinnow et al., 2001). A nested PCR followed by restricted fragment
length polymorphism (RFLP) (Tang et al., 2000) has been applied to speciate cultures of
Mycoplasma -like-colonies in our laboratory. Genus differentiation of Mycoplasma and
Acholeplasma species can be performed at the nested PCR steps. The nested PCR products are
digested using a restriction enzyme where species unique DNA fragment patterns can be used to
distinguish Mycoplasma species. Real-time PCR technology has recently been exploited in
clinical microbiology. It is a promising tool with an excellent sensitivity and specificity, very fast
3
and suitable for high throughput of samples with an inherent quantitative ability (Cai et al., 2005;
Espy et al., 2006; Koskinen et al., 2009; Taponen et al., 2009). Development of a real-time PCR technique to detect major mycoplasma mastitis causing pathogens directly from milk samples may be a superior choice for the diagnosis of this disease given its abilities to rapidly determine, quantify, and distinguish Mycoplasma species.
REFERENCES
Abu-Amero, K.K., Halablab, M.A., Miles, R.J., 1996, Nisin resistance distinguishes
Mycoplasma spp. from Acholeplasma spp. and provides a basis for selective growth
media. Appl Environ Microbiol 62, 3107-3111.
Biddle, M.K., Fox, L.K., Hancock, D.D., 2003, Patterns of mycoplasma shedding in the milk of
dairy cows with intramammary mycoplasma infection. J Am Vet Med Assoc 223, 1163-
1166.
Biddle, M.K., Fox, L.K., Hancock, D.D., Gaskins, C.T., Evans, M.A., 2004, Effects of storage
time and thawing methods on the recovery of Mycoplasma species in milk samples from
cows with intramammary infections. J Dairy Sci 87, 933-936.
Bushnell, R.B., 1984, Mycoplasma mastitis. Vet Clin North Am Large Anim Pract 6, 301-312.
Cai, H.Y., Bell-Rogers, P., Parker, L., Prescott, J.F., 2005, Development of a real-time PCR for
detection of Mycoplasma bovis in bovine milk and lung samples. J Vet Diagn Invest 17,
537-545.
Counter, D.E., 1978, A severe outbreak of bovine mastitis asssociated with Mycoplasma
bovigenitalium and Acholeplasma laidlawii . Vet Rec 103, 130-131.
4
Espy, M.J., Uhl, J.R., Sloan, L.M., Buckwalter, S.P., Jones, M.F., Vetter, E.A., Yao, J.D.,
Wengenack, N.L., Rosenblatt, J.E., Cockerill, F.R., 3rd, Smith, T.F., 2006, Real-time
PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol
Rev 19, 165-256.
Fox, L.K., Kirk, J.H., Britten, A., 2005, Mycoplasma mastitis: a review of transmission and
control. J Vet Med B Infect Dis Vet Public Health 52, 153-160.
Gardella, R.S., DelGiudice, R.A., Tully, J.G., 1983, Section F7 Immunofluorescence, In: Tully,
J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press, New York, pp.
431-440.
Ghadersohi, A., Coelen, R.J., Hirst, R.G., 1997, Development of a specific DNA probe and PCR
for the detection of Mycoplasma bovis . Vet Microbiol 56, 87-98.
Gonzalez, R.N., Wilson, D.J., 2003, Mycoplasmal mastitis in dairy herds. Vet Clin North Am
Food Anim Pract 19, 199-221.
Hayman, B., Hirst, R., 2003, Development of a semi-nested PCR for the improved detection of
Mycoplasma bovis from bovine milk and mucosal samples. Vet Microbiol 91, 91-100.
Hogan, J.S., Gonzalez, R.N., Harmon, R.J., Nickerson, S.C., Oliver, S.P. Pankey, J.W., Smith,
K.L., 1999, Laboratory handbook on bovine mastitis. National Mastitis Council, Inc,
Wisconsin, pp. 151-188.
Hotzel, H., Heller, M., Sachse, K., 1999, Enhancement of Mycoplasma bovis detection in milk
samples by antigen capture prior to PCR. Mol Cell Probes 13, 175-178.
Hotzel, H., Sachse, K., Pfutzner, H., 1996, Rapid detection of Mycoplasma bovis in milk samples
and nasal swabs using the polymerase chain reaction. J Appl Bacteriol 80, 505-510.
5
Koskinen, M.T., Holopainen, J., Pyorala, S., Bredbacka, P., Pitkala, A., Barkema, H.W., Bexiga,
R., Roberson, J., Solverod, L., Piccinini, R., Kelton, D., Lehmusto, H., Niskala, S.,
Salmikivi, L., 2009, Analytical specificity and sensitivity of a real-time polymerase chain
reaction assay for identification of bovine mastitis pathogens. J Dairy Sci 92, 952-959.
Pan, I.J., Ogata, M., 1969, New sero-types of Mycoplasma laidlawii isolated from mastitic milk
and urogenital tracts of cattle. II. Typing of M. laidlawii by biological and serological
methods. Nippon Juigaku Zasshi 31, 313-324.
Pinnow, C.C., Butler, J.A., Sachse, K., Hotzel, H., Timms, L.L., Rosenbusch, R.F., 2001,
Detection of Mycoplasma bovis in preservative-treated field milk samples. J Dairy Sci 84,
1640-1645.
Tang, J., Hu, M., Lee, S., Roblin, R., 2000, A polymerase chain reaction based method for
detecting Mycoplasma/Acholeplasma contaminants in cell culture. J Microbiol Methods
39, 121-126.
Taponen, S., Salmikivi, L., Simojoki, H., Koskinen, M.T., Pyorala, S., 2009, Real-time
polymerase chain reaction-based identification of bacteria in milk samples from bovine
clinical mastitis with no growth in conventional culturing. J Dairy Sci 92, 2610-2617.
BIBLIOGRAPHY OF PUBLISHED AND SUBMITTED MANUSCRIPTS
Boonyayatra, S., Fox, L.K., Besser, T.E., Sawant, A., Gay, J.M., 2010, Effects of storage
methods on the recovery of Mycoplasma species from milk samples. Vet Microbiol 144,
210-213.
6
CHAPTER 2
LITERATURE REVIEW
2.1. Mycoplasma species
Mycoplasmas are members of the class Mollicutes . Taxonomy of this class is outlined in
Table 1. Mycoplasmas are the smallest self-replicating organisms with the diameter as small as
300 nm. Mycoplasma was first isolated in 1898 as reported by Nocard and Roux (Nocard and
Roux, 1990). The first species to be isolated is M. mycoides subsp. mycoides causing disease in cattle herds at that time. The current number of recognized Mycoplasma species is 102 (Razin et al., 1998). Members of Mollicutes such as Mycoplasma species and Acholeplasma species, are distinguished phenotypically from other bacteria by their minute size (diameters ranging from
0.3 µm to 0.8 µm) and total lack of a cell wall. The genome size range of Mycoplasmas is 580-
1350 kb, about one-sixth that of Escherichia coli , with a low G+C content of 23-40%. They are parasites or commensal organisms of humans and animals. Most human-associated and animal- associated Mycoplasmas adhere to host cells. Only a few species are recognized to be able to internalize into host cells (Razin et al., 1998). Mycoplasma species commonly found to infect cattle include M. alkalescens, M. alvi, M. arginini, M. bovigenitalium, M. bovirhinis, M. bovis,
M. bovoculi, M. californicum, M. canadense, M. dispar, M. mycoides subsp. mycoides , and M. verecundam . Some of these species are highly pathogenic whereas others are either moderately pathogenic or apparently nonpathogenic. Phase variation is a common mechanism among
Mycoplasma species and is thought to be involved in microbial survival, leading to the emergence of varied intra-clonal populations that adapt quickly to new environments.
Mycoplasma bovis and M. mycoides subsp. mycoides are the two bovine mycoplasmas which
7
have been extensively studied for their pathogenicities (Rosengarten et al., 1994; Behrens et al.,
1994; Pilo et al., 2007). A major characterized virulence factor shared between these two species
and among other Mycoplasma species is the phase or antigenic variation which is mediated by
the characteristics of variable surface proteins, Vsp family proteins. Variability of these proteins
on Mycoplasmas helps them to avoid recognition by the host immune system, which may lead to development of chronic infections.
2.2. Mycoplasma mastitis in dairy cattle
Mycoplasma mastitis has been characterized as a contagious mastitis pathogen. However, the pattern of its outbreak generally associates with farms with low bulk tank milk somatic cell counts with frequent cases of clinical mastitis (Fox et al., 2005). The primary source of new mycoplasma mastitis outbreaks in dairy herds is suspected to be the introduction of replacement animals (Bushnell, 1984; Gonzalez and Wilson, 2003; Jasper, 1981). Therefore, large expanding herds with relatively high rates of importation of animals usually have higher risk for mycoplasma mastitis (Fox et al., 2003; Thomas et al., 1981). As a contagious pathogen,
Mycoplasma appears to be transmitted from cow-to-cow at milking time via fomites or through direct contact during other times (Fox et al., 2005). It is also suspected that Mycoplasma can be internally transferred from an extramammary organ to the mammary gland (Biddle et al., 2004;
Jain et al., 1969). Mycoplasmas can be isolated from mucous membranes of various body sites especially the respiratory and urogenital tracts of healthy animals; therefore, other than transmitting from udder to udder during milking time, the colonization by Mycoplasmas of the respiratory system may also be the reservoir for intramammary infection (Mackie et al., 2000).
Antibiotics targeting cell wall synthesis, such as beta lactam antibiotics, should not be used to
8
treat mycoplasma infections as this pathogen group lacks a cell wall. Bushnell (1984) suggested
that treatment is not very efficient and can prolong the mycoplasma mastitis outbreak within the
herd despite results of some studies where showed success in using aminoglycoside, macrolide,
and fluoroquinolone antibiotics for mycoplasma mastitis therapy was reported (Ball and
Campbell, 1989; Ayling et al., 2000). Thus, the often recommended strategy to control
mycoplasma mastitis is to identify infected animals and prevent exposure of those infected
animals to naive animals by segregation and/or culling.
In 1961, mycoplasma bovine mastitis was first reported in the United States in
Connecticut (Hale et al., 1962). The causative agent was later identified as M. bovis .
Mycoplasma bovis is the most common Mycoplasma to be associated with mastitis outbreaks in
dairy cows. Additionally, 11 other Mycoplasma species have also been reported to be associated with outbreaks including M. alkalescens, M. arginini, M. bovigenitalium, M. bovirhinis, M. californicum, M. canadense, M. dispar, Mycoplasma species group 7, Mycoplasma F-38,
Acholeplasma laidlawii , and A. axanthum (Gonzalez and Wilson, 2003). Among these species,
M. bovis, M. californicum, M. bovigenitalium, M. alkalescens and M. canadense are 5 major species causing mastitis in dairy herds.
Mycoplasma bovis is the most important mycoplasma mastitis agent. Other than
intramammary infection, it can also cause abortion, infertility, arthritis, keratoconjunctivitis,
otitis media, pneumonia, and subcutaneous abscesses in cattle (Bushnell, 1984; Fish et al., 1985;
Kinde et al., 1993; Rosendal and Martin, 1986; Walz et al., 1997). Mycoplasma californicum and
M. bovigenitalium are also frequently reported as causative agents for mycoplasma mastitis,
especially in California for the past 50 years (Jasper, 1982; Kirk et al., 1997). Mycoplasma
canadense has been also consistently reported and M. alkalescens has been reported many times
9
in California (Jasper, 1982). Clinical mastitis caused by M. bovigenitalium, M. californicum, M.
canadense and M. alkalescens appear to be less severe, and infected cows can recover sooner compared to cows with M. bovis infection (Jasper, 1982).
Acholeplasma laidlawii has been considered to be a nonpathogenic saprophytic contaminant when it is found in milk (Bushnell, 1984; Jasper, 1979). However, it is possible that this organism can be associated with mastitis outbreak (Pan and Ogata, 1969; Counter, 1978).
Therefore, distinguishing between ‘saprophytic’ and ‘parasitic’ Acholeplasma laidlawii should be performed when it is necessary to determine an outbreak of this microorganism.
2.3. Effect of storage methods on survival of Mycoplasma
For control and prevention purposes, monitoring of bulk tank milk cultures for
Mycoplasma species has been used for a screening test of presence of Mycoplasma in a herd.
Because Mycoplasma species are fastidious species, the sensitivity of mycoplasma mastitis detection from culturing milk directly onto an agar plate may be as low as 60% (Guterbock and
Blackmer, 1984). Milk samples are usually cultured for identification of infected animals.
Although culturing fresh milk samples has been suggested as a means of maximizing the detection of Mycoplasma species (Biddle et al., 2004), the submission of fresh milk samples is often not practical for many dairy operators because of their distance from diagnostic laboratories and the convenience of storing samples for analysis in batches. Thus milk samples waiting for culture are often kept in a refrigerator or frozen for an extended period of time before submission to a laboratory.
The effect of storage of milk samples at refrigerator temperatures on recovery of
Mycoplasma species is not well understood. There are a number of studies that have reported
10
changes in viability of Mycoplasma species while stored in sterile liquid media. Human
associated Mycoplasma species were reported to survive less than 30 days at 4 °C in culture
broth (Ford, 1962). In contrast, Nagatomo et al. (2001) reported a longer survival period for
Mycoplasma species associated with animals, with some species still viable at 59 day in
pleuropneumonia-like-organism (PPLO) broth stored at refrigerated temperatures. Cheng et al.
(2007) reported the decreasing recovery of M. hyorhinis from biopharmaceutical process with
6 the reduction up to 3 log 10 of titers after 4 weeks of high-dose cultures (~10 CFU/ml) stored at 4
°C. A study on the survival of M. bovis in milk sample stored at 5 °C was recently published
(Vyletelova, 2010). Here it was reported that the total counts of M. bovis in milk samples was reduced approximately 0.5 log 10 after 5 weeks of refrigeration. Thus, it is likely that survival of
Mycoplasma species in milk samples are reduced when refrigerated for an extended period of time.
Storage time and temperature may affect survival of pathogens in milk samples. Even though many studies have shown that freezing has no effect on the recovery of Staphylococcus aureus from milk samples (Bashandy and Heider, 1979; Luedecke et al., 1972; Murdough et al.,
1996; Schukken et al., 1989), several studies have shown a significant decrease in the recovery of various other mastitis pathogens from frozen milk samples including Eschericia coli ,
Streptococcus agalactiae and Streptococcus non-agalactiae species (Bashandy and Heider, 1979;
Luedecke et al., 1972; Storper et al., 1982; Pankey et al., 1987; Schukken et al., 1989).
Moreover, Biddle et al. (2004) observed that freezing suppressed recovery of Mycoplasma species from milk samples. They showed that a 3-4 log 10 reduction in viable counts of
Mycoplasma species with frozen storage for 4 weeks. Moreover, their study also indicated recovery of Mycoplasma from frozen milk samples decreased with increasing episodes of
11
freezing and thawing. Similar findings were reported recently by Vyletelova (2010). After 5 weeks of freezing at -30 °C and -80 °C, the viable count of M. bovis in milk samples was decreased as much as 0.7 and 0.1 log 10 , respectively. These findings suggest that Mycoplasma species are highly sensitive to freezing and thawing.
Glycerol is an example of a widely used cryoprotective additive in microbiology that might improve the recovery of this pathogen from frozen milk samples. As a highly hydrophilic molecule, glycerol can easily enter the cell through water channels of cell membranes. Inside the cell, glycerol molecules colligate intracellular water, which consequently decreases the freezing- point. This phenomenon can protect cells from damage during cooling process by precluding excessive dehydration, inhibiting osmotic shock and preventing the formation of large ice crystals within the cell (Hubalek, 2003). Even though the cryoprotective effect of glycerol on mastitis pathogens in milk has not been reported, the addition of glycerol to the milk sample as a cryopreservative might enhance the recovery of Mycoplasma species from frozen milk samples at culture and consequently reduce false negative results from culture.
2.4. Discrimination between Mycoplasma and Acholeplasma
Microbiological culture from a milk sample is still the standard for the diagnosis of mycoplasma mastitis (Hogan et al., 1999). Isolation of Mycoplasma is usually performed on modified Hayflick’s or Hayflick medium. Growth may be seen after 3 days of incubation at 37
°C in a moist 10% CO 2 incubator or 5-7 days when the pathogen is incubated in a moist candle jar. Plates are examined for colonies under low power on a stereomicroscope. Incubation should proceed 7-10 days before plates are diagnosed as negative.
12
Acholeplasma species can also grow and form Mycoplasma -like-colonies on modified
Hayflick’s or Hayflick medium. Therefore, discrimination between Mycoplasma and
Acholeplasma is recommended for mycoplasma mastitis diagnosis by culture. A major difference between Mycoplasma species and Acholeplasma species and other bacterial L-forms is their nutrient requirement for sterol. Mycoplasma species are unable to synthesize sterols or fatty acids
and thus require exogenous cholesterol (or a related sterol) and an appropriate long-chain fatty
acid for growth (McElhaney, 1983). Sterol constitutes from 20% to 40% of the total membrane
lipid in M. mycoides (Rodwell, 1963) and M. hominis (Rottem et al., 1973). Acholeplasma
species are also unable to synthesize sterols but do not require exogenous cholesterol for growth
(Saito et al., 1978). Acholeplasma species are capable of synthesizing straight-chained saturated
fatty acids; however, some members of this genus also require exogenous unsaturated fatty acids
for optimal growth, whereas others do not (McElhaney, 1983). Cholesterol may constitute from
8%-12% of the cell membrane (de Kruyff et al., 1972; Razin, 1975).
2.5. Digitonin
The tests currently used to evaluate sterol needs include an indirect procedure, which is
based on the measurement of growth inhibition by digitonin, and a direct and quantitative
analysis of the growth response of the mycoplasma to cholesterol (Tully, 1983). Digitonin is a
plant glycoalkaloid saponin detergent obtained from Digitalis purpurea (Elias et al., 1978;
Nishikawa et al., 1984). Structure of digitonin is shown in Figure 1. Digitonin is able to form
water-insoluble 1:1 complexes called digitonides with cholesterol and other 3 β-hydroxysteroles
(Severs and Robenek, 1983). When a cell is treated with digitonin, digitonin can form a complex
in the membrane (Akiyama et al., 1980), thus reducing the freely available cholesterol capable of
13
interacting with other membrane constituents, and apparently causing considerable
rearrangements in the lipid bilayer that lead to increased permeability and cell lysis (Rothblat and
Smith, 1961; Rottem and Razin, 1972). The digitonin sensitivity test was first adapted to a paper
disc growth inhibition test called digitonin disc diffusion assay by Freundt et al. (1973). The test
essentially involves the culture in broth of the test organism followed by transfer of the growth
media onto an agar plate. A paper disc saturated with 1.5% digitonin is placed on the surface of
the agar, followed by incubation of the culture and measurement of zones of inhibited growth
around the paper disc can indicate the sensitivity of the organism to digitonin. Sterol-requiring
members of the Mollicutes like Mycoplasma species give growth inhibition zones of ≥ 5 mm.
Although Acholeplasmas are generally resistant with no zone of inhibition surrounding the digitonin disc, some species can show a zone of growth inhibition up to 3 mm. (Freundt et al.,
1973).
2.6. Nisin
Nisin is a pentacyclic peptide consisting of 34 amino acids produced by Lactococcus lactis subsp. lactis . Within these 34 residues, 13 residues have been post-translationally modified. Two kinds of nisin are naturally produced by lactococci; nisin A and Z, which are different by only a single amino acid residue at position 27; histidine in nisinA and asparagine in nisin Z. Structure of nisin A is shown in Figure 2. Nisin can inhibit growth of various gram positive bacteria (Gross and Morell, 1971), and causing damage to the outer membrane of some gram negative bacteria such as Escherichia coli and Salmonella species. (Stevens et al., 1991).
Nisin can create pores in the membrane which consequently results in an extensive efflux of various compounds from the cytoplasm, such as amino acids, potassium, inorganic phosphate,
14
pre-accumulated rubidium, glutamate and ATP (Abee et al., 1994; Ruhr and Sahl, 1985) as depicted in Figure 3. The increase in the membrane permeability causes a complete dissipation of both transmembrane potential ( ψ ) and pH gradient ( pH) which are components of the proton motive force (PMF; p) (Abee et al., 1994; Bruno et al., 1992; Bruno and Montville,
1993; Garcera et al., 1993). The PMF drives ATP synthesis and transporting of ions and metabolites (Harold, 1986). Collapse of PMF leads to cell death through a rapid cessation of all biosynthetic processes. The cationic nature of nisin allows it to bind to lipid bilayers through electrostatic interactions with phospholipid head groups; therefore, a large amount of anionic lipids are required for efficient nisin binding (Breukink et al., 2000; Breukink et al., 1997;
Driessen et al., 1995; Giffard et al., 1997; Martin et al., 1996; Moll et al., 1997; Winkowski et al., 1996). The process of pore formation by nisin is shown in Figure 4. As explained by Bauer and Dicks (2005), the process of pore formation is started by binding of the C-terminus of nisin to the anionic lipids via electrostatic interactions. After that, the N-terminus of nisin is inserted into the lipid phase of the membrane. Then, a transient pore is formed by distortion of lipid bilayer through the short-lived transmembrane orientation of the nisin molecules.
Action of nisin on Mollicutes was first revealed in 1986. In a study of a wide range of bacteria and fungi, Henning et al. (1986) found that growth of A. laidlawii was more sensitive to nisin than that of M. mycoides . Moreover, Kordel and Sahl (1986) also showed that 1 mM nisin did not affect the intracellular ATP concentration of M. hominis confirming its resistance to nisin. In 1996, Abu-Amero et al. suggested a possibility of performing a nisin disc diffusion assay to distinguish Mycoplasma from Acholeplasma (Abu-Amero et al., 1996). They studied 11
Mycoplasma species and 5 Acholeplasma species and showed that when filter paper discs containing 20 nmol of nisin were applied on agar plates covered with Acholeplasma species, they
15
gave clear inhibition zones ranged from 3.5 to 7.0 mm after incubation. In contrast, there were no zones of inhibition detected from any Mycoplasma species. In this study, they also investigated some mode of nisin action against Acholeplasmas . They found that nisin was able to stimulate oxygen uptake by Acholeplasma but not by Mycoplasma species. Their explanation is that the nisin resistance of Mycoplasma species could be due to the nature of their transport systems, particularly for sugars via phosphoenolpyruvate-dependent sugar phosphotransferase transport system (PTS), which is absent in Acholeplasmas . Moreover, they also postulated that the resistance of Mycoplasmas to nisin might be due to the high cholesterol content of their membranes causing a reduction of membrane fluidity. Because the activity of nisin increases as membrane fluidity increases (Ming and Daeschel, 1993), nisin can effectively inhibit growth of
Acholeplasmas but not Mycoplasmas .
2.7. Nested PCR technique
Molecular biology techniques have been used for many bacterial genus and species identification. For Mycoplasma and Acholeplasma species, most of molecular techniques are developed for identification of its contamination into cell culture. Tang et al. (2000) suggested a nested PCR method (2-step PCR) for detecting Mycoplasma species and Acholeplasma species that contaminate cell cultures. They designed two sets of primers to develop a duplex nested
PCR assay. One set is specific for Mycoplasma species and another set is specific only for
Acholeplasma laidlawii . Because A. laidlawii has at least two rRNA operons with the insertion of tRNA genes in the 16S-23S rRNA intergenic spacer region (Nakagawa et al., 1992), the target region of the reaction, a double banded PCR product with the size of 426 bp and 219 bp was consistently detected. In contrast, a single DNA amplicon ranging from 236 to 365 bp was
16
produced from all commonly Mycoplasma contaminants. This feature provides a practical way to discriminate A. laidlawii from Mycoplasma species. However, the system proposed will identify
Mycoplasma after culture and thus it is not expected that sensitivity of detection due to inadequate DNA recovery will be of concern. Thus a one-step PCR will be performed in this study using a second set of primers.
2.8. Speciation of Mycoplasma species
The standard methods for definitive speciation of Mycoplasma species are based on reactivity with specific antisera. The first serological test and the most commonly used technique is the growth inhibition (GI) test (Edward and Fitzgerald, 1954). In addition to GI test, metabolism inhibition (MI; Taylor-Robinson, 1983) and immunofluorescence (IF; Bradbury,
1998; Gardella et al., 1983) are the other two techniques frequently used for identification of
Mycoplasma and Acholeplasma species. These methods are based on either the ability of specific antisera to inhibit growth or metabolism or the demonstration of reactivity with specific antisera using either a fluorescence or chromogen-based detection system, and require the isolation of
Mycoplasma -like-colonies prior to conducting the test. The serological test adds an additional 24 to 48 hours to complete the identification of Mycoplasma species after 7 to 10 days of growing
Mycoplasma -like-colonies. Given the contagious nature of the disease, this long period of diagnosis can increase the likelihood that Mycoplasma infected animals will contact and transmit the pathogen to naïve animals. A less complicated and reduced time dependent method to identify cows with mycoplasma mastitis is needed.
Other techniques that do not require the isolation of viable Mycoplasma species, such as enzyme linked immunosorbant assays (ELISA) (Byrne et al., 2000; Ghadersohi et al., 2005;
17
Nunez et al., 2008) can be used in place of culture for the diagnosis of mycoplasma mastitis.
However, only ELISA tests detecting M. bovis have been reported. Moreover, except for one
study by Byrne et al. (2000) that performed ELISA on milk samples, the ELISA tests demand the
collection of blood samples, which is more invasive than collection of milk samples. It should be
emphasized that ELISA may not be specific to mastitis because it detects antibodies presented in
any pathogen-contacted animals including animals having infection of organs other than
mammary glands. Application of polymerase chain reaction (PCR) based techniques
(Ghadersohi et al., 1997; Hotzel et al., 1999; Hotzel et al., 1996; Pinnow et al., 2001) is another
approach to detect Mycoplasma species directly from milk samples without requirement for isolation. Ghadersohi et al. (1997) successfully developed a specific probe for M. bovis with a very low sensitivity of detection, 10 – 20 CFU/ml in milk when it is used in a dot blot hybridization assay after performing PCR. Hotzel et al. (1999) developed a monoclonal antibodies specific for M. bovis and used it to capture antigen prior to PCR to reduce the problem of the presence of PCR inhibitors in DNA extracted from milk. Pinnow and co-workers (2001) were able to detect M. bovis from 2-year preservative-treated frozen milk samples using nested-
PCR with a very low detection limit at 5.1 CFU/ml of milk. However, even though PCR based
techniques are very promising with a very low detection limit (5 – 500 CFU/ml), they are not
widely used by standard laboratories for primary Mycoplasma species identification. Not all mycoplasma IMI are caused by M. bovis. The development of a culture-independent method to detect all major mycoplasma mastitis agents directly from milk samples, either preserved or frozen, would improve mycoplasma mastitis diagnosis.
To overcome problems of long time spent for definitive identification of Mycoplasma species, many PCR-based strategies have been developed for detection and speciation of this
18
genus. Hirose et al. (2001) successfully developed a PCR method based on the amplification of
16S rRNA gene to detect M. alkalescens, M. bovigenitalium, M. bovirhinis , and M. bovis in milk.
However, with highly conserved regions of 16S rRNA sequences, cross-amplification of primers with a species other than the target species can easily occur (Kobayashi et al., 1998). In 1999, a nested PCR amplifying 16S-23S rRNA intergenic spacer region was developed (Baird et al.,
1999) for identification of Mycoplasma species after the enrichment cultures of milk samples.
Differential gradient gel electrophoresis (DGGE) of 16S rRNA PCR products was also reported to successfully identify 13 bovine Mycoplasmas (McAuliffe et al., 2005). However, there are some drawbacks with this technique including a long period of electrophoresis (18 hours), the difficulties in differentiation of M. bovis from M.canadense , and the apparent inability of this method to identify Mycoplasma species directly from milk samples. In our laboratory, a nested
PCR followed by RFLP (Tang et al., 2000) has been applied to speciate cultures of Mycoplasma - like-colonies. This method employs PCR to differentiate Mycoplasma species from
Acholeplasma species. For speciation the nested PCR product has to be digested using a
restriction enzyme giving a species-specific pattern of DNA fragments after performing gel
electrophoresis. This technique requires at least 24 hours to complete the speciation, and it has
not been successfully used directly with milk samples. Therefore, development of a new
technique that can complete the diagnosis including speciation of Mycoplasma species within
hours of milk sample collection would be an improvement over the current procedures.
2.9. Real-time PCR
Real-time PCR technology has recently been exploited in clinical microbiology. It is a
promising tool with an excellent sensitivity and specificity, very fast and suitable for high
19
throughput of samples with an inherent quantitative ability (Espy et al., 2006). The real-time
PCR system is capable of detecting PCR products as they accumulate and will accurately quantify nucleic acid. When the real-time PCR was first developed (Higuchi et al., 1992;
Higuchi et al., 1993), the system consisted of an adapted thermal cycler to irradiate the samples with ultraviolet light, the intercalator ethidium bromide in each amplification reaction, with detection of the resulting fluorescence with a computer-controlled cooled charge-coupled device
(CCD) camera. Amplification during the PCR reaction produces increasing amounts of double- stranded DNA of PCR products. Double-stranded DNA bound by ethidium bromide results in increasing fluorescent signals.
Two kinds of chemistries have been used in real-time PCR: double-stranded DNA binding dyes and fluorogenic probes. The intercalator ethidium bromide was first used in real- time PCR by Higuchi et al. (1992). SYBR Green is another double-stranded DNA binding dye that has been developed and has become a more commonly used dye for real-time PCR
(Morrison et al., 1998). Even though use of a DNA binding dye for real-time detection of PCR allows detection of double-stranded PCR products produced during PCR, the fluorescent signals come from both specific and non-specific products. Thus, any mis-priming events will generate false positive signals when a double-stranded DNA binding dye is used for real-time detection.
Moreover, because multiple molecules of dye can bind to a single molecule of PCR product, the amount of fluorescent signal is dependent on the mass of double-stranded DNA produced in the reaction. Therefore, if the amplification efficiencies are the same, amplification of a longer product will generate more signal than a shorter one giving lower sensitivity of the reaction for the shorter PCR product. In contrast to using dye, using fluorogenic probes in the 5’ nuclease assay allows the real-time PCR reaction to detect only specific amplification products. The
20
property of 5’ nuclease activity of Taq DNA polymerase enables the target-specific product to be detected when the target probe is cleaved during PCR (Holland et al., 1991). A probe is a short piece of sequence, usually 20 to 30 nucleotides, complementary to a region of target sequence, which is able to anneal to its target sequence at a higher annealing temperature before the annealing of primers. This allows the probe to be cleaved during amplification by the 5’ nuclease activity of Taq DNA polymerase when the enzyme extends from an upstream primer into the region of the probe. The first developed probe was labeled with 32 P on its 5’ end and blocked at its 3’ end so it could not act as a primer (Holland et al., 1991). In 1993, Lee et al. developed a fluorogenic probe to reduce the time spent for post-PCR processing for analysis of probe degradation. A fluorogenic probe has both a reporter fluorescent dye and a quencher dye attached. Three parameters affect the performance of the 5’ nuclease assay: the quenching of the intact probe, its hybridization efficiency and the efficiency of cleavage by the polymerase. While the probe is intact, the proximity of the quencher inhibits the fluorescence emission from the reporter dye by Förster resonance energy transfer (FRET) through space. Thus, during amplification, increasing cleavage of probe from increasing production of target PCR products, results in increased fluorescence from the reporter dye that is not quenched (Figure 5). The advantage of fluorogenic probes over DNA binding dyes is that specific hybridization between probe and target is required to generate a fluorescent signal. Non-specific amplification due to mis-priming or primer-dimer artifact does not generate a signal. Moreover, probe and target can be labeled with different, distinguishable reporter dyes allowing the detection of multiple targets in a single PCR reaction (multiplex real-time PCR).
Real-time PCR has recently been applied to use for the diagnosis of mastitis causing pathogens (Cai et al., 2005; Gillespie and Oliver, 2005; Koskinen et al., 2009; Taponen et al.,
21
2009). Gillespie and Oliver (2005) had successfully employed a multiplex real-time PCR assay
for simultaneous detection of Staphylococcus aureus, Streptococcus agalactiae and Strep. uberis
directly from milk samples. With an overnight enrichment of milk samples before performing
DNA extraction, their designed real-time PCR assay showed an excellent detection limit of less
than 1 CFU/ml with an extremely high sensitivity and specificity of detection of these 3 major
mastitis pathogens. Another real-time PCR assay detecting bovine mastitis pathogens was
recently reported (Koskinen et al., 2009). The study revealed the accuracy of a commercial PCR
reaction kit, the PathoProof Mastitis PCR Assay (Finzymes Oy) which is reported to detect 11
major pathogen species or species groups responsible for bovine mastitis with 100% sensitivity
and 100% specificity within 4 hours (Koskinen et al., 2009). Additionally, another study
reported the ability of this real-time PCR assay (the PathoProof Mastitis PCR Assay) to detect
mastitis pathogens in milk samples from bovine clinical mastitis with no growth in conventional
culturing (Taponen et al., 2009). Using real-time PCR technique, results of this study
demonstrated successful detection of mastitis pathogens in 43% of samples that did not have
cultivable bacteria. These data revealed a potential ability to reduce false negative results of the
conventional culture method for identification of mastitis pathogens from milk samples.
However, this real-time PCR reaction kit cannot detect Mycoplasma species.
In the past 5 years, a number of real-time PCR assays have been developed to detect
mastitis caused by infection of M. bovis . Cai et al. (2005) reported the development of a real-
time PCR targeting 16S rRNA gene for detection of M. bovis in milk and lung samples. As
mentioned previously, DNA sequence in 16S rRNA region is very similar between M. bovis and
M. agalactiae ; therefore, their designed real-time PCR assay amplified the targeted region of both species. However, in their study, they were able to specifically differentiate M. bovis from
22
M. agalactiae based on their different melting peaks of the fluorescence resonance energy
transfer (FRET) probes. Based on their applied DNA extraction method and real-time PCR
assay, a detection limit was reported at 550 CFU/ml of M. bovis from a milk sample. In 2009,
Sachse et al. described a novel real-time PCR assay with the capability to detect M. bovis directly from milk, nasal swabs and conjunctival swabs. Their designated probe and primers targeted 3’- terminal region of the oppD gene with an excellent detection limit of 1 copy number of DNA from culture and 100 CFU/ml of M. bovis in milk (Sachse et al., 2009). Another study utilizing real-time PCR to detect M. bovis directly from milk and tissue samples was published this year
(Rossetti et al., 2010). They described a successful new specific real-time PCR assay targeting the uvrC gene of M. bovis directly from milk and tissue lysate. When milk lysate of the samples were tested by real-time PCR and by culture method in parallel, the test sensitivity of their designed real-time PCR was equivalent to the test sensitivity of the culture method with the detection limit of 2.0 x 10 3 ± 2.8 x 10 2 CFU/ml (Rossetti et al., 2010). Although the assay described by Cai et al. (2005) and Rossetti et al. (2010) appears to have applicability to mycoplasma mastitis diagnosis, sensitivities of detection suggest both assays would miss perhaps as many as 20% of the infected cows (Biddle et al., 2003). Of the three most recently described real-time PCR techniques, none detect mycoplasma organisms other than M. bovis , which may be the cause of a mycoplasma mastitis outbreak.
2.10. Conclusion and Hypothesis
The ability to detect Mycoplasma species in milk samples of cows with mastitis may not be sufficiently sensitive given the difficulties associated with culture and shedding rates in cows.
Additionally, standard culture is used as a presumptive technique and identification is made at
23
the level of a mollicute, a mycoplasma like organism. Improvements to the standard culture procedures that would result in a more sensitive Mycoplasma identification system should be investigated.
A previous study demonstrated that freezing samples reduced the recovery of viable
Mycoplasma species from milk samples (Biddle et al., 2004). The authors of this study recommended the culture of fresh milk samples for optimum diagnosis of mycoplasma mastitis.
Submission of fresh samples for mycoplasma culture is often difficult given the logistics of collection and shipping of milk samples from farm to laboratory. An evidence of a detrimental effect of storing a milk sample at the refrigerated temperature (5 °C) prior culturing was recently reported (Vyletelova, 2010). The study showed a decline of M. bovis counts from fresh to 1, 2, 3,
4 and 5 weeks of storing milk in a refrigerator. Therefore, a first study was conducted to test the hypotheses that storing milk samples at the refrigerated temperature (5 °C) for duration of 1 to 5 days would reduce the mycoplasma counts recovered from standard culture of milk samples. An ancillary study was run in parallel to determine if the addition of glycerol, a common cryopreservative, to milk samples prior to freezing would improve the recovery of Mycoplasma from frozen milk samples.
The study to determine longevity of Mycoplasma in refrigerated and frozen milk was designed to test a procedure to improve the sensitivity of standard culture. To improve the specificity, a method to discriminate between Mycoplasma species and Acholeplasma species would be valuable. The digitonin disc diffusion assay has been used as a standard method to distinguish between these two genera. Two other techniques, nisin disc diffusion assay and PCR, have also been used as procedures to distinguish between Mycoplasma species and
Acholeplasma species. It was hypothesized that the digitonin, nisin and PCR tests have the
24
equivalent efficiency to discriminate between the two genera, and allow proper classification of
Mycoplasma species that cause mastitis.
Given the characteristic of fastidious growing conditions needed by Mycoplasma , and
the time-consuming nature of the standard culture method, a diagnostic test of mycoplasma
mastitis that is more sensitive, less time consuming, and can speciate mycoplasma mastitis
pathogens would be valuable. The development of real-time PCR assays to detect 3 major
mycoplasma mastitis pathogens: M. bovis, M. californicum and M. bovigenitalium was proposed to prevail over the limitations of the standard culture procedures. It was hypothesized that a real- time PCR assays can detect the three major mycoplasma mastitis agents with a high degree of agreement (>95% agreement) with the identification by 16S rRNA partial sequencing. This study was designed to be a first step in the development of a rapid speciation of mycoplasma mastitis agents directly from a milk sample.
In conclusion, the overall goal of the studies proposed was to improve the efficiency of the diagnosis of mycoplasma mastitis in dairy cows. Accurate diagnosis is required to most effectively control and prevent contagious mycoplasma mastitis by dairy managers and consulting veterinarians.
25
REFERENCES
Abee, T., Rombouts, F.M., Hugenholtz, J., Guihard, G., Letellier, L., 1994, Mode of Action of
Nisin Z against Listeria monocytogenes Scott A Grown at High and Low Temperatures.
Appl Environ Microbiol 60, 1962-1968.
Abu-Amero, K.K., Halablab, M.A., Miles, R.J., 1996, Nisin resistance distinguishes
Mycoplasma spp. from Acholeplasma spp. and provides a basis for selective growth
media. Appl Environ Microbiol 62, 3107-3111.
Akiyama, T., Takagi, S., Sankawa, U., Inari, S., Saito, H., 1980, Saponin-cholesterol interaction
in the multibilayers of egg yolk lecithin as studied by deuterium nuclear magnetic
resonance: digitonin and its analogues. Biochemistry 19, 1904-1911.
Ayling, R.D., Baker, S.E., Peek, M.L., Simon, A.J., Nicholas, R.A.J., 2000
Comparison of in vitro activity of danofloxacin, florfenicol, oxytetracycline,
spectinomycin and tilmicosin against recent field isolates of Mycoplasma bovis . Vet
Record 146, 745–747.
Baird, S.C., Carman, J., Dinsmore, R.P., Walker, R.L., Collins, J.K., 1999, Detection and
identification of Mycoplasma from bovine mastitis infections using a nested polymerase
chain reaction. J Vet Diagn Invest 11, 432-435.
Ball, H.J., Campbell, J.N., 1989, Antibiotic treatment of experimental Mycoplasma californicum
mastitis. Vet Rec 125, 377-378.
Bashandy, E.Y., Heider, L.E., 1979, The effect of freezing of milk samples on the cultural
results. Zentralbl Veterinarmed B 26, 1-6.
Bauer, R., Dicks, L.M., 2005, Mode of action of lipid II-targeting lantibiotics. Int J Food
Microbiol 101, 201-216.
26
Behrens, A., Heller, M., Kirchhoff, H., Yogev, D., Rosengarten, R., 1994, A family of phase-
and size- variant membrane surface lipoprotein antigens (Vsps) of Mycoplasma bovis .
Infect Immun 62, 5075-5084.
Biddle, M.K., Fox, L.K., Hancock, D.D., 2003, Patterns of mycoplasma shedding in the milk of
dairy cows with intramammary mycoplasma infection. J Am Vet Med Assoc 223, 1163-
1166.
Biddle, M.K., Fox, L.K., Hancock, D.D., Gaskins, C.T., Evans, M.A., 2004, Effects of storage
time and thawing methods on the recovery of Mycoplasma species in milk samples from
cows with intramammary infections. J Dairy Sci 87, 933-936.
Bradbury, J.M., 1998, Identification of mycoplasmas by immunofluorescence. Methods Mol Biol
104, 119-125.
Breukink, E., Ganz, P., de Kruijff, B., Seelig, J., 2000, Binding of Nisin Z to bilayer vesicles as
determined with isothermal titration calorimetry. Biochemistry 39, 10247-10254.
Breukink, E., van Kraaij, C., Demel, R.A., Siezen, R.J., Kuipers, O.P., de Kruijff, B., 1997, The
C-terminal region of nisin is responsible for the initial interaction of nisin with the target
membrane. Biochemistry 36, 6968-6976.
Bruno, M.E., Kaiser, A., Montville, T.J., 1992, Depletion of proton motive force by nisin in
Listeria monocytogenes cells. Appl Environ Microbiol 58, 2255-2259.
Bruno, M.E., Montville, T.J., 1993, Common Mechanistic Action of Bacteriocins from Lactic
Acid Bacteria. Appl Environ Microbiol 59, 3003-3010.
Bushnell, R.B., 1984, Mycoplasma mastitis. Vet Clin North Am Large Anim Pract 6, 301-312.
27
Byrne, W.J., Ball, H.J., Brice, N., McCormack, R., Baker, S.E., Ayling, R.D., Nicholas, R.A.,
2000, Application of an indirect ELISA to milk samples to identify cows with
Mycoplasma bovis mastitis. Vet Rec 146, 368-369.
Cai, H.Y., Bell-Rogers, P., Parker, L., Prescott, J.F., 2005, Development of a real-time PCR for
detection of Mycoplasma bovis in bovine milk and lung samples. J Vet Diagn Invest 17,
537-545.
Cheng, H.S., Shen, C.W., Wang, S.R., 2007, Effect of storage conditions on detection of
mycoplasma in biopharmaceutical products. In Vitro Cell Dev Biol Anim 43, 113-119.
Counter, D.E., 1978, A severe outbreak of bovine mastitis asssociated with Mycoplasma
bovigenitalium and Acholeplasma laidlawii . Vet Rec 103, 130-131. de Kruyff, B., Demel, R.A., van Deenen, L.L., 1972, The effect of cholesterol and epicholesterol
incorporation on the permeability and on the phase transition of intact Acholeplasma
laidlawii cell membranes and derived liposomes. Biochim Biophys Acta 255, 331-347.
Driessen, A.J., van den Hooven, H.W., Kuiper, W., van de Kamp, M., Sahl, H.G., Konings,
R.N., Konings, W.N., 1995, Mechanistic studies of lantibiotic-induced permeabilization
of phospholipid vesicles. Biochemistry 34, 1606-1614.
Edward, D.G., Fitzgerald, W.A., 1954, Inhibition of growth of pleuropneumonia-like organisms
by antibody. J Pathol Bacteriol 68, 23-30.
Elias, P.M., Goerke, J., Friend, D.S., Brown, B.E., 1978, Freeze-fracture identification of sterol-
digitonin complexes in cell and liposome membranes. J Cell Biol 78, 577-596.
Espy, M.J., Uhl, J.R., Sloan, L.M., Buckwalter, S.P., Jones, M.F., Vetter, E.A., Yao, J.D.,
Wengenack, N.L., Rosenblatt, J.E., Cockerill, F.R., 3rd, Smith, T.F., 2006, Real-time
28
PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol
Rev 19, 165-256.
Fish, N.A., Rosendal, S., Miller, R.B., 1985, The Distribution of Mycoplasmas and Ureaplasmas
in the Genital Tract of Normal Artificial Insemination Bulls. Can Vet J 26, 13-15.
Ford, D.K., 1962, Culture of Human Genital "T-Strain" Pleuropneumonia-Like Organisms. J
Bacteriol 84, 1028-1034.
Fox, L.K., Hancock, D.D., Mickelson, A., Britten, A., 2003, Bulk tank milk analysis: factors
associated with appearance of Mycoplasma sp. in milk. J Vet Med B Infect Dis Vet
Public Health 50, 235-240.
Fox, L.K., Kirk, J.H., Britten, A., 2005, Mycoplasma mastitis: a review of transmission and
control. J Vet Med B Infect Dis Vet Public Health 52, 153-160.
Freundt, E.A., Andrews, B.E., Erno, H., Kunze, M., Black, F.T., 1973, The sensitivity of
mycoplasmatales to sodium-polyanethol-sulfonate and digitonin. Zentralbl Bakteriol Orig
A 225, 104-112.
Garcera, M.J., Elferink, M.G., Driessen, A.J., Konings, W.N., 1993, In vitro pore-forming
activity of the lantibiotic nisin. Role of protonmotive force and lipid composition. Eur J
Biochem 212, 417-422.
Gardella, R.S., DelGiudice, R.A., Tully, J.G., 1983, Section F7 Immunofluorescence, In: Tully,
J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press, New York, pp.
431-440.
Ghadersohi, A., Coelen, R.J., Hirst, R.G., 1997, Development of a specific DNA probe and PCR
for the detection of Mycoplasma bovis . Vet Microbiol 56, 87-98.
29
Ghadersohi, A., Fayazi, Z., Hirst, R.G., 2005, Development of a monoclonal blocking ELISA for
the detection of antibody to Mycoplasma bovis in dairy cattle and comparison to
detection by PCR. Vet Immunol Immunopathol 104, 183-193.
Giffard, C.J., Dodd, H.M., Horn, N., Ladha, S., Mackie, A.R., Parr, A., Gasson, M.J., Sanders,
D., 1997, Structure-function relations of variant and fragment nisins studied with model
membrane systems. Biochemistry 36, 3802-3810.
Gillespie, B.E., Oliver, S.P., 2005, Simultaneous detection of mastitis pathogens, Staphylococcus
aureus, Streptococcus uberis , and Streptococcus agalactiae by multiplex real-time
polymerase chain reaction. J Dairy Sci 88, 3510-3518.
Gonzalez, R.N., Wilson, D.J., 2003, Mycoplasmal mastitis in dairy herds. Vet Clin North Am
Food Anim Pract 19, 199-221.
Gross, E., Morell, J.L., 1971, The structure of nisin. J Am Chem Soc 93, 4634-4635.
Guterbock, W.M., Blackmer, P.E., 1984, Veterinary interpretation of bulk tank milk.
Vet Clin North Am Food Anim Pract 6, 257–268.
Hale, H.H., Helmboldt, C.F., Plastridge, W.N., Stula, E.F., 1962, Bovine mastitis caused by a
Mycoplasma species. Cornell Vet 52, 582-591.
Harold, F.M., 1986, Transcellular ion currents in tip-growing organisms: where are they taking
us? Prog Clin Biol Res 210, 359-366.
Henning, S., Metz, R., Hammes, W. P., 1986, Studies on the mode of action of nisin. Int J Food
Microbiol 3, 121-134.
Higuchi, R., Dollinger, G., Walsh, P.S., Griffith, R., 1992, Simultaneous amplification and
detection of specific DNA sequences. Biotechnology (N Y) 10, 413-417.
30
Higuchi, R., Fockler, C., Dollinger, G., Watson, R., 1993, Kinetic PCR analysis: real-time
monitoring of DNA amplification reactions. Biotechnology (N Y) 11, 1026-1030.
Hirose, K, Kawasaki, H, Kotani, K, Tanaka, A., Abiko, K., Ogawa, H., 2001,
Detection of Mycoplasma in mastitic milk by PCR analysis and culture
method. J Vet Med Sci 63, 691-693.
Hogan, J.S., Gonzalez, R.N., Harmon, R.J., Nickerson, S.C., Oliver, S.P. Pankey, J.W., Smith,
K.L., 1999, Laboratory handbook on bovine mastitis. National Mastitis Council, Inc,
Wisconsin, pp. 151-188.
Holland, P.M., Abramson, R.D., Watson, R., Gelfand, D.H., 1991, Detection of specific
polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of
Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88, 7276-7280.
Hotzel, H., Heller, M., Sachse, K., 1999, Enhancement of Mycoplasma bovis detection in milk
samples by antigen capture prior to PCR. Mol Cell Probes 13, 175-178.
Hotzel, H., Sachse, K., Pfutzner, H., 1996, Rapid detection of Mycoplasma bovis in milk samples
and nasal swabs using the polymerase chain reaction. J Appl Bacteriol 80, 505-510.
Hubalek, Z., 2003, Protectants used in the cryopreservation of microorganisms. Cryobiology 46,
205-229.
Jain, N.C., Jasper, D.E., Dellinger, J.D., 1969, Serologic response of cows to Mycoplasma under
experimental and field conditions. Am J Vet Res 30, 733-742.
Jasper, D.E., 1979, Bovine mycoplasmal mastitis. J Am Vet Med Assoc 175, 1072-1074.
Jasper, D.E., 1981, Bovine mycoplasmal mastitis. Adv Vet Sci Comp Med 25, 121-157.
Jasper, D.E., 1982, The role of Mycoplasma in bovine mastitis. J Am Vet Med Assoc 181, 158-
162.
31
Kinde, H., Daft, B.M., Walker, R.L., Charlton, B.R., Petty, R., 1993, Mycoplasma bovis
associated with decubital abscesses in Holstein calves. J Vet Diagn Invest 5, 194-197.
Kirk, J.H., Glenn, K., Ruiz, L., Smith, K., 1997, Epidemiologic analysis of Mycoplasma spp
isolated from bulk-tank milk samples obrained from dairy herds that were members of
milk cooperative. J Am Vet Med Assoc 211, 1036-1038.
Kobayashi, H., Hirose, K., Worarach, A., Paugtes, P., Ito, N., Morozumi, T., Yamamoto, K.,
1998, In vitro amplification of the 16S rRNA genes from Mycoplasma bovirhinis,
Mycoplasma alkalescens and Mycoplasma bovigenitalium by PCR. J Vet Med Sci 60,
1299-1303.
Kordel, M., Sahl, H.G., 1986, Susceptibility of bacterial, eukaryotic and artificial membranes to
the disruptive action of the cationic peptides Pep 5 and nisin. FEMS Microbiol Lett 34,
139-144.
Koskinen, M.T., Holopainen, J., Pyorala, S., Bredbacka, P., Pitkala, A., Barkema, H.W., Bexiga,
R., Roberson, J., Solverod, L., Piccinini, R., Kelton, D., Lehmusto, H., Niskala, S.,
Salmikivi, L., 2009, Analytical specificity and sensitivity of a real-time polymerase chain
reaction assay for identification of bovine mastitis pathogens. J Dairy Sci 92, 952-959.
Lee, L.G., Connell, C.R., Bloch, W., 1993, Allelic discrimination by nick-translation pcr with
fluorogenic probes. Nucleic Acids Res 21, 3761-3766.
Luedecke, L.O., Forster, T.L., Williams, K., Hillers, J.K., 1972, Effect of freezing and storage at
-20 C on survival of mastitis pathogens. J Dairy Sci 55, 417-418.
Mackie, D.P., Finlay, D., Brice, N., Ball, H.J., 2000, Mixed mycoplasma mastitis outbreak in a
dairy herd. Vet Rec 147, 335-336.
32
Martin, I., Ruysschaert, J.M., Sanders, D., Giffard, C.J., 1996, Interaction of the lantibiotic nisin
with membranes revealed by fluorescence quenching of an introduced tryptophan. Eur J
Biochem 239, 156-164.
McAuliffe, L., Ellis, R.J., Lawes, J.R., Ayling, R.D., Nicholas, R.A., 2005, 16S rDNA PCR and
denaturing gradient gel electrophoresis; a single generic test for detecting and
differentiating Mycoplasma species. J Med Microbiol 54, 731-739.
McAuliffe, O., Ross, R.P., Hill, C., 2001, Lantibiotics: structure, biosynthesis and mode of
action. FEMS Microbiol Rev 25, 285-308.
McElhaney, R.N., 1983, Section D4 Manipulation of membrane lipid composition, In: Tully,
J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press, New York, pp.
235-239.
Ming, X.T., Daeschel, M.A., 1993, Nisin resistance of foodborne bacteria and the specific
resistance responses of Listeria monocytogenes scott-a. J. Food Prot. 56, 944-948.
Moll, G.N., Clark, J., Chan, W.C., Bycroft, B.W., Roberts, G.C., Konings, W.N., Driessen, A.J.,
1997, Role of transmembrane pH gradient and membrane binding in nisin pore
formation. J Bacteriol 179, 135-140.
Morrison, T.B., Weis, J.J., Wittwer, C.T., 1998, Quantification of low-copy transcripts by
continuous SYBR Green I monitoring during amplification. Biotechniques 24, 954-958,
960, 962.
Murdough, P.A., Deitz, K.E., Pankey, J.W., 1996, Effects of freezing on the viability of nine
pathogens from quarters with subclinical mastitis. J Dairy Sci 79, 334-336.
33
Nagatomo, H., Takegahara, Y., Sonoda, T., Yamaguchi, A., Uemura, R., Hagiwara, S., Sueyoshi,
M., 2001, Comparative studies of the persistence of animal mycoplasmas under different
environmental conditions. Vet Microbiol 82, 223-232.
Nakagawa, T., Uemori, T., Asada, K., Kato, I., Harasawa, R., 1992, Acholeplasma laidlawii has
tRNA genes in the 16S-23S rRNA intergenic spacer of the rRNA operon. J Bacteriol 174,
8163-8165.
Nishikawa, M., Nojima, S., Akiyama, T., Sankawa, U., Inoue, K., 1984, Interaction of digitonin
and its analogs with membrane cholesterol. J Biochem 96, 1231-1239.
Nocard, Roux, 1990, The microbe of pleuropneumonia. 1896. Rev Infect Dis 12, 354-358.
Nunez, C., Salinas, E.M., Maya, J.J.M., Hernandez, L., 2008, Detection of subclinical bovine
mastitis caused by mycoplasmosis by indirect ELISA test and isolation. Veterinaria
Mexico 39, 161-171.
Paila, Y.D., Pucadyil, T.J., Chattopadhyay, A., 2005, The cholesterol-complexing agent digitonin
modulates ligand binding of the bovine hippocampal serotonin 1A receptor. Mol Membr
Biol 22, 241-249.
Pan, I.J., Ogata, M., 1969, New sero-types of Mycoplasma laidlawii isolated from mastitic milk
and urogenital tracts of cattle. II. Typing of M. laidlawii by biological and serological
methods. Nippon Juigaku Zasshi 31, 313-324.
Pankey, J.W., Wadsworth, J.K., Metha, H., Murdough, P.A., 1987, Effects of storage no viability
of mastitis pathogens. J Dairy Sci 70(Suppl.1), 132 (Abstr.).
Pilo, P., Frey, J., Vilei, E.M., 2007, Molecular mechanisms of pathogenicity of
Mycoplasma mycoides subsp. mycoides SC. Vet J 174, 513-521.
34
Pinnow, C.C., Butler, J.A., Sachse, K., Hotzel, H., Timms, L.L., Rosenbusch, R.F., 2001,
Detection of Mycoplasma bovis in preservative-treated field milk samples. J Dairy Sci 84,
1640-1645.
Razin, S., 1975, Cholesterol incorporation into bacterial membranes. J Bacteriol 124, 570-572.
Razin, S., Yogev, D., Naot, Y., 1998, Molecular biology and pathogenicity of mycoplasmas.
Microbiol Mol Biol Rev 62, 1094-1156.
Rodwell, A.W., 1963, The Steroid Growth-Requirement of Mycoplasma mycoides . J Gen
Microbiol 32, 91-101.
Rosendal, S., Martin, S.W., 1986, The association between serological evidence of mycoplasma
infection and respiratory disease in feedlot calves. Can J Vet Res 50, 179-183.
Rosengarten, R., Behrens, A., Stetefeld, A., Heller, M., Ahrens, M.,Sachse, K., Yogev, D.,
Kirchhoff, H., 1994, Antigen heterogeniety among isolates of Mycoplasma bovis is
generated by high frequency variation of diverse membrane surface proteins. Infect
Immun 62, 5066-5074.
Rossetti, B.C., Frey, J., Pilo, P., 2010, Direct detection of Mycoplasma bovis in milk and tissue
samples by real-time PCR. Mol Cell Probes in press .
Rothblat, G.H., Smith, P.F., 1961, Nonsaponifiable lipids of representative pleuropneumonia-like
organisms. J Bacteriol 82, 479-491.
Rottem, S., Cirillo, V.P., de Kruyff, B., Shinitzky, M., Razin, S., 1973, Cholesterol in
mycoplasma membranes. Correlation of enzymic and transport activities with physical
state of lipids in membranes of Mycoplasma mycoides var. capri adapted to grow with
low cholesterol concentrations. Biochim Biophys Acta 323, 509-519.
35
Rottem, S., Razin, S., 1972, Isolation of mycoplasma membranes by digitonin. J Bacteriol 110,
699-705.
Ruhr, E., Sahl, H.G., 1985, Mode of action of the peptide antibiotic nisin and influence on the
membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles.
Antimicrob Agents Chemother 27, 841-845.
Sachse, K., Salam, H.S.H., Diller, R., Schubert, E., Hoffmann, B., Hotzel, H., (in press) 2009,
Use of a novel real-time PCR technique to monitor and quantitate Mycoplasma bo vis
infection in cattle herds with mastitis and respiratory disease. The Veterinary Journal.
Saito, Y., Silvius, J.R., McElhaney, R.N., 1978, Membrane lipid biosynthesis in Acholeplasma
laidlawii b: elongation of medium- and long-chain exogenous fatty acids in growing
cells. J Bacteriol 133, 66-74.
Schukken, Y.H., Grommers, F.J., Smit, J.A., Vandegeer, D., Brand, A., 1989, Effect of freezing
on bacteriologic culturing of mastitis milk samples. J Dairy Sci 72, 1900-1906.
Severs, N.J., Robenek, H., 1983, Detection of microdomains in biomembranes. An appraisal of
recent developments in freeze-fracture cytochemistry. Biochim Biophys Acta 737, 373-
408.
Stevens, K.A., Sheldon, B.W., Klapes, N.A., Klaenhammer, T.R., 1991, Nisin treatment for
inactivation of Salmonella species and other gram-negative bacteria. Appl Environ
Microbiol 57, 3613-3615.
Storper, M., Ziv, G., Saran, A. 1983. Effect of storing milk samples at -18 °C on the viability of
certain udder pathogens. Refuah Vet 39, 1-2.
36
Tang, J., Hu, M., Lee, S., Roblin, R., 2000, A polymerase chain reaction based method for
detecting Mycoplasma/Acholeplasma contaminants in cell culture. J Microbiol Methods
39, 121-126.
Taponen, S., Salmikivi, L., Simojoki, H., Koskinen, M.T., Pyorala, S., 2009, Real-time
polymerase chain reaction-based identification of bacteria in milk samples from bovine
clinical mastitis with no growth in conventional culturing. J Dairy Sci 92, 2610-2617.
Taylor-Robinson, D., 1983, Section F4 Metabolism Inhibition Tests, In: Tully, J.G., Razin, S.
(Eds.) Methods in mycoplasmology I. Academic Press, New York, pp. 411-418.
Thomas, C.B., Willeberg, P., Jasper, D.E., 1981, Case-control study of bovine mycoplasmal
mastitis in California. Am J Vet Res 42, 511-515.
Tully, J.G., 1983, Section E5 Tests for digitonin sensitivity and sterol requirement, In:
Tully, J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press,
New York, pp. 355-362.
Vyletelova, M., 2010, The survival of Mycoplasma bovis at different temperatures,
Czech J Food Sci 28, 74-78.
Walz, P.H., Mullaney, T.P., Render, J.A., Walker, R.D., Mosser, T., Baker, J.C., 1997, Otitis
media in preweaned Holstein dairy calves in Michigan due to Mycoplasma bovis . J Vet
Diagn Invest 9, 250-254.
Winkowski, K., Ludescher, R.D., Montville, T.J., 1996, Physiochemical characterization of the
nisin-membrane interaction with liposomes derived from Listeria monocytogenes . Appl
Environ Microbiol 62, 323-327.
37
TABLES
TABLE 1. Taxonomy of the class of Mollicutes (adapted from Razin et al., 1998)
Classification Number of Genome Cholesterol Distinctive Habitat
recognized size requirement properties
species (kb)
Order I: Mycoplasmatales Yes Humans and
Family I: Mycoplasmataceae animals
Genus I: Mycoplasma 102 580-1350 Optimum growth
at 37 °C
Genus II: Ureaplasma 6 760-1170 Urea hydrolysis
Order II: Entomoplasmatales Insects and
Family I: Entomoplasmataceae plants
Genus I: Entomoplasma 5 790-1140 Yes Optimum growth
at 30 °C
Genus II: Mesoplasma 12 870-1100 No 0.04% Tween 80
required in serum-
free medium
Family II: Spiroplasmataceae Helical motile Insects and
Genus I: Spiroplasma 33 780-2220 Yes filaments plants
Order III: Acholeplasmatales Animals,
Family I: Acholeplasmataceae Optimum growth some plants,
Genus: Acholeplasma 13 1500-1650 No at 30 – 37 °C insects
Order IV: Anaeroplasmatales Oxygen-sensitive Bovine/Ovin
Family: Anaeroplasmataceae anaerobes e rumen
Genus I: Anaeroplasma 4 1500-1600 Yes
Genus II: Asteroleplasma 1 1500 No
Undefined taxonomic status Not defined 640-1185 Not known Uncultured in vitro Insects,
Phytoplasma plants
38
FIGURES
FIGURE 1. Chemical structure of digitonin (Paila et al., 2005, permission granted by Journal of Molecular Membrane Biology, Taylor & Francis Ltd, Philadelphia, PA, USA)
39
FIGURE 2. Structure of nisin A (McAuliffe et al., 2001, permission granted by FEMS
Microbiology Review, John Wiley and Sons, Inc, Hoboken, NJ, USA).
40
FIGURE 3. General model of the ‘barrel stave’ mechanism of pore formation by peptides
(McAuliffe et al., 2001, permission granted by FEMS Microbiology Review, John Wiley and
Sons, Inc, Hoboken, NJ, USA)
41
FIGURE 4. Models of pore formation by nisin. (A) Barrel-stave pore. (B, C) General models for pore formation. Step1: binding of nisin via its C-terminal. Step2: insertion of nisin into the membrane. The depth of insertion depends on the percentage of anionic lipids and nisin concentration. Step3: wedge/magainin-like pore. B and C represent pore formation initiated by translocation of the C-terminus and N-terminus, respectively. Step 4: translocation of the peptide to the inside of the membrane. (Bauer and Dicks, 2005, permission granted by Internationa
Journal of Food Microbiology, Elsevier Limited, Oxford, United Kingdom)
42
FIGURE 5. Step-wise reaction of real-time PCR using a fluorogenic probe (the Taqman assay,
Applied Biosystems, Foster City, CA, USA)
43
CHAPTER 3
Effects of storage methods on the recovery of Mycoplasma species from milk samples
INTRODUCTION
Mycoplasm a species are Mollicute s known to be able to cause clinical and subclinical mastitis in dairy cattle. Mastitis associated with Mycoplasma has been reported worldwide (Fox et al., 2005). Numerous species of Mycoplasma have been reported to be associated with mastitis in dairy farms. Among all reported cases, Mycoplasma bovis, M. californicum, M. alkalescens,
M. bovigenitalium and M. canadense are the most commonly found to cause bovine mastitis
(Gonzalez and Wilson, 2003). Mycoplasma species are classified as a contagious pathogen, capable of transmitting easily from cow-to-cow (Gonzalez and Wilson, 2003) and treatment is usually unsuccessful (Bushnell, 1984). Therefore, control of mycoplasma mastitis may be best
achieved through the identification and segregation or culling of infected cows, which are the
infection reservoirs (Fox et al., 2005). Mycoplasma species are difficult to isolate which makes
diagnosis of infection challenging. Because specialized media, modified Hayflicks, and
incubation for several days in 10% CO 2 are required (Hogan et al., 1999), many laboratories may
not routinely culture milk for mycoplasma organisms. Additionally, cows with mycoplasma
mastitis may shed the pathogen intermittently and shedding of Mycoplasma species into milk of
infected cows may be as low as <100 colony forming unit (CFU)/ml, below the threshold of
detection by standard culture methods (Biddle et al., 2003). These difficulties increase the
importance of milk sample handling before culture in an effort to avoid false negative results.
Although culturing fresh milk samples has been suggested as a means of maximizing the
detection of Mycoplasma species (Biddle et al., 2004), the submission of fresh milk samples is
44
often not practical for many dairy operators because of their distance from diagnostic
laboratories and the convenience of storing samples for analysis in batches. Thus milk samples
waiting for culture are often kept in a refrigerator or frozen for an extended period of time before
submission to a laboratory. Storage time and temperature may affect survival of pathogens in
milk samples. Several studies have shown a significant decrease in the recovery of various
mastitis pathogens from frozen milk samples (Luedecke et al., 1971; Bashandy et al., 1979;
Storper et al., 1982; Pankey et al., 1987; Schukken et al., 1989). Moreover, Biddle and
colleagues (2004) observed that freezing suppressed recovery of Mycoplasma species from milk samples. Glycerol is an example of a widely used cryoprotective additive in microbiology that might improve the recovery of this pathogen from frozen milk samples. Being a highly hydrophilic molecule, glycerol can easily enter the cell through water channels of cell membranes. Inside the cell, glycerol molecules colligate intracellular water which consequently decreases the freezing-point. This phenomenon can protect cells from damage during cooling process by precluding excessive dehydration, inhibiting osmotic shock and preventing the formation of large ice crystals within the cell (Hubalek, 2003). However, the cryoprotective effect of glycerol on mastitis pathogens in milk has not been reported.
The effect of refrigerating a milk sample on recovery of Mycoplasma species by standard culture has not been assessed. Also, the addition of glycerol to the milk sample as a cryopreservative might enhance the recovery of Mycoplasma species from frozen milk samples at culture. The objectives of this study were: 1) to determine the effects of refrigerating milk samples for various periods of time on Mycoplasm a species viability assessed by culture; and 2) to determine the effects of glycerol addition at different concentrations on the viability of several species of Mycoplasma as determined by culture of milk samples.
45
MATERIALS AND METHODS
Mycoplasma strains
Two strains of each of 5 species: M. bovis, M. californicum, M. bovigenitallium, M. canadense and M. alkalescens , were selected, original sources being the American Type Culture
Collection (ATCC, Manassas, VA, USA), and the diagnostic laboratories at the University of
California (UCD, Davis, CA, USA) and Cornell University (CU, Ithaca, NY, USA). Strains were: M. bovis ATCC25523, M. bovis ATCC27368, M. californicum ATCC33461, M. californicum UCD8, M. bovigenitalium ATCC19852, M. bovigenitalium ATCC14173, M. canadense ATCC29418, M. canadense CU21113, M. alkalescens CU21146 and M. alkalescens
CU22261. Two hundred microliters (µl) of each strain were cultured with 10 ml of plueropneumonia-like organism (PPLO or Mycoplasma) broth and incubated at 37 °C, 10% CO 2 for 4 days.
Inoculation of milk samples
The PPLO cultures were centrifuged at 5000 x g for 30 minutes to sediment the bacteria.
The mycoplasma cell pellets were resuspended with phosphate buffer saline solution (PBS) and adjusted for their concentration by measuring the optical density at wavelength of 540 nm
(OD 540 ) using a spectophotometer. All Mycoplasma -PBS solutions were adjusted to have OD 540
= 0.2, which was expected to contain approximately 10 8 CFU/ml of Mycoplasma . Ten-fold serial dilutions were then made. One milliliter of each of 3 dilutions of resuspended culture was inoculated in 9 ml of bulk tank milk that was free of Mycoplasma to create 3 different starting concentrations of Mycoplasma in milk: high, medium and low concentration. The expected concentrations of Mycoplasma in inoculated milk samples for high, medium and low were 10 6,
46
10 4 and 10 2 CFU/ml, respectively. For each of the three concentrations, milk was spilt into 4 different tubes to determine the effect of refrigeration, Experiment I. The first tube, a fresh sample, was the control for the experiment. The 3 refrigeration treatments included refrigeration
(5° C) for 1 day, for 3 days, and for 5 days. l. In Experiment II, four treatments of glycerol addition (v/v) to the inoculated milk included 0% glycerol, 10% glycerol, 30% glycerol and 50% glycerol, which were then frozen at -20 °C for 1 week. After refrigeration and after thawing, 100
µl of each milk sample was removed and cultured on Modified Hayflicks agar plates (Hogan et
al., 1999) and incubated for 7-10 days at 37 °C, 10% CO 2 before enumeration of colonies. The
experiment was replicated with the identical methods.
Statistical analysis
Mycoplasma count data were log 10 transformed before analysis. Mycoplasma counts for
different species and different storage methods were compared using analysis of variance
(ANOVA). Mixed model analysis was performed using Proc Mixed by SAS version 9.1 (SAS
Institute, Cary, NC). Storage methods and species were analyzed as fixed effects whereas
starting concentrations, strains, and replication were analyzed as random effects. The criteria for
statistical significant was P <0.05.
RESULTS
A total of 540 inoculated milk samples were assayed; 240 samples for refrigeration study
and 300 samples for glycerol addition study. The effects of refrigeration are shown in Table 1.
Refrigerated milk mycoplasma counts were lower than those from fresh milk samples after 5
days of refrigeration (P<0.05). The effects of freezing milk samples with various concentrations
47
of glycerol addition are shown in Table 2. All frozen milk samples had lower number of
mycoplasma counts compared to those of fresh milk. Frozen milk with 10% and 30% glycerol
had greater mycoplasma counts compared to those of frozen milk without glycerol (P<0.05). No
significant interactions of species and storage methods were detected in this study (P>0.05).
DISCUSSION
The trend indicated a reduction in the recovery of Mycoplasma species from milk over time with refrigerated storage and refrigeration beyond 3 days had a significant negative effect on the recovered number of Mycoplasma species from milk. The reduction in the amount of
Mycoplasma species can increase the probability of having false negative results from in vitro culture (Biddle et al., 2004). Several studies reported the change in viability of Mycoplasma species based on their survival in sterile liquid media. Human mycoplasmas were reported to survive less than 30 days at 4 °C in cultured broth (Ford, 1962). In contrast, Nagatomo et al.
(2001) reported a longer survival period for animal mycoplasmas under similar refrigerated conditions with some species still viable at 59 day in PPLO broth. A study on the viability of M. bovis in milk sample stored at 5 °C was recently published (Vyletelova, 2010). They reported that the total count of M. bovis in milk samples was reduced approximately 0.5 log 10 after 5 weeks of refrigeration. Mycoplasma species in milk not collected aseptically, such as bulk tank milk samples, may suffer from refrigerated storage as a result of the overgrowth of other bacteria which may change the physicochemical properties of the milk media. Celestino and colleagues
(1996) revealed that the proportion of psychrotrophic bacteria in the total plate count increased from 47% in fresh milk to 80% after storage at 4 °C for two days. Moreover, they reported an increase in enzyme activities, notably lipolysis and proteolysis, occurred after two days in
48
refrigerated milk. These changes subsequently increased free fatty acids and lowered pH in milk.
Because Mycoplasma species are sensitive to changing pH and overgrowth of other bacteria
(Boughton, 1979; Nicholas and Baker, 1998), refrigerating milk samples for long periods of time
may increase the risk of false-negative tests for mycoplasma mastitis. It had been suggested that
when a milk sample has to be stored for more than 2 days before culturing for suspected
Mycoplasma species, the milk sample should be frozen or kept in liquid nitrogen (Hogan et al.,
1999). However, most frozen milk samples usually are kept in the freezing part of the
conventional refrigerator with the temperature around -20 °C, which is warmer than the preferred
temperature at -30 °C or lower (Hogan et al., 1999). The data presented in the current study
indicates that storage at -20 °C reduces mycoplasma counts, which may increase the chance of
false negative results. False negative results could increase from to 20% to 45% when milk
samples were frozen for 1 week to 4 weeks, respectively (Biddle et al., 2004). The addition of
glycerol to milk as a cryopreservative was considered to improve the recovery of Mycoplasma
species from frozen milk. We conjectured that glycerol would rapidly penetrate into mycoplasma
cells and effectively alleviate cell damage caused by the formation of intracellular and
extracellular ice crystalization (Raccach et al., 1975). Our results showed that adding glycerol to
milk prior freezing at the concentration from 10% to 30% can improve the number of recovered
Mycoplasma species from frozen milk. Moreover, adding glycerol at higher concentrations, such
as 50%, may be detrimental to the recovery of Mycoplasma species. Although freezing milk with any addition of glycerol led to a decrease in recoverable Mycoplasma species , the decrease was not as great as without glycerol addition. Thus, this study reveals a possibility of adding glycerol to milk to preserve Mycoplasma species before isolation in laboratories when frozen storage of samples is the best option.
49
The aim of mastitis diagnosis is to isolate the causative pathogen from a milk sample.
The mean reduction of the number of recovered Mycoplasma species reported in this study was approximately 0.3 log 10 when fresh milk samples were compared to 5-day refrigerated milk samples and approximately 1.0 log 10 when fresh milk samples were compared to frozen milk samples without glycerol addition. Reductions of this magnitude may not significantly increase the risk of a false negative result. Sensitivity of detection will be in large part a function of the number of pathogens in the milk sample and the volume of sample cultured. When samples have relatively large number of mycoplasma pathogens in milk such as 10 x 10 6 CFU/ml in some infected mammary quarters, a 1.0 log 10 reduction in the number of recovered pathogens due to storage will not affect sensitivity of detecting an infected cow. However, it may affect the diagnosis when an infected cow sheds a very small amount the organism. As indicated by Biddle and co-workers (2003), infected cows can shed as less than 10,000 CFU/ml of Mycoplasma species for more than 20% (it will be greater than 10%, 2 of 10 cows virtually never shed this organism) of the time. It is very critical to find the infected cows to prevent the transmission of this contagious pathogen. Therefore it would be advisable to culture fresh milk samples to maximize the detection of Mycoplasma species in milk because sample handling by refrigeration
or freezing can reduce the number of the pathogens.
In conclusion, evidence from this study indicates that milk samples should be stored
under refrigerated temperature for less than 5 days prior to submission for culture for
Mycoplasma species. In addition to refrigeration, findings confirm that freezing milk samples
reduces the number of Mycoplasma species recovered by culture. Moreover, the addition of
glycerol at 10% to 30% (v/v) can be used as a cryopreservative to enhance Mycoplasma species
recovery from frozen milk. For dairy operators and attending veterinarians, this study suggests
50
that milk samples submitted for mycoplasma diagnosis should be sent as fresh as possible because the number of viable Mycoplasma species decreases with time which may result in failure to detect the pathogen. Transit time of 3 days from farm to laboratory, if samples are held at refrigerated temperatures, should not significantly decrease recovery of Mycoplasma species from milk. If milk samples need to be held longer before culturing, freezing milk after adding
10% to 30% of glycerol (v/v) as a cryoprotective additive is suggested. This application can reduce damage from freezing and thawing methods, and improve the recovery of Mycoplasma species from frozen milk.
ACKNOWLEDGMENTS
We are grateful to Dorothy Newkirk, and Veerasak Punyapornwithaya for their excellent assistance. This study was published as a short communication in Veterinary Microbiology July
29, 2010, volume 144, page 210-213. Permission to reproduce the article was granted by Elsevier on October 12, 2010.
51
REFERENCES
Bashandy, E. Y., Heider, L. E., 1979. The effect of freezing milk samples on the cultural results.
Zentralbl. Veterinaermed. Reihe B. 26, 1-6.
Biddle, M. K., Fox, L. K., Hancock, D. D., 2003. Patterns of mycoplasma shedding in the milk
of dairy cows with intramammary mycoplasma infection. J. Am. Vet. Med. Assoc. 223,
1163-1166.
Biddle, M. K., Fox, L. K., Hancock, D. D., Gaskins, C. T., Evans, M. A., 2004. Effects of
storage time and thawing methods on the recovery of Mycoplasma species in milk
samples from cows with intramammary infections. J. Dairy Sci. 87, 933-936.
Boughton, E., 1979. Mycoplasma bovis mastitis. Vet. Bull. 49, 377-387.
Bushnell, R. B., 1984. Mycoplasma mastitis. Vet. Clin. N. Am. Food Anim. Pract. 6, 301-312.
Celestino, E. L., Lyer, M., Roginski, H., 1996. The effects of refrigerated storage on the quality
of raw milk. Aust. J. Dairy Technol. 51, 59-63.
Ford, D. K., 1962. Culture of human genital “T-strain” pleuropneumonia-like organisms. J.
Bacteriol. 84, 1028-1034.
Fox, L. K., Kirk, J. H., Britten, A., 2005. Mycoplasma mastitis: a review of transmission and
control. J. Vet. Med. B. 52, 153-160.
Gonzalez, R. N., Wilson, D. J., 2003. Mycoplasma mastitis in dairy herds. Vet. Clin. North Am.
Food Anim. Pract. 19, 199-221.
Hogan, J. S., Gonzalez, R. N., Harmon, R. J., Nickerson, S. C., Oliver, S. P., Pankey, J. W.,
Smith, K. L., 1999. Laboratory handbook on bovine mastitis. National Mastitis Council,
Wisconsin, pp. 151-153.
Hubalek, Z. 2003. Protectants used in the cryopreservation of microorganisms. Cryobiology. 46,
52
205-229.
Luedecke, L. O., Forster, T. L., Williams, K., Hillers, J. K., 1971. Effect of freezing and storage
at -20 °C on survival of mastitis pathogens. J. Dairy Sci. 55, 417-418.
Nagatomo, H., Takegahara, Y., Sonoda, T., Yamagushi, A., Uemura, R., Hagiwara, S.,
Sueyoshi, M., 2001. Comparative studies of the persistence of animal mycoplasmas
under different environmental conditions. Vet. Microbiol. 82, 223-232.
Nicholas, R., Baker, S., 1998. Recovery of Mycoplasmas from animals. In: Miles, R., Nicholas,
R. (Eds.), Mycoplasma Protocols, Humana Press, Totowa, New Jersey, pp. 37-43.
Pankey, J. W., Wadsworth, J. K., K. Metha, H., Murdough, P. A., 1987. Effects of storage on
viability of mastitis pathogens. J. Dairy Sci. 70(Suppl.1), 132. (Abstr.)
Raccach, M., Rottem, S., Razin, S., 1975. Survival of frozen Mycoplasmas. Appl. Microbiol. 30,
167-171.
SAS/STAT 9.1 User’s Guide, 2008. SAS Institute Inc., North Carolina
Schukken, Y. H., J. Smit, A. H., Grommers, F. J., Vandegeer, D., Brand, A., 1989. Effect of
freezing on bacteriologic culturing on mastitis milk samples. J. Dairy Sci. 72, 1900-1906.
Storper, M., Ziv, G., Saran, A. 1983. Effect of storing milk samples at -18 °C on the viability of
certain udder pathogens. Refuah Vet. 39, 1-2.
53
TABLES
TABLE 1. Mycoplasma countsa from fresh and refrigerated milk samples
Storage conditions Mycoplasma counts Significant differences b
Least squares mean ± SE
(Log 10 CFU/ml)
Fresh 4.43 ± 0.28 A
Refrigeration (5°C) for 1day 4.45 ± 0.27 A
Refrigeration (5°C) for 3days 4.29 ± 0.28 AB
Refrigeration (5°C) for 5days 4.10 ± 0.29 B
a Mycoplasma counts are a compilation of the mean counts of all isolates for the respective treatment. Isolates were two strains of each of 5 species: M. bovis, M. californicum, M. bovigenitalium, M. canadense and M. alkalescens .
bDifferent letters indicate statistically significant differences in least square means of
mycoplasma counts between treatments, P<0.05.
54
TABLE 2. Mycoplasma counts a from fresh and frozen milk samples with various concentrations of glycerol addition b
Storage conditions Mycoplasma counts Significant differences c
Least squares mean ± SE
(Log 10 CFU/ml)
Fresh 4.56 ± 0.22 A
0% glycerol in frozen milk 3.71 ± 0.27 C
10% glycerol in frozen milk 4.16 ± 0.23 B
30% glycerol in frozen milk 4.06 ± 0.22 B
50% glycerol in frozen milk 3.45 ± 0.26 C
a Mycoplasma counts are a compilation of the mean counts of all isolates for the respective treatment. Isolates were two strains of each of 5 species: M. bovis, M. californicum, M. bovigenitallium, M. canadense and M. alkalescens . b Glycerol addition was made to achieve final concentrations of 10%, 30% and 50%, volume to volume.
cDifferent letters indicate statistically significant differences in least square means of mycoplasma counts between treatments, P<0.05.
55
CHAPTER 4
Discrimination between Mycoplasma and Acholeplasma using digitonin disc diffusion assay,
nisin disc diffusion assay, and conventional PCR
INTRODUCTION
Mycoplasma species have been reported to cause severe mastitis in dairy cattle
worldwide (Fox et al., 2005). Mycoplasma species are categorized as contagious pathogens
which can be readily transmitted from cow-to-cow. Treatment of mycoplasma mastitis is not
very effective and can lead to a chronic and/or subclinical infection (Bushnell, 1984). Therefore,
segregation and culling of infected animals has been suggested to prevent exposure of infected
animals to naïve animals in an infected herd. Precise detection of infected animals at an early
stage is a critical component of a mycoplasma mastitis control strategy.
Direct culture of a milk sample on blood agar plates has been the standard initial step in
the determination of most etiologic agents causing mastitis (Hogan et al., 1999). Mycoplasma
species are fastidious pathogens and have special growth requirements. Isolation of these
organisms requires specific medium; modified Hayflick’s (Hogan et al., 1999). Then inoculated
media is incubated at 37 °C in a moist 10% CO 2 environment as Mycoplasma require low
oxygen tension. Acholeplasma laidlawii is a common non pathogenic saprophytic contaminant in
the dairy environment and is occasionally found in both tank-milk and cow-milk samples
(Bushnell, 1984; Jasper, 1982). Acholeplasma laidlawii is normally considered a non-pathogenic agent (Jasper, 1981) although some studies reported the isolation of this species from mastitic milk (Pan and Ogata, 1969; Counter, 1978). Acholeplasma species can not be distinguished from
Mycoplasma species on modified Hayflick’s medium. Therefore, additional discriminatory tests
56
are needed to distinguish between Mycoplasma and Acholeplasma. A major difference between
Mycoplasma species and Acholeplasma species is their sterol requirement. Mycoplasma species
are unable to synthesize sterols or fatty acids and thus require exogenous sterol from media
(McElhaney, 1983). Acholeplasma species do not require exogenous cholesterol for growth
(Saito et al., 1978). The digitonin disc diffusion assay can be used to distinguish between
Mycoplasma and Acholeplasma based on the different sterol nutrient requirements. Digitonin can
form a complex with sterol, interrupting the uptake of exogenous sterol by Mycoplasma but not
Acholeplasma. Thus growth of Mycoplasma but not Acholeplasma is inhibited by digitonin.
An antimicrobial peptide nisin can also be used to differentiate between Acholeplasma
species and Mycoplasma species. Nisin is produced by Lactococcus lactis and can inhibit growth of most gram-positive and some gram-negative bacteria. Abu-Amero et al. (1996) reported that nisin readily inhibited growth of Acholeplasma species whereas Mycoplasma species were
substantially less affected by nisin. Therefore, they proposed that a nisin disc diffusion assay on
agar plates could be used to distinguish between these two genera.
Mycoplasma species and Acholeplasma species can also be distinguished based on their genotypic characteristics. A duplex-nested PCR method for detection has been reported (Tang et al., 2000). This PCR assay was designed to target 16S-23S rRNA intergenic spacer region (ITS).
Because more than one operon of tRNA genes in the targeted ITS region are usually presented in the genome of Acholeplasmas but not in the genome of Mycoplasmas , more than one size of amplicon are usually detected with Acholeplasmas whereas only one size of amplicon is
presented with Mycoplasmas . As a result Tang et al., (2000) were able to discriminate
Acholeplasma species from other Mycoplasma species using a PCR assay.
57
Discrimination of Acholeplasma species from Mycoplasma species has been practiced using the digitonin and/or the nisin disc diffusion assay, and by PCR methods, for several years.
These are tests that can be commonly employed by veterinary diagnostic laboratories. Yet what is not known is how comparable these tests of mollicute genera and if discrimination between genera by these tests can be made using isolates from mastitic milk representing several different species. A comparison of techniques used to discriminate Mycoplasma species from other
Mollicutes is needed to improve the accuracy of diagnosis of mycoplasma mastitis. The objective of this study was to determine the agreement for genus identification of Mycoplasma species and
Acholeplasma species obtained from the digitonin and nisin disc diffusion assays, and PCR; to the 16S rRNA partial sequence analysis as a gold standard.
MATERIALS AND METHODS
Organisms.
A total of 268 isolates of unknown species from bovine sources, primarily milk samples from cows with mastitis, and presumptively identified as Mycoplasma from isolation on modified Hayflick’s agar (BBL , Franklin Lakes, NJ, USA), were included in the study.
Additionally, 12 reference strains were chosen (Table 1). Filtration-cloning technique was applied to all isolates as described by Tully (1983). In brief, all isolates were subcultured and filtered through 0.45 µm three times to obtain a dominant clone from stock cultures. A single colony of each isolate was punched from the agar plate and grown in PPLO broth (Hardy
Diagnostics, Santa Maria, CA, USA), in a 10 % CO 2, environment for 4 days. Glycerol (30% v/v) was added to cultured broth before storage at -85 °C until use.
58
Digitonin disc diffusion assay.
The digitonin disc diffusion assays were performed as described by Tully (1983).
Digitonin stock solution of 1.5% (w/v) in 95% ethanol was made by adding 75 mg of digitonin
(Sigma-Aldrich, St. Louis, MO, USA) to 5 ml of 95% ethanol and storing at 4 °C. Digitonin
discs were made by adding 25 µl of the stock solution to 6 mm blank paper disc (BD, Sparks,
MD, USA). All digitonin discs were dried overnight at room temperature and stored at 4 °C until
use.
Both unknown and reference mollicutes were cultured in PPLO broth and incubated at
10% CO 2 for 4 days. Then, 200 µl of each culture was spread on modified Hayflick’s agar plate.
Digitonin discs were pressed gently to the surface of the agar after the inoculum had dried. Plates were incubated for 4 – 7 days at 37 °C in a 10 % CO 2 incubator. After incubation, all plates were examined under the stereomicroscope and the zones of inhibition were measured from the edge of the disc to the edge of clear zone of no growth (mm). Positive digitonin tests were considered when the clear zone was >5 mm, negative digitonin tests had zones <3 mm, and all else was considered an ambiguous result.
Nisin disc diffusion assay.
Nisin solution at the concentration of 5.16 mg/ml (ImmuCell Corp., Portland, ME, USA) was used as a stock solution. A ten fold dilution was made from the stock solution. Twenty microliters from the stock solution (N0: 103.2 µg) and the dilution (N-1: 10.32 µg) was added to a separate 6 mm blank paper disc (BD, Sparks, MD, USA). All nisin discs were dried overnight at room temperature and stored at 4 °C until use. Test organisms were cultured and plated as described for the digitonin disc assay. Nisin discs, both N0 and N-1, were applied to the agar
59
plates and incubated for 4 – 7 days at 37 °C in a 10 % CO 2 incubator. After incubation, all plates were examined under the stereomicroscope and measured for the zone of inhibition (mm).
According to the results reported by Abu-Amero et al. (1996), a positive nisin test, was indicated by the presence of a visible growth inhibition zone around the nisin disc. A negative nisin test was indicated by the lack of any inhibition zone.
Genomic DNA extraction for PCR.
Mycoplasma isolates were re-cultured in PPLO broth and incubated at 37 °C in a 10%
CO 2 incubator for 4 days. After incubation, the DNA extraction was performed on all cultures by following instructions for extraction of gram-negative bacterial genomic DNA (Invitrogen,
Carlsbad, CA, USA). Briefly, all cultured isolates were centrifuged at 5000 x g for 25 minutes to sediment mycoplasma cells. The mycoplasma cell pellets were re-suspended with a digestion buffer. Cell lysate was prepared by adding 20 µl of Proteinase K to the re-suspension and incubated at 55 °C for 45 minutes. After incubation, 20 µl of RNase A was added to each cell lysate and incubated at room temperature for 2 minutes. Then, 200 µl of lysis-binding buffer and
200 µl of 96 – 100 % ethanol were added to the cell lysate. The cell lysate was then transferred into a DNA binding column. The cell lysate loaded DNA binding column was centrifuged at
10,000 x g for 1 minute. The DNA binding column was washed twice; first with 500 µl of washing buffer 1 and centrifuged at 10,000 x g for 1 minute, and then with 500 µl of washing buffer 2 and centrifuged at maximum speed for 3 minutes. After washing, the genomic DNA was eluted out by adding 75 µl of elution buffer, and then the tube was centrifuged at maximum speed for 1 minute. All genomic DNA extracts were frozen at -80 °C until used for PCR.
60
Discrimination between Acholeplasma species and Mycoplasma species using conventional
PCR.
A one-step PCR was performed as adapted from Tang et al. (2000). PCR was performed
in a total volume of 50 µL containing 1x PCR buffer (20 mM Tris-HCl, 2 mM MgCl2, and 50
mM KCl; pH 8.4 ), 50 µM of each of deoxynucleoside triphosphates (dNTPs), 20 pmol of each
primer, and 1 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). A set of primers
including F2, R2 and R34 was used to amplify the 16S-23S rRNA intergenic spacer regions of
Mycoplasma and Acholeplasma . Sequences and targets of these primers are shown in Table 2.
Five microliters of DNA extract was used as a template by adding into a 45 µL of reaction
mixture. The thermal cycling protocol was programmed: initial denaturation at 94 °C for 30 s, followed by 35 cycles of denaturation at 94 °C for 30 s, primer annealing at 55 °C for 2 minutes,
and extension at 72 °C for 2 minutes. A final extension was performed at 72 °C for 5 minutes.
The final PCR products were electrophoresed on a 2% agarose gel and DNA bands were
visualized by UV fluorescence. The presence of a single band of PCR product indicated the
presence of Mycoplasma species. The presence of > 1 band of PCR product indicated the
presence of Acholeplasma species.
16S rRNA partial sequencing.
Identifications of all 281 isolates were confirmed using 16S rRNA partial sequencing as a gold standard. A region of approximately 1500 base pairs of the 16S rRNA gene was amplified using a universal primer pair; pH and pA as listed in Table 2 (Stakenborg et al., 2005). The PCR reaction mixture in the total volume of 50 µL included 3 U of Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA), 1x PCR buffer (20 mM Tris-HCl, 1.5 mM MgCl2, and 50 mM KCl; pH
61
8.4), 50 µM of each of dNTPs, 10 pmol of each primer and 1 µL of the genomic DNA as template. The thermal cycling protocol involved initial denaturation at 95 °C for 3 minutes followed by 35 cycles of denaturation at 94 °C for 15 s, primer annealing at 57 °C for 15 s and extension at 72 °C for 2 minutes. A final extension was performed at 72 °C for 5 minutes. The
PCR products were purified according directions (Roche, Indianapolis, IN, USA) and submitted for sequencing using primer pA (Macrogen Corp., Rockville, MD, USA). Nucleotide sequences were compared with GenBank database using the Basic Local Alignment Search Tool (BLAST;
Altschul et al., 1990). A nucleotide sequence was identified as a species giving the highest hit of at least 98% identity from BLAST search.
Statistical analysis.
All isolate assays were replicated. If results of each replicate did not agree, a third assay was performed. The definitive identification of an isolate was then given when results of 2 out of
3 replicates agreed. Genera classification by digitonin disc and nisin disc diffusion assay, and
PCR, were compared with results from 16S rRNA partial sequencing and presented as percentage agreement. For all techniques exact kappa analysis with 95% confident interval (CI) was used as a statistical test of agreement (Stokes et al., 2000) with the gold standard, 16S rRNA partial sequencing technique using PROC FREQ in SAS 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Mycoplasma isolates identified by 16S rRNA partial sequencing.
Two hundred and eighty Mycoplasma isolates from various sources were included in the study, 234 isolates (83.57%) were originally isolated from milk samples and 46 isolates
62
(16.43%) were originally isolated from other organs. In this collection, 278 isolates (99.29%)
were identified as Mycoplasma species based on the results of 16S rRNA partial sequencing.
Two isolates (0.71%) of A. axanthum were identified; one was a reference isolate (ATCC25176) and the other was from an ear swab solution of a dairy cow in Pennsylvania State. The distribution of Mycoplasma and Acholeplasm a isolates was listed in Table 3.
Discrimination between Mycoplasma and Acholeplasma using digitonin disc diffusion assay.
Of 280 isolates, 275 isolates showed zones of growth inhibition (+ and +/-) around the discs, ranging in size from 3 to 20 mm, mean ± SE of 11.07 ± 0.12 mm. An example of positive
results (Mycoplasma species) is shown in Figure 1, and an example of negative results
(Acholeplasma species) is shown in Figure 2. Descriptive statistics of zones of growth inhibition were indicated in Table 4. Zones of inhibition observed from M. bovigenitalium and M. bovis
were the largest with the means ± SE of 14.67 ± 0.70 and 11.85 ± 0.08, respectively. Five
isolates were categorized as negative which included 2 isolates of A. axanthum , 2 isolates of M.
yeatsii and 1 isolate of M. cottewii (Table 4).
All of the M. bovis isolates tested (n=231) had zones of growth inhibition of > 5 mm
threshold. Thus at this threshold M .bovis had 100% agreement with the 16S rRNA partial
sequencing technique. Equivalent agreements with M. bovigenitalium (6/6) and M. agalactiae
(4/4) isolates are also observed. Percentages of agreement for M. calfornicum and M. alkalescens
were only 34.78% (8/23) and 50% (2/4), using the 5 mm threshold (Table 4). The overall
Mycoplasma species agreement of digitonin disc diffusion assay to 16S rRNA partial sequencing
technique was 90.36% (253/280) using the ≥ 5 mm threshold, a significant agreement between
these two tests (P=0.0111) with the kappa of 0.1131 (95% CI: -0.0309, 0.2571).
63
In contrast, when the presence of zones of inhibition ≥ 3 mm was considered to be the threshold for a positive test, accuracy of digitonin disc diffusion assay presented as agreement with 16S rRNA partial sequencing technique was 100% for all Mycoplasma species except M. yeatsii (0%) and M. cottewii (0%) as shown in Table 5. Using the 3 mm threshold the overall agreement of digitonin disc diffusion assay to 16S rRNA partial sequencing technique was
98.93% (277/280) giving a significant agreement between these two tests (P<0.0001) with the kappa of 0.5670 (95% CI: 0.1277, 1.0000) as shown in Table 5.
Discrimination between Mycoplasma and Acholeplasma using nisin disc diffusion assay.
No zones of nisin inhibited growth were seen by any Mycoplasma tested. Both isolates of
A. axanthum had zones of growth inhibition with the nisin disc diffusion assay for both N0 and
N-1 discs. An example of negative results ( Mycoplasma species) was shown in Figure 1, and an
example of positive results ( Acholeplasma species) was shown in Figure 2. Ranges of zones of
inhibition were 3 – 8 mm and 1 – 6 mm for N0 and N-1, respectively. Mean ± SE of zones of inhibition for nisin disc diffusion assay were 5 ± 1.08 mm and 2.5 ± 1.19 mm for N0 and N-1.
Medians of zones of inhibition of nisin disc diffusion assay were 4.5 mm and 1.5 mm for N0 and
N-1. All Mycoplasma and Acholeplasma isolates were correctly identified with the percentage
agreement with 16S rRNA partial sequencing of 100%.
Discrimination between Mycoplasma and Acholeplasma using PCR technique.
The amplicons of all Mycoplasma and Acholeplasma isolates correctly identified each
genus; Mycoplasma always yielded a single amplicon and Acholeplasma yielded 2 amplicons as
64
demonstrated in Figure 3. The PCR test resulted in a 100% agreement with 16S rRNA partial
sequencing.
DISCUSSION
The thrust of the study was to contrast accuracy of Mycoplasma species and
Acholeplasma species identification using the digitonin, nisin disc diffusion, and PCR assays as compared to the gold standard 16S rRNA partial sequencing technique. All isolates tested by nisin test and PCR tests were in perfect agreement (100%) with the gold standard. Results obtained from the digitonin disc diffusion assay, using a threshold either >5 mm or >3 mm for the presence of zone of growth inhibition, showed a significant agreement with the gold standard. Moreover, the discordant results observed from only 9 isolates out of 234 bovine milk isolates (3.85 %). Therefore, the results obtained from the digitonin disc diffusion assay were still reasonably to be used to distinguish between the two genera originally isolated from mastitis cases. These findings indicate that all 3 techniques performed in this study can be used to distinguish Mycoplasma species and Acholeplasma species isolated from bovine origin.
Two hundred and thirty four isolates tested in this study (83.57%) were from milk samples, cows with clinical mastitis. Of these mastitis isolates, 91.88% (215/234), 5.13%
(12/234), and 0.85% (2/234) were M. bovis, M. californicum, and M. bovigenitalium , and only
2.14% (5/234) were identified to be other species. This finding is consistent with other studies done in California that M. bovis is the most prevalent Mycoplasma species, followed by M. californicum and M. bovigenitalium, isolated from samples of clinical mastitis cases (Jasper,
1980) and bulk-tank milk samples (Kirk et al., 1997).
Digitonin disc diffusion assay has been used as a standard method to discriminate
Acholeplasma species from Mycoplasm a species in many laboratories capable of culturing
65
Mollicutes as suggested by Subcommittee on the Taxonomy of Mollicutes (1995). In the current
study, all isolates identified to be M. bovis , M. bovigenitalium and M. agalactiae were accurately distinguished to be Mycoplasma based on the presence of zone of growth inhibition using either
>5 mm or >3 mm as a threshold. Using the zone of growth inhibition threshold of >5 mm as
suggested by Tully (1983), 65.22% (15/23) of M. californicum isolates and 50% (2/4) of M.
alkalescens isolates were misclassified. When the presence of zone of growth inhibition of >3 mm was considered to be the threshold, all mycoplasma isolates originally isolated from milk samples were correctly categorized to be Mycoplasma species. There were only 3 isolates originally isolated from bovine lung tissues; 2 M. yeatsii isolates, and 1 M. cottewii isolate that were slightly sensitive to digitonin (1 mm of zone of growth inhibition) and thus would be misclassified regardless of the threshold of zone of inhibition used. Our results for these 3 isolates differs from another report where the sensitivity to digitonin was greater as measured by zone of growth inhibition of 6 to 11 mm for M. yeatsii and M. cottewii (DaMassa et al., 1994).
It appears that zones of growth inhibition by the digitonin disc diffusion assay vary by species. Larger zones of growth inhibition (mean ± SE) were observed for M. bovigenitalium
(14.67 ± 0.70 mm) and M. bovis (11.85 ± 0.08 mm) compared to M. californicum (5.33 ± 0.19 mm) , M. arginini (3.88 ± 0.30 mm) and M. alkalescens (3.88 ± 0.30 mm). Thurmond et al.
(1989) reported larger zones for M. arginini (12 mm) and M. californicum (9.74 mm) whereas small zones were observed for M. canadense (8.35 mm) and M. alkalescens (7.87 mm). In the
current study the digitonin disc diffusion assay correctly identified Acholeplasma isolates.
However, there were only 2 isolates of A. axanthum tested. There are some studies which
demonstrated some variation of zones of inhibition of Acholeplasma species isolated from
bovine origin. Freundt et al. (1973) and Jurmanová (1975) reported the zones of inhibition of
66
Acholeplasma species to digitonin ranged from 0.5 to 1.5 mm. Thurmond et al. (1996) reported
zones of inhibition among 20 isolates of A. laidlawii ranged from 1-4 mm. More isolates of
Acholeplasma species included in the study would be necessary to investigate variation of zone of inhibition by digitonin.
Abu-Amero et al. (1996) reported that the nisin disc diffusion assay could be used to discriminate between Acholeplasma from Mycoplasma . They tested the sensitivity of nisin to 5
Acholeplasma species and 11 Mycoplasma species. All 5 Acholeplasma species had zones of inhibition whereas all 11 Mycplasma species did not show any zone of inhibition. Findings herein were similar in that growth of all Acholeplasma and no Mycoplasma were inhibited by the nisin discs at two concentration levels. Again, with only 2 Acholeplasma species tested, the ability to evaluate the variation in Acholeplasma responses to an inhibitory substance, nisin, is considerably diminished. Although the two levels of nisin applied to the filter discs, 103.2 µg
(N0) versus 10.32 µg (N-1) yielded equivalent results, the small population of Acholeplasma species tested makes it difficult to draw conclusions on the optimum level of nisin to use.
The PCR also had 100% agreement with the gold standard. The lack of Acholeplasma species isolates to test lessens the ability to truly determine the accuracy of the PCR technique described by Tang et al. (2000). Yet the results reported herein are consistent with previous findings that identified 2 PCR products by Acholeplasma species and one PCR product by all
Mycoplasma species as described (Tang et al., 2000).
In conclusion, this study suggests a high and comparable efficiency of using nisin and digitonin disc diffusion assays and PCR to distinguish Mycoplasma and Acholeplasma species.
Thus the study confirms those of others that all the assays can distinguish between Acholeplasma
species and Mycoplasma species, although the lack of Acholeplasma species tested in the current
67
study limits confidence in accuracy of discrimination. Choosing a technique to use to discriminate between Mycoplasma and Acholeplasma species depends upon the instrumentation requirements, labor, and costs and toxicity of chemicals. Our results indicate that the nisin and digitonin disc diffusion assays, and PCR assay, can be used to confirm that a mollicute presumptively identified as a Mycoplasma species is not Acholeplasma .
ACKNOWLEDGMENTS
We would like to thank ImmuCell Corp. (Portland, ME, USA), especially Dr. Joseph
Crabb, for his kindly supply of nisin. We are grateful to Dorothy Newkirk, and Veerasak
Punyapornwithaya for their excellent assistance.
REFERENCES
Abu-Amero, K.K., Halablab, M.A., Miles, R.J., 1996, Nisin resistance distinguishes
Mycoplasma spp. from Acholeplasma spp. and provides a basis for selective growth
media. Appl Environ Microbiol 62, 3107-3111.
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J., 1990, Basic local alignment
search tool. J Mol Biol 215, 403-410.
Brown, M.B., Gionet, P., Senior, D.F., 1990, Identification of Mycoplasma felis and Mycoplasma
gateae by an immunobinding assay. J Clin Microbiol 28, 1870-1873.
Bushnell, R.B., 1984, Mycoplasma mastitis. Vet Clin North Am Large Anim Pract 6, 301-312.
Counter, D.E., 1978, A severe outbreak of bovine mastitis asssociated with Mycoplasma
bovigenitalium and Acholeplasma laidlawii . Vet Rec 103, 130-131.
68
DaMassa, A.J., Tully, J.G., Rose, D.L., Pitcher, D., Leach, R.H., Cottew, G.S., 1994,
Mycoplasma auris sp. nov. , Mycoplasma cottewii sp. nov. , and Mycoplasma yeatsii sp.
nov. , new sterol-requiring Mollicutes from the external ear canals of goats. Int J Syst
Bacteriol 44, 479-484.
Delves-Broughton, J., 1990, Nisin and its uses as a food preservative. Food Technol 44, 100-117.
Fox, L.K., Kirk, J.H., Britten, A., 2005, Mycoplasma mastitis: a review of transmission and
control. J Vet Med B Infect Dis Vet Public Health 52, 153-160.
Freundt, E.A., Andrews, B.E., Erno, H., Kunze, M., Black, F.T., 1973, The sensitivity of
mycoplasmatales to sodium-polyanethol-sulfonate and digitonin. Zentralbl Bakteriol Orig
A 225, 104-112.
Gonzalez, R.N., Wilson, D.J., 2003, Mycoplasmal mastitis in dairy herds. Vet Clin North Am
Food Anim Pract 19, 199-221.
Hogan, J.S., Gonzalez, R.N., Harmon, R.J., Nickerson, S.C., Oliver, S.P. Pankey, J.W., Smith,
K.L., 1999, Laboratory handbook on bovine mastitis. National Mastitis Council, Inc,
Wisconsin, pp. 151-188.
International Committee on Systematic Bacteriology Subcommittee on the Taxonomy
of Mollicutes , 1995, Minimum Standards for Description of New Species of the Class
Mollicutes (Division Tenericutes). Int J Syst Bacteriol 45, 605-612.
Jasper, D.E., 1980, Prevalence of mycoplasma mastitis in the Western states. Calif.
Vet 4, 24-26.
Jasper, D.E., 1981, Bovine mycoplasmal mastitis. Adv Vet Sci Comp Med 25, 121-157.
Jasper, D.E., 1982, The role of Mycoplasma in bovine mastitis. J Am Vet Med Assoc 181, 158-
162.
69
Jurmanová, K., 1975, A contribution to tentative identification of bovine mycoplasmas. Zbl Vet
Med B 22, 529-534.
Kirk, J.H., Glenn, K., Ruiz, L., Smith, E., 1997, Epidemiologic analysis of Mycoplasma spp
isolated from bulk-tank milk samples obtained from dairy herds that were members of a
milk cooperative. J Am Vet Med Assoc 211, 1036-1038.
Liehmann, L., Degasperi, B., Spergser, J., Niebauer, G.W., 2006, Mycoplasma felis arthritis in
two cats. J Small Anim Pract 47, 476-479.
McElhaney, R.N., 1983, Section D4 Manipulation of membrane lipid composition, In: Tully,
J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press, New York, pp.
235-239.
Pan, I.J., Ogata, M., 1969, New sero-types of Mycoplasma laidlawii isolated from mastitic milk
and urogenital tracts of cattle. II. Typing of M. laidlawii by biological and serological
methods. Nippon Juigaku Zasshi 31, 313-324.
Pfützner, H., Baumgärtner, B., Wehnert, C., 1986, The control of mycoplasma infections in
cattle. Monatshefte für Veterinärmedizin 41, 577-579.
Saito, Y., Silvius, J.R., McElhaney, R.N., 1978, Membrane lipid biosynthesis in Acholeplasma
laidlawii b: elongation of medium- and long-chain exogenous fatty acids in growing
cells. J Bacteriol 133, 66-74.
Stakenborg, T., Vicca, J., Butaye, P., Maes, D., De Baere, T., Verhelst, R., Peeters, J., de Kruif,
A., Haesebrouck, F., Vaneechoutte, M., 2005, Evaluation of amplified rDNA restriction
analysis (ARDRA) for the identification of Mycoplasma species . BMC Infect Dis 5, 46.
70
Stokes, M.E., Charles, S. D., Gary, G.K., 2000, Chapter 5: the s x r table, In: Stokes, M.E.,
Charles, S. D., Gary, G.K. (Eds.) Categorical data analysis using the SAS ® System,
Second Edition. SAS Institute Inc., North Carolina, pp. 112-116.
Taylor, T.M., Davidson, P.M., Zhong, Q., 2007, Extraction of nisin from a 2.5% commercial
nisin product using methanol and ethanol solutions. J Food Prot 70, 1272-1276.
Tang, J., Hu, M., Lee, S., Roblin, R., 2000, A polymerase chain reaction based method for
detecting Mycoplasma/Acholeplasma contaminants in cell culture. J Microbiol Methods
39, 121-126.
Thurmond, M.C., Holmberg, C.A., Luiz, D.M., 1989, Evaluation of a digitonin disk assay to
discriminate between acholeplasma and mycoplasma isolates from bovine milk. Cornell
Vet 79, 71-81.
Tully, J.G., 1983, Section E5 Tests for digitonin sensitivity and sterol requirement, In:
Tully, J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press,
New York, pp. 355-362.
71
TABLES
TABLE 1. Sources of reference strains of Mycoplasma species and Acholeplasma species
Organisms Origin of isolates Source
M. bovis Bovine mastitic milk ATCC a 25025
M. bovis Bovine mastitic milk ATCC 25523
M. bovis Bovine mastitic milk Cornell University 22253
M. californicum Bovine mastitic milk ATCC 33461
M. bovigenitalium Bovine genital tract ATCC 14173
M. alkalescens Bovine nasal cavity ATCC 29103
M. alkalescens Bovine mastitic milk Cornell University 21146
M. agalactiae Mastitic goat milk ATCC 35890
M. arginini Lung of sheep with pneumonia ATCC 23243
M. bovirhinis Bovine respiratory tract ATCC 27748
M. leachii sp. nov Arthritic joint of a calf IOM b Mollicutes Collection; N29 Leach
strains
A. axanthum Murine leukemia tissue culture ATCC 25176
a American Type Culture Collection, Manassas, VA, USA.
b International Organization of Mycoplasmology, West Lafayette, IN, USA.
72
TABLE 2. Sequences of primers and targeted regions
Primers Sequences Targets
F2 5’-GTG(C/G)GG(A/C)TGGATCACCTCCT-3’ 16S-23 S rRNA intergenic spacer
R2 5’-GCATCCACCA(A/T)A(A/T)AC(C/T)CTT-3’ region of Mycoplasma species
R34 5’-CCACTGTGTGCCCTTTGTTCCT-3’ 16S-23 S rRNA intergenic spacer
region of Acholeplasma species
pA 5’-AGAGTTTGATCCTGGCTCAG-3’ 16S rRNA gene
pH 5’-AAGGAGGTGATCCAGCCGCA-3’
73
TABLE 3. Distribution of isolates of Mycoplasma species and Acholeplasma species as identified by 16S rRNA partial sequencing
Species identification from Total number of isolates
16S rRNA partial sequencing (number of reference strains)
M. bovis 231 (2)
M. californicum 23 (1)
M. bovigenitalium 6 (1)
A. axanthum 2 (1)
M. alkalescens 4 (2)
M. arginini 4 (1)
M. yeatsii 2
M. cottewii 1
M. bovirhinis 1 (1)
M. felis 1
M. leachii (Bovine serogr.7) 1 (1)
M. agalactiae 4 (1)
Total 280
74
TABLE 4. Descriptive statistics of zone of growth inhibition (mm) observed with the digitonin disc diffusion assay
Species Min Max Median Mean ± SE
M. bovis 6 20 12 11.85 ± 0.08
M. californicum 3 8 5 5.33 ± 0.19
M. bovigenitalium 11 19 14.5 14.67 ± 0.70
M. alkalescens 3 14 7.5 7.75 ± 0.91
M. agalactiae 6 11 9 9.13 ± 0.52
M. arginini 3 5 4 3.88 ± 0.30
M. bovirhinis 3 4 3.5 3.5 ± 0.50
M. felis 4 5 4.5 4.5 ± 0.50
M. leachii 4 4 4 4 ± 0.00
M. yeatsii 0 1 1 0.75 ± 0.25
M. cottewii 1 1 1 1 ± 0.00
A. axanthum 0 0 0 0
75
TABLE 5. Agreement of genera determination by digitonin disc diffusion assay with 16S rRNA
partial sequencing
Species Agreement with 16S rRNA partial sequencing technique (%)
Zone of growth inhibition >5 Zone of growth inhibition >3
mm a mm a
M. bovis 100% (231/231) 100% (231/231)
M. californicum 34.78% (8/23) 100% (23/23)
M. bovigenitalium 100% (6/6) 100% (6/6)
M. alkalescens 50% (2/4) 100% (4/4)
M. agalactiae 100%(4/4) 100%(4/4)
M. arginini 0%(0/4) 100%(4/4)
M. bovirhinis 0%(0/1) 100%(1/1)
M. felis 0%(0/1) 100%(1/1)
M. leachii 0%(0/1) 100%(1/1)
M. yeatsii 0%(0/2) 0%(0/2)
M. cottewii 0%(0/1) 0%(0/1)
A. axanthum 100%(0/2) 100%(0/2)
Total 90.36% (253/280) 98.93% (277/280)
aZones of growth inhibition thresholds tested at >5 mm and >3 mm to signify Mycoplasma species.
76
FIGURES
N0 disc N-1 disc
digitonin disc
FIGURE 1. Example plate of Mycoplasma species with a zone of inhibition only presented
around digitonin disc
77
N0 disc N-1 disc
digitonin disc
FIGURE 2. Example plate of Acholeplasma species with a zone of inhibition only presented
around nisin discs with both 103.2 µg (N0) and 10.32 µg (N-1)
78
1 2 3 4 5 6 7 8 9 10 11
FIGURE 3. Electrophoretic gel of amplicons of some reference strains of Mycoplasma species
and Acholeplasma species. Lane 1 and 11: 100 bp molecular ladder, lane 2: M. bovis ATCC
25025, lane 3: M. bovis ATCC 25523, lane 4: M. californicum ATCC 33461, lane 5: M.
bovigenitalium ATCC 14173, lane 6: M. alkalescens ATCC 29103, lane 7: M. bovirhinis ATCC
27748, lane 8: M. agalactiae ATCC 35890, lane 9: M. arginini ATCC 23243, lane 10: A. axanthum ATCC 25176
79
CHAPTER 5
Identification of Mycoplasma species using novel real-time PCR assays and PCR-RFLP
technique
INTRODUCTION
Mycoplasma species were first recognized as a cause of contagious mastitis in dairy cattle in the United States in 1961 (Hale et al, 1962). Since then, mycoplasma mastitis has been reported throughout the country and many regions of the world (Fox et al, 2005). M. bovis is the most common species to be associated with bovine mastitis, with perhaps as many as 49% to
60% of all mycoplasma mastitis isolates have been speciated as M. bovis (Jasper, 1979; Kirk et
al., 1997). Although less common, M. californicum and M. bovigenitalium have been frequently
reported to be associated with mastitis in dairy cows in many regions through out the world
(Jasper, 1982; Mackie et al., 1986; Jurmanová et al., 1983; Infante-Martínez et al., 1999; Kirk et
al., 1997; Hirose et al., 2001) and are perhaps the next two most prevalent species causing
mycoplasma mastitis.
The slow growth and fastidious nutritional requirements of Mycoplasma species in vitro
are an impediment to identification of this genus in the laboratory. Applications of highly
specific and sensitive polymerase chain reaction (PCR) techniques have been used to overcome
this problem. Nested PCR followed by restricted fragment length polymorphism (RFLP) has
been used to identify isolates of suspected Mycoplasma species (Tang et al., 2000). Even though
this technique seems to be promising for identification of Mycoplasma species directly from
biological samples, it requires 2 steps of PCR and a long period of incubation for enzyme
digestion, requiring approximately 18 to 30 hours to complete the diagnosis.
80
Application of real-time PCR techniques can overcome the difficulties associated with
the culture of Mycoplasma species in vitro and the length of time need to speciate by
conventional PCR. Real-time PCR methods have been used for more than a decade (Heid et al.,
1996) and facilitate the screening of large numbers of samples within a few hours with an
excellent sensitivity and specificity. Fluorescence detection of specific PCR products and
accumulation of this signal for each PCR cycle in a real-time basis allow quantitation of template
DNA (Leutenegger, 2001). Utilizing fluorgenic probes (TaqMan ) make the real-time PCR assay to be highly specific to detect the pathogen because only a specific target sequence in amplicons is recognized.
This study was proposed to develop 3 novel real-time PCR assays detecting 3 most common mycoplasma mastitis agents including M. bovis , M. californicum and M.
bovigenitalium . To validate these newly developed real-time PCR assays, the conventional PCR
described by Tang et al. (2000) was also performed with the same samples and results were
compared using 16S rRNA gene partial sequencing as a gold standard.
MATERIALS AND METHODS
Organisms.
A total of 268 isolates of unknown species from bovine sources, primarily milk samples
from cows with mastitis, and presumptively identified as Mycoplasma from isolation on
modified Hayflick’s agar, were included in the study. Additionally, 12 reference strains were
chosen (Table 1). Filtration-cloning technique was applied to all isolates as described by Tully
(1983). In brief, all isolates were subcultured and filtered through 0.45 µm three times to obtain a
dominant clone from stock cultures. A single colony of each isolate was punched from the agar
81
plate and grown in pleuropneumonia-like-organism (PPLO) broth (BBL , Franklin Lakes, NJ,
USA), in a 10 % CO 2 environment for 4 days. Glycerol (30% v/v) was added to cultured broth
before storage at -85 °C until use.
Primers and probes design for M. bovis, M. californicum and M. bovigenitalium .
Primer and probe design was performed using the Qiagen online tool
(http://www1.qiagen.com/products/pcr/quantitect/customassays.aspx ). Three different house
keeping genes; fusA, rpoB , and 16S-23S rRNA intergenic spacer region (ITS) were selected for
M. bovis , M. californicum and M. bovigenitalium , respectively. The fusA gene encodes for elongation factor G. The rpoB encodes for RNA polymerase beta subunit. The ITS encodes for a short region between the 16S and 23S subunits of ribosomal RNA. Primers and probes were tested for interactions using the online Oligo Analysis tool ( http://www.operon.com/technical/
toolkit.aspx ). The oligonucleotide sequences were tested for their specificity by searching against
GenBank database using the Basic Local Alignment Search Tool (BLAST; Altschul et al., 1990).
All primers and probes were found to be specific for the target genes of the target species with no
cross-matching with other bovine Mycoplasma species . The sequences of primers and probes were shown in Table 2.
Quantitative testing of the real-time PCR assays.
Real-time PCR results were given in terms of the cycle threshold (C T) which is defined as
the fractional cycle number at which the fluorescence passes the fixed threshold. To establish the
quantitative ability of each real-time PCR assay, a plot of the initial amount of DNA for a set of
standards versus C T or a standard curve was generated. Target sequences in fusA , rpoB , and ITS
82
genes were cloned into pIDTSMART-AMP plasmids (Integrated DNA technologies, Coralville,
IA, USA) and used to create standard curves for M.bovis , M. californicum and M. bovigenitalium real-time PCR assays, respectively. A standard curve with 6 dilutions containing 6 copy numbers of targeted DNA: 10 5, 10 4, 10 3, 10 2, 10 and 1 copy; was generated for each species as shown in
Figures 3-5. Quantitation of the amount of target in unknown samples was accomplished by
measuring C T and using the standard curve to determine starting amount of DNA.
Genomic DNA extraction for PCR.
Mycoplasma isolates were re-cultured in PPLO broth and incubated at 37 °C in a 10%
CO 2 incubator for 4 days. After incubation, the DNA extraction was performed on all cultures by
following instructions for extraction of gram-negative bacterial genomic DNA (Invitrogen,
Carlsbad, CA, USA). Briefly, all cultured isolates were centrifuged at 5000 x g for 25 minutes to
sediment mycoplasma cells. The mycoplasma cell pellets were re-suspended with a digestion
buffer. Cell lysate was prepared by adding 20 µl of Proteinase K to the re-suspension and
incubated at 55 °C for 45 minutes. After incubation, 20 µl of RNase A was added to each cell
lysate and incubated at room temperature for 2 minutes. Then, 200 µl of lysis-binding buffer and
200 µl of 96 – 100 % ethanol were added to the cell lysate. The cell lysate was then transferred
into a DNA binding column. The cell lysate loaded DNA binding column was centrifuged at
10,000 x g for 1 minute. The DNA binding column was washed twice; first with 500 µl of
washing buffer 1 and centrifuged at 10,000 x g for 1 minute, and then with 500 µl of washing
buffer 2 and centrifuged at maximum speed for 3 minutes. After washing, the genomic DNA was
eluted out by adding 75 µl of elution buffer, and then the tube was centrifuged at maximum
speed for 1 minute. All genomic DNA extracts were frozen at -80 °C until used for PCR.
83
For other gram positive bacteria, genomic DNA was extracted according to the protocol
described by Pitcher et al. (1989). Briefly, DNA was extracted from a cell pellet after overnight
culture. Cell pellet was reconstituted in Tris-EDTA (TE) buffer. Five microliter of lysostaphin
and 100 µl of lysozyme was added to the reconstituted cell pellet, and then incubated at 37 °C for
2 hours. After incubation, 500 µl of lysis buffer and 250 µl of ammonium acetate was added, and then set on ice for 10 minutes. An equal volume of chloroform in isoamyl alcohol was added to the tube, and then centrifuged at 13,000 x g for 15 minutes. The upper aqueous phase containing
DNA was collected and transferred into a new tube. An equal volume of chloroform in isoamyl alcohol was added, and then centrifuged again at 13,000 x g for 15 minutes. The upper aqueous phase was collected and transferred into a new tube. Isopropanol was added at the volume of
0.56x of the volume of the upper aqueous phase liquid collected, and then set at -20 °C for 2
hours. The tube was centrifuged at 13,000 x g for 5 minutes, and supernatant was then removed.
Five repeats of DNA washing were performed by adding 1 ml of absolute ethanol and
centrifuged at 13,000 x g for 5 minutes. The DNA pellet was air-dried. After completely dried,
50 µl of sterile distilled water was added to dissolve the DNA and frozen at -85 °C until use.
Real-time PCR.
The PCR reaction was initiated by combining 5 µL of the extracted DNA with 12.5 µL of
2x Master Mix, 10 pmol of each primer and 5 pmol of probe according to the Qiagen Quantitect
Probe PCR kit’s manual (Qiagen, Valencia, CA, USA). The amplification and detection was
performed on Step One Plus ® (Applied Biosystems, Foster City, CA, USA) real-time PCR
instrument. The thermal cycling protocols which were identical for all 3 assays included 15
minutes of pre-denaturation at 95 °C and 45 cycles of 15 seconds of denaturation at 94 °C and 60
84
seconds of annealing at 60 °C. Each reaction was classified as positive or negative for a target based on obtaining a C T below or above 37, respectively (Bustin, 2004).
PCR-RFLP.
A one-step PCR followed by RFLP was performed as adapted from Tang et al. (2000).
PCR was performed in a total volume of 50 µL containing 1x PCR buffer (20 mM Tris-HCl, 2 mM MgCl2, and 50 mM KCl; pH 8.4 ), 50 µM of each of deoxynucleoside triphosphates
(dNTPs), 20 pmol of each primer, and 1 U Taq DNA polymerase (Invitrogen, Carlsbad, CA,
USA). A set of primers including F2, R2 and R34 was used to amplify the 16S and 23S rRNA intergenic spacer regions of Mycoplasma and Acholeplasma . Sequences and targets of these primers are shown in Table 2. Five microliters of DNA extract was used as a template by adding into a 45 µL of reaction mixture. The thermal cycling protocol was programmed: initial denaturation at 94 °C for 30 seconds, followed by 35 cycles of denaturation at 94 °C for 30 seconds, primer annealing at 55 °C for 2 minutes, and extension at 72 °C for 2 minutes. A final extension was performed at 72 °C for 5 minutes. The final PCR products were electrophoresed on a 2% agarose gel and DNA bands were visualized by UV fluorescence. After performing
PCR, all PCR products were digested by a restriction enzyme, ASE1. The digested PCR products were electrophoresed on a 2% agarose gel and patterns of DNA fragments were visualized by
UV fluorescence. Identification of M. bovis , M. californicum , M. bovigenitalium and other species was given to each isolate by comparing the patterns of DNA fragments to the patterns observed with the reference strains of M. bovis , M. californicum , and M. bovigenitalium .
85
16S rRNA partial sequencing.
Identifications of all 280 isolates were confirmed using 16S rRNA partial sequencing as a gold standard. A region of approximately 1500 base pairs of the 16S rRNA gene was amplified using a universal primer pair; pH and pA as listed in Table 2 (Stakenborg et al., 2005). The PCR reaction mixture in the total volume of 50 µL included 3 U of Taq DNA polymerase (Invitrogen,
Carlsbad, CA, USA), 1x PCR buffer (20 mM Tris-HCl, 1.5 mM MgCl 2, and 50 mM KCl; pH
8.4), 50 µM of each of dNTPs, 10 pmol of each primer and 1 µL of the genomic DNA as template. The thermal cycling protocol involved initial denaturation at 95 °C for 3 minutes followed by 35 cycles of denaturation at 94 °C for 15 seconds, primer annealing at 57 °C for 15 seconds and extension at 72 °C for 2 minutes. A final extension was performed at 72 °C for 5 minutes. The PCR products were purified according directions (Roche, Indianapolis, IN, USA) and submitted for sequencing using primer pA (Macrogen Corp, Rockville, MD, USA).
Nucleotide sequences were compared with GenBank database using the Basic Local Alignment
Search Tool (BLAST; Altschul et al., 1990). A nucleotide sequence was identified as a species giving the highest hit of at least 98% identity from BLAST search.
Statistical analysis.
All isolate assays were replicated. If results of each replicate did not agree, a third replicate was performed. Therefore, a definitive identification by real-time PCR was given to a sample when a consistent presence of C T <37 for an assay was observed in two different replicates. For PCR-RFLP, a definitive identification of an isolate was given when the similar
DNA fragment pattern was observed. For both techniques exact kappa analysis with 95% confident interval (CI) was used as a statistical test of agreement (Stokes et al., 2000) with the
86
gold standard, 16S rRNA partial sequencing technique using PROC FREQ in SAS 9.2 (SAS
Institute, Cary, NC, USA).
RESULTS
Mycoplasma isolates identified by 16S rRNA partial sequencing.
Two hundred and eighty Mycoplasma isolates from various sources were included in the
study, 234 isolates (83.57%) were originally isolated from milk samples and 46 isolates
(16.43%) were from other organs. In this collection, 278 isolates (99.29%) were identified as
Mycoplasma species based on the results of 16S rRNA partial sequencing. Two isolates (0.71%) of A. axanthum were identified; one was a reference isolate (ATCC25176) and the other was from an ear swab solution of a dairy cow in Pennsylvania State. The distribution of Mycoplasma and Acholeplasm a isolates was listed in Table 3.
Identification of M. bovis , M. californicum , and M. bovigenitalium using PCR-RFLP.
The patterns of amplicons before and after digestion by ASE1 of M. bovis , M.
californicum and M. bovigenitalium were illustrated in Figure 1. The sizes of digested amplicon
for M. bovis were 140, 125 and 115 bp and for M. bovigenitalium were 265 and 115 bp.
Amplicon of M. californicum (370 bp) was not cut by ASE1. All M.bovis isolates (231/231) and
all M. californicum isolates (23/23) were correctly identified compared with the identification by
16S rRNA partial sequencing as the gold standard; perfect agreement (100%) for both species as
shown in Table 1. Four of 6 M. bovigenitalium isolates were identified correctly, 66% agreement
with the gold standard (Table 1). Amplicons of two M. bovigenitalium isolates were not digested
by ASE1 resulting in an electrophoretic pattern similar to those of M. californicum isolates as
87
shown in Figure 2, lanes 2 and 4. These 2 isolates that the gold standard identified as M. bovigenitalium were misidentified by PCR-RFLP and thus would be considered as M. bovigenitalium false negative results. Since these isolates were identified as M. californicum by
PCR-RFLP, they would be considered as false positive M. californicum results. Based on the miss-interpretation of those two M. bovigenitalium isolates, agreement analyses for identification of M. bovigenitalium (kappa = 0.7965, 95% CI: 0.5214, 1.0000, P <0.0001) and M. californicum
(kappa = 0.9544, 95% CI: 0.8916, 1.0000, P <0.0001) using PCR-RFLP were statistically significant.
Test specificity and detection limit of novel real-time PCR assays
Genomic DNA of 15 eubacterial species and 13 representative Mollicutes were tested to define the specificity of detection (Table 4). All M. bovis , M. californicum and M. bovigenitalium strains produced the expected amplification signal, and a log-linear dependence of CT value on mycoplasma copy number with the specific real-time PCR assay was observed
(Figures 3-5). No specific products from other Mycoplasma species and eubacterial species were detected by real-time PCR, and cross-reactivity was not observed with related ruminant
Mycoplasmas , such as M. agalactiae , M. bovirhinis , M. arginini , M. alkalescens , M. ovipneumonia and M. leachii .
To determine detection limits of the novel real-time PCR assays, the pIDTSMART-AMP plasmids cloned with target sequences of each real-time PCR assay were used as template DNA.
The detection limit of all 3 assays with the plasmids was as low as 1-10 copies of targeted DNA
(Figures 3-5). A C T of 37 is the detection limit of 1 copy of M. californicum, and approximately
10 copies of M. bovis and M. bovigenitalium.
88
Identification of M. bovis , M. californicum , and M. bovigenitalium using novel real-time
PCR assays.
All M.bovis (231/231), M. californicum (23/23), and M. bovigenitalium (6/6) isolates were correctly identified compared to the identification by 16S rRNA partial sequencing being a gold standard, giving a perfect agreement (100%) for all 3 species as shown in Table 1.
However, there were 4 isolates which were identified by the gold standard as M. bovis. These isolates by real-time PCR had CT values below the threshold (C T <37) with M. californicum assay. To investigate the possibility of cross amplification, targeted region for M. californicum assay was amplified for those 4 isolates using primers used with real-time PCR assay for M. californicum . Amplicons obtained from those 4 isolates were sequenced and searched for similarity against GenBank data base. All 4 amplicons were 100% matched with the target sequence of M. californicum suggesting that truly both M. bovis and M. californicum were presented and that 16S rRNA sequence analysis did not detect M. californicum . Assuming that the gold standard was infallible, and these 4 samples contained M. bovis only, then the exact kappa analysis of M. californicum real-time PCR assay indicated a significant agreement with the gold standard (kappa = 0.9122, 95% CI: 0.8271, 0.9973, P<0.0001).
DISCUSSIONS
The goal of the study was to develop real-time PCR assays to detect the 3 most common mycoplasma mastitis agents: M. bovis , M. californicum , and M. bovigenitalium . All 3 assays correctly detected the specific target regions selected without cross amplification with other
Mycoplasma species or other bacteria. Several real-time PCR assays have been reported to detect
M. bovis in many kinds of biological samples. Cai et al. (2005) successfully developed a real-
89
time PCR assay using fluorescence resonance energy transfer (FRET) probes to detect M. bovis
in milk and lung samples. Their system targeted a region in 16S rRNA gene which gave positive
results with both M. bovis and M. agalactiae . To distinguish between these species they
measured the melting temperature of probes. The detection limits they reported were 550
CFU/ml of milk (Cai et al., 2005). Sachse et al. (2009) reported a novel real-time PCR assay
detecting M. bovis from nasal and conjunctival swabs and from milk samples. This real-time
PCR assay targeted the 3’-terminal region of the oppD gene encoding for an oligopeptide permease and member of the ABC-transporter family. Sachse et al. (2009) reported the detection limit of their assay to be 100 CFU/ml of milk. Recently, Rossetti et al. (2010) developed a new real-time PCR assay to detect M. bovis from milk lysate. Their assay targeted a region in uvrC gene encoding for a part of exinuclease. The detection limit they reported was 2,000 CFU/ml of milk (Rossetti et al., 2010). Our newly developed real-time PCR assay targeted fusA gene
encoding for elongation factor G of M. bovis . The real-time PCR assays detecting M. bovis
targeting oppD (Sachse et al., 2009), uvrC (Rossetti et al., 2010) and fusA have the advantages
that they appear to be free of cross-amplification with DNA template of M. agalactiae .
The current study is a first reporting successful development of real-time PCR assays to detect M. californicum and M. bovigenitalium . Both M. californicum and M. bovigenitalium have been reported to be associated with mastitis in the United States and other countries (Jasper,
1981; Jurmanova et al., 1983; Mackie et al., 1986; Osman et al., 2008). Even though the severity of the disease caused by both species seems to be less compared with the disease caused by M. bovis , they are also characterized by their ability to transmit from cow-to-cow (Jasper, 1981).
Therefore, these newly developed real-time PCR assays enhance the opportunity to detect not only M. bovis , but other common mycoplasma mastitis agents. A number of techniques have
90
been developed to detect Mycoplasma species, primarily for detection of cell culture
contamination (Hay et al., 1989; Harasawa et al., 1993). We have applied a PCR-RFLP
technique (Tang et al., 2000) to speciate Mycoplasma species in our laboratory. This technique
was developed to detect cell culture contamination and has never been tested with Mycoplasma
strains found in cattle. Excellent agreement of PCR-RFLP identificiation of M. bovis and M.
californicum isolated from milk with 16S rRNA partial sequencing was found. The PCR-RFLP
failed to correctly identify 2 M. bovigenitalium isolates; one was originally from a vaginal swab and another one was originally from mastitic milk.
In this study a cut-off value of C T<37 was used to discriminate between a positive detection as opposed to no detection of an isolate using the real-time PCR assay. This cut-off value gave a detection limit for the M. californicum assay of 1 copy of target DNA (Figure 5) whereas the detection limits for M. bovis and M. bovigenitalium assays were approximately 10 copies of target DNA (Figures 3 and 4). The choice of a cut-off value of C T<37 is consistent with that used by Bustin (2004) who suggested the use of C T<37 value to guard against a false positive result due to a technical errors as noted by weak signals present in negative controls
(Bustin, 2004). Using this cut-off value of C T<37, four M. bovis isolates that were thought to be of a single species after filter cloning were identified as positive with both M. bovis and M. californicum . Those isolates were later confirmed to have both M. bovis and M. californicum.
Thus, the specificity using this cut-off value was still excellent although 4 false positive results
based on comparisons to the gold standard; 16S rRNA partial sequencing, were observed.
Because 16S rRNA partial sequencing assay is a qualitative PCR-based technique, only one
dominant species presented in a sample can be detected. Real-time PCR assays can detect and
quantify very low amounts of DNA template in a sample. Therefore real-time PCR assays can
91
detect more than one species even though those species may be presented in a very low amount in a sample. For this reason, the novel real-time PCR assays may be more superior compared to other conventional nucleic acid detection techniques used to identify mixed infection samples.
These novel real-time PCR assays were developed to overcome the difficulties of the diagnosis of mycoplasma mastitis using the in vitro culture technique. The developed real-time
PCR assays have the potential to be more rapid compared with the standard culture technique if the assays could be applied directly to milk samples. Currently speciation using the developed real-time PCR is made from isolates previously cultured and presumptively identified. Yet the use of primers and probes that are specific and that have excellent agreement with the gold standard tests for the two most prevalent mycoplasma mastitis species indicates that the procedure has potential to be developed into a routine mastitis diagnostic technique. Further development of the real-time PCR assays, combining all three in a single multiplex real test that can be used directly with milk samples should be attempted.
ACKNOWLEDGMENTS
We are grateful to Dorothy Newkirk, Daniel Righter and Veerasak Punyapornwithaya for their excellent assistance. We would like to thank Dr. Ziv Raviv and Dr. Amy Wetzel from the
Ohio State University for their cooperation. This study was partially granted by 2009 Graduate
Student and House Officer Research Awards, College of Veterinary Medicine, Washington State
University.
92
REFERENCES
Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J., 1990, Basic local alignment
search tool. J Mol Biol 215, 403-410.
Bustin, S.A., 2004, Quantification of nucleic acids by PCR, In: Bustin, S.A. (Ed.) An A-Z of
quantitative PCR. IUL Press, California, pp. 3-29.
Cai, H.Y., Bell-Rogers, P., Parker, L., Prescott, J.F., 2005, Development of a real-time PCR for
detection of Mycoplasma bovis in bovine milk and lung samples. J Vet Diagn Invest 17,
537-545.
Fox, L.K., Kirk, J.H., Britten, A., 2005, Mycoplasma mastitis: a review of transmission and
control. J Vet Med B Infect Dis Vet Public Health 52, 153-160.
Hale, H.H., Helmboldt, C.F., Plastridge, W.N., Stula, E.F., 1962, Bovine mastitis caused by a
Mycoplasma species. Cornell Vet 52, 582-591.
Harasawa, R., Mizusawa, H., Nozawa, K., Nakagawa, T., Asada, K., Kato, I., 1993, Detection
and tentative identification of dominant mycoplasma species in cell cultures by restriction
analysis of the 16S-23S rRNA intergenic spacer regions. Res Microbiol 144, 489-493.
Hay, R.J., Macy, M.L., Chen, T.R., 1989, Mycoplasma infection of cultured cells. Nature 339,
487-488.
Heid, C.A., Stevens, J., Livak, K.J., Williams, P.M., 1996, Real-time quantitative PCR. Genome
Res 6, 986-994.
Hirose, K, Kawasaki, H, Kotani, K, Tanaka, A., Abiko, K., Ogawa, H., 2001,
Detection of Mycoplasma in mastitic milk by PCR analysis and culture
method. J Vet Med Sci 63, 691-693.
Infante, M. F., Aguado S. J., Jasper, D.E., 1999, Mastitis outbreak due to Mycoplasma
93
californicum and Mycoplasma canadense in a commercial dairy herd in the
state of Jalisco, México. Rev Lat-Amer Microbiol 41, 117-120.
Jasper, D.E., 1979, Bovine mycoplasmal mastitis. J Am Vet Med Assoc 175, 1072-1074.
Jasper, D.E., 1981, Bovine mycoplasmal mastitis. Adv Vet Sci Comp Med 25, 121-157.
Jasper, D.E., 1982, The role of Mycoplasma in bovine mastitis. J Am Vet Med Assoc 181, 158-
162.
Jurmanová, K., Hájková, M., Védova, J., 1983, Further evidence of the involvement of
Mycoplasma californicum in bovine mastitis in Europe. Vet Rec 112, 608.
Kirk, J.H., Glenn, K., Ruiz, L., Smith, K., 1997, Epidemiologic analysis of Mycoplasma spp
isolated from bulk-tank milk samples obrained from dairy herds that were members of
milk cooperative. J Am Vet Med Assoc 211, 1036-1038.
Leutenegger, C.M., 2001, The real-time TaqMan PCR and applications in veterinary medicine.
Vet Sci Tomorrow 1, 1-15.
Mackie, D.P., Ball, H.J., Logan, E.F., 1986, Mycoplasma californicum mastitis in the dry dairy
cow. Vet Rec 119, 350-351.
Osman, K.M., Abd El-Razik, K.A., Barbar, E.E., ELShafey, D.Y.H., Arafa, A.A., 2008,
Molecular typing of Mycoplasma species recovered from bovine mastitis. Global
Veterinaria 2, 360-368.
Pitcher, D.G., Saunders, N.A., Owen, R.J., 1989, Rapid extraction of bacterial genomic DNA
with guanidine thiocyanate. Lett Appl Microbiol 8, 151-156.
Rossetti, B.C., Frey, J., Pilo, P., (in press) 2010, Direct detection of Mycoplasma bovis in milk
and tissue samples by real-time PCR. Mol Cell Probes.
94
Sachse, K., Salam, H.S.H., Diller, R., Schubert, E., Hoffmann, B., Hotzel, H., (in press) 2009,
Use of a novel real-time PCR technique to monitor and quantitate Mycoplasma bo vis
infection in cattle herds with mastitis and respiratory disease. The Veterinary Journal.
Stakenborg, T., Vicca, J., Butaye, P., Maes, D., De Baere, T., Verhelst, R., Peeters, J., de Kruif,
A., Haesebrouck, F., Vaneechoutte, M., 2005, Evaluation of amplified rDNA restriction
analysis (ARDRA) for the identification of Mycoplasma species . BMC Infect Dis 5, 46.
Stokes, M.E., Charles, S. D., Gary, G.K., 2000, Chapter 5: the s x r table, In: Stokes, M.E.,
Charles, S. D., Gary, G.K. (Eds.) Categorical data analysis using the SAS ® System,
Second Edition. SAS Institute Inc., North Carolina, pp. 112-116.
Tang, J., Hu, M., Lee, S., Roblin, R., 2000, A polymerase chain reaction based method for
detecting Mycoplasma/Acholeplasma contaminants in cell culture. J Microbiol Methods
39, 121-126.
Tully, J.G., 1983, Section E5 Tests for digitonin sensitivity and sterol requirement, In:
Tully, J.G., Razin, S. (Eds.) Methods in mycoplasmology I. Academic Press,
New York, pp. 355-362.
95
TABLES
TABLE 1. Mycoplasma species and other bacterial species tested for specificity of the novel real-time PCR assays a
Organisms Origin of isolates Source
M. bovis Real-time PCR Real-time PCR Real-time PCR M. californicum M. bovigenitalium M. bovis Bovine mastitic milk ATCC b 25025 + - -
M. bovis Bovine mastitic milk ATCC 25523 + - -
M. bovis Bovine mastitic milk CU c 22253 + - -
M. californicum Bovine mastitic milk ATCC 33461 - + -
M. bovigenitalium Bovine genital tract ATCC 14173 - - +
M. alkalescens Bovine nasal cavity ATCC 29103 - - -
M. alkalescens Bovine mastitic milk CU 21146 - - -
M. agalactiae Mastitic goat milk ATCC 35890 - - -
M. arginini Lung of sheep with ATCC 23243 - - -
pneumonia
M. bovirhinis Bovine respiratory tract ATCC 27748 - - -
M. leachii sp. nov Arthritic joint of a calf IOM d N29 Leach - - -
strains
M. ovipneumonia Ovine respiratory tract ATCC 25922 - - -
A. axanthum Murine leukemia tissue ATCC 25176 - - -
culture
Escherichia coli Clinical isolates ATCC 25922 - - -
96
TABLE 1. Mycoplasma species and other bacterial species tested for specificity of the novel real-time PCR assays (continued)
Organisms Origin of isolates Source
M. bovis Real-time PCR Real-time PCR Real-time PCR M. californicum M. bovigenitalium
Staphylococcus Human ATCC 11631 - - -
simulans
S. epidermidis Human ATCC 12228 - - -
S. epidermidis Human (Catheter sepsis) ATCC 35984 - - -
S. equorum Horse skin ATCC 43958 - - -
S. haemolyticus Human skin ATCC 29970 - - -
S. gallinarum Chicken nares ATCC 35539 - - -
S. hyicus Pig with exudative epidermitis ATCC 11249 - - -
S. intermedius Pigeon nares ATCC 29663 - - -
S. caprae Goat milk ATCC 35538 - - -
S. capitis Human ATCC 35661 - - -
S. chromogenes Pig skin ATCC 43764 - - -
S. aureus Bovine mastitic milk ATCC 29740 - - -
Streptococcus uberis Bovine udder infection ATCC 27958 - - -
Strep. dysgalactiae Bovine udder infection ATCC 27957 - - -
a Isolates with a + sign were positively identified by real-time PCR as that species and those with a – sign were not
identified, using C T value of 37 as the threshold of determination
b American Type Culture Collection, Manassas, VA, USA.
c Cornell University, Ithaca, NY, USA
d International Organization of Mycoplasmology, West Lafayette, IN, USA.
97
TABLE 2. Sequences of primers and probes used in the study and their targeted regions
Name Sequences Targets
F2 5’-GTG(C/G)GG(A/C)TGGATCACCTCCT-3’ 16S-23S rRNA
R2 5’-GCATCCACCA(A/T)A(A/T)AC(C/T)CTT-3’ intergenic spacer region
of Mycoplasma species
R34 5’-CCACTGTGTGCCCTTTGTTCCT-3’ 16S-23S rRNA
intergenic spacer region
of Acholeplasma
species
pA 5’-AGAGTTTGATCCTGGCTCAG-3’ 16S rRNA gene
pH 5’-AAGGAGGTGATCCAGCCGCA-3’
MbF 5’-TAATGCACGCAAACTCTCGTAGT-3’ fusA gene of M. bovis
MbR 5’-TGTCACCAGTTGTTGTGCCTT-3’
MbP 6FAM 5’-ACCAACAGCAGCAACAATATCACCTGC-3’BHQ1
McF 5’-GCACTTAGACGAAAGAGGGATT-3’ rpoB gene of M.
McR 5’-GGATTATCATCACCTTTGGGACT-3’ californicum
McP 6FAM5’-CGTGTTGGTTCGGAAGTGGTTCCAG-3’BHQ1
MbvgF 5’-CTTTCTACGGAGTACAAAGCTAAT-3’ 16S and 23 S intergenic
MbvgR 5’-GAGAGAATTGTTCYCTCAAAACTA-3’ spacer region of M.
MbvgP 6FAM5’-TATCGTCATGGCTTGGTTAGGTCCCA-3’BHQ1 bovigenitalium
98
TABLE 3. Distribution of isolates of Mycoplasma species and Acholeplasma species as identified by 16S rRNA partial sequencing
Species identification from Total number of isolates
16S rRNA partial sequencing (number of reference strains)
M. bovis 231 (2)
M. californicum 23 (1)
M. bovigenitalium 6 (1)
A. axanthum 2 (1)
M. alkalescens 4 (2)
M. arginini 4 (1)
M. yeatsii 2
M. cottewii 1
M. bovirhinis 1 (1)
M. felis 1
M. leachii (Bovine serogr.7) 1 (1)
M. agalactiae 4 (1)
Total 280
99
TABLE 4. Identification of Mycoplasma species and Acholeplasma species isolates using PCR-
RFLP and real-time PCR
Species a Total PCR-RFLP Real-time PCR M. bovis M. bovis Other species Other species M. californicum M. californicum M. bovigenitalium M. bovigenitalium
M. bovis 231 231 0 0 0 231 4 0 0
M. californicum 23 0 23 0 0 0 23 0 0
M. bovigenitalium 6 0 2 4 0 0 0 6 0
M. alkalescens 4 0 0 0 4 0 0 0 4
M. agalactiae 4 0 0 0 4 0 0 0 4
M. arginini 4 0 0 0 4 0 0 0 4
M. yeatsii 2 0 0 0 2 0 0 0 2
M. cottewii 1 0 0 0 1 0 0 0 1
M. felis 1 0 0 0 1 0 0 0 1
M. bovirhinis 1 0 0 0 1 0 0 0 1
M. leachii 1 0 0 0 1 0 0 0 1
A. axanthum 2 0 0 0 2 0 0 0 2
aSpecies identified by 16S rRNA partial sequencing
100
FIGURES
1 2 3 4 5 6
A.
1 2 3 4 5
B.
FIGURE 1. Electrophoretic gel of amplicons before digestion (A) and after digestion by ASE1
(B). A. Lane 1 and 6: 100 bp molecular ladder, lane 2: M. bovis ATCC 25025, lane 3: M. bovis
ATCC 25523, lane 4: M. californicum ATCC 33461, lane 5: M. bovigenitalium ATCC 14173. B.
Lane 1 and 5: 100 bp molecular ladder, lane 2: M. bovis ATCC 25025, lane 3: M. californicum
ATCC 33461, lane 4: M. bovigenitalium ATCC 14173
101
1 2 3 4 5 6 7
FIGURE 2. Digested amplicons obtained from 6 M. bovigenitalium isolates. Lane 1: precision mass molecular ladder (bands from top to bottom represent 1000, 700, 500, 200 and 100 bp), lane 2 to 6: field isolates of M. bovigenitalium , lane 7: M. bovigennitalium ATCC 14173
102
y = -1.3082Ln(x) + 39.671 45 R2 = 0.9942 40 35 30 25 20 15 Cycle Threshold 10 5 0 100000 10000 1000 100 10 1 Template DNA (copies)
FIGURE 3. Standard curve of M. bovis real-time PCR assay using pIDTSMART-AMP plasmids cloned with the target sequence in fusA gene of M. bovis
103
y = -1.5413Ln(x) + 40.14 45 R2 = 0.9996 40 35 30 25 20 15
Cycle Threshold 10 5 0 100000 10000 1000 100 10 1 Template DNA (copies)
FIGURE 4. Standard curve of M. bovigenitalium real-time PCR assay using pIDTSMART-AMP plasmids cloned with the target sequence in 16S-23S intergenic spacer region of M. bovigenitalium
104
y = -1.5351Ln(x) + 36.775 40 R2 = 0.9973 35 30 25 20 15
Cycle threshold Cycle 10 5 0 100000 10000 1000 100 10 1 Template DNA (copies)
FIGURE 5. Standard curve of M. californicum real-time PCR assay using pIDTSMART-AMP plasmids cloned with the target sequence in rpoB gene of M. californicum
105
CHAPTER 6
CONCLUSIONS
Mycoplasma mastitis has been categorized as a contagious mastitis and appears to be a problem of large herds and as therefore expected has increasing herd prevalence. Culturing bulk- tank milk has been suggested as for routine herd prevalence. Once a bulk-tank milk sample becomes positive, diagnostic tests at the cow level is recommended to find infected animals and consequently segregate and/or cull those infected animals to prevent transmission. Therefore, diagnosis of mycoplasma mastitis has played a major role in controlling and preventing a mycoplasma mastitis outbreak.
Direct culture of milk sample to confirm the presence of Mycoplasma species has been
used as a standard method for the diagnosis of mycoplasma mastitis. Despite the fact that culture
fresh milk samples is recommended to maximize the detection, milk samples are generally stored
in a refrigerator or a freezer for a period of time before culture. Findings in Chapter 3 indicate
that storing milk samples in a refrigerator for less than 5 days would not cause a significant
reduction of recoverable Mycoplasma by culture. In addition, results from this study provide
evidence to support that when milk samples need to be frozen before testing, it is suggested to
add glycerol 10% – 30% (v/v) prior freezing to improve the survival of Mycoplasma in frozen milk. These findings are practical and can be applied by dairy operators, veterinarians and laboratory technicians, to maximize the detection of Mycoplasma .
Presumptive identification of mollicutes can be made on modified Hayflick’s agar using standard mycoplasma culture techniques. But such culture techniques can not discriminate
Acholeplasma species from Mycoplasma species. Results in Chapter 4 indicate that a commonly
106
used technique; digitonin disc diffusion assay, is a reliable method to be used to distinguish these two genera with mycoplasma mastitis isolates. Additionally, two other techniques; nisin disc diffusion assay and PCR, have been validated and may be a more accurate measure to distinguish the genera, compared to the digitonin disc diffusion assay. All 3 techniques can be used to distinguish between Mycoplasma and Acholeplasma , which is very necessary to perform in order to increase the specificity of the diagnosis of mycoplasma mastitis.
Identification at the species level of Mycoplasma is important for dairy operators and veterinarians since different species may have different clinical characteristics and transmission pathways, and consequently have different control strategies. Speciation techniques based on the standard culture method is very time-consuming; therefore, PCR based techniques were the focus of the last study. Three novel real-time PCR assays to detect 3 most common mycoplasma mastitis agents were developed and their efficiencies were compared with a proven PCR-RFLP technique. The novel real-time PCR assays showed an equivalent efficiency compared to the
PCR-RFLP technique, but it is a lot less time consuming. The novel real-time PCR assays seem to be a promising diagnostic technique which can be used either as a screening test or a confirmation test for mycoplasma mastitis.
In this dissertation, all studies focus to improve the accuracy and efficiency not only by validation of some techniques that have been used in the process of diagnosis, but also by developing or suggesting some new techniques that can prevail the limitation of some currently used methods.
107
APPENDIX
A. RAW DATA
A.1: Chapter 3 (Refrigeration experiment)
Treatment Organism Strain Starting Concentration Replication CFU/ml
Fresh M.californicum ATCC33461 high 1 24500
Fresh M.californicum ATCC33461 medium 1 0
Fresh M.californicum ATCC33461 low 1 0
R1day M.californicum ATCC33461 high 1 18000
R1day M.californicum ATCC33461 medium 1 0
R1day M.californicum ATCC33461 low 1 0
R3day M.californicum ATCC33461 high 1 14000
R3day M.californicum ATCC33461 medium 1 0
R3day M.californicum ATCC33461 low 1 0
R5day M.californicum ATCC33461 high 1 11000
R5day M.californicum ATCC33461 medium 1 0
R5day M.californicum ATCC33461 low 1 0
Fresh M.californicum UCD8 high 1 15000
Fresh M.californicum UCD8 medium 1 0
Fresh M.californicum UCD8 low 1 0
R1day M.californicum UCD8 high 1 25000
R1day M.californicum UCD8 medium 1 0
R1day M.californicum UCD8 low 1 0
R3day M.californicum UCD8 high 1 0
108
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M.californicum UCD8 medium 1 0
R3day M.californicum UCD8 low 1 0
R5day M.californicum UCD8 high 1 0
R5day M.californicum UCD8 medium 1 0
R5day M.californicum UCD8 low 1 0
Fresh M.canadense ATCC29418 high 1 21300000
Fresh M.canadense ATCC29418 medium 1 237000
Fresh M.canadense ATCC29418 low 1 2230
R1day M.canadense ATCC29418 high 1 17150000
R1day M.canadense ATCC29418 medium 1 220000
R1day M.canadense ATCC29418 low 1 1630
R3day M.canadense ATCC29418 high 1 8650000
R3day M.canadense ATCC29418 medium 1 105500
R3day M.canadense ATCC29418 low 1 970
R5day M.canadense ATCC29418 high 1 620000
R5day M.canadense ATCC29418 medium 1 23000
R5day M.canadense ATCC29418 low 1 50
Fresh M.canadense CU21113 high 1 12800000
Fresh M.canadense CU21113 medium 1 125500
Fresh M.canadense CU21113 low 1 1300
R1day M.canadense CU21113 high 1 11900000
R1day M.canadense CU21113 medium 1 120500
R1day M.canadense CU21113 low 1 1060
R3day M.canadense CU21113 high 1 4000000
109
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M.canadense CU21113 medium 1 95000
R3day M.canadense CU21113 low 1 410
R5day M.canadense CU21113 high 1 935000
R5day M.canadense CU21113 medium 1 25500
R5day M.canadense CU21113 low 1 40
Fresh M.bovigenitalium ATCC19852 high 1 7700000
Fresh M.bovigenitalium ATCC19852 medium 1 60000
Fresh M.bovigenitalium ATCC19852 low 1 300
R1day M.bovigenitalium ATCC19852 high 1 7750000
R1day M.bovigenitalium ATCC19852 medium 1 71500
R1day M.bovigenitalium ATCC19852 low 1 0
R3day M.bovigenitalium ATCC19852 high 1 8950000
R3day M.bovigenitalium ATCC19852 medium 1 113000
R3day M.bovigenitalium ATCC19852 low 1 630
R5day M.bovigenitalium ATCC19852 high 1 6350000
R5day M.bovigenitalium ATCC19852 medium 1 59500
R5day M.bovigenitalium ATCC19852 low 1 700
Fresh M. bovis ATCC25523 high 1 12650000
Fresh M. bovis ATCC25523 medium 1 123500
Fresh M. bovis ATCC25523 low 1 2000
R1day M. bovis ATCC25523 high 1 15250000
R1day M. bovis ATCC25523 medium 1 173000
R1day M. bovis ATCC25523 low 1 2000
R3day M. bovis ATCC25523 high 1 10950000
110
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M. bovis ATCC25523 medium 1 111500
R3day M. bovis ATCC25523 low 1 1000
R5day M. bovis ATCC25523 high 1 12200000
R5day M. bovis ATCC25523 medium 1 127500
R5day M. bovis ATCC25523 low 1 1000
Fresh M. bovis ATCC27368 high 1 23250000
Fresh M. bovis ATCC27368 medium 1 234000
Fresh M. bovis ATCC27368 low 1 2000
R1day M. bovis ATCC27368 high 1 12150000
R1day M. bovis ATCC27368 medium 1 133000
R1day M. bovis ATCC27368 low 1 1000
R3day M. bovis ATCC27368 high 1 9550000
R3day M. bovis ATCC27368 medium 1 89500
R3day M. bovis ATCC27368 low 1 1000
R5day M. bovis ATCC27368 high 1 7650000
R5day M. bovis ATCC27368 medium 1 86000
R5day M. bovis ATCC27368 low 1 0
Fresh M.bovigenitalium ATCC14173 high 1 16200000
Fresh M.bovigenitalium ATCC14173 medium 1 155000
Fresh M.bovigenitalium ATCC14173 low 1 0
R1day M.bovigenitalium ATCC14173 high 1 13800000
R1day M.bovigenitalium ATCC14173 medium 1 139000
R1day M.bovigenitalium ATCC14173 low 1 2000
R3day M.bovigenitalium ATCC14173 high 1 9550000
111
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M.bovigenitalium ATCC14173 medium 1 119500
R3day M.bovigenitalium ATCC14173 low 1 0
R5day M.bovigenitalium ATCC14173 high 1 10250000
R5day M.bovigenitalium ATCC14173 medium 1 102000
R5day M.bovigenitalium ATCC14173 low 1 1000
Fresh M. alkalescens CU21146 high 1 18650000
Fresh M. alkalescens CU21146 medium 1 181000
Fresh M. alkalescens CU21146 low 1 1000
R1day M. alkalescens CU21146 high 1 18500000
R1day M. alkalescens CU21146 medium 1 202500
R1day M. alkalescens CU21146 low 1 2000
R3day M. alkalescens CU21146 high 1 17450000
R3day M. alkalescens CU21146 medium 1 169500
R3day M. alkalescens CU21146 low 1 2000
R5day M. alkalescens CU21146 high 1 2530000
R5day M. alkalescens CU21146 medium 1 27000
R5day M. alkalescens CU21146 low 1 0
Fresh M. alkalescens CU22261 high 1 17750000
Fresh M. alkalescens CU22261 medium 1 196500
Fresh M. alkalescens CU22261 low 1 3000
R1day M. alkalescens CU22261 high 1 20900000
R1day M. alkalescens CU22261 medium 1 220500
R1day M. alkalescens CU22261 low 1 3000
R3day M. alkalescens CU22261 high 1 18900000
112
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M. alkalescens CU22261 medium 1 196500
R3day M. alkalescens CU22261 low 1 2000
R5day M. alkalescens CU22261 high 1 17900000
R5day M. alkalescens CU22261 medium 1 149500
R5day M. alkalescens CU22261 low 1 2000
Fresh M.californicum ATCC33461 high 2 5150000
Fresh M.californicum ATCC33461 medium 2 80500
Fresh M.californicum ATCC33461 low 2 705
R1day M.californicum ATCC33461 high 2 4550000
R1day M.californicum ATCC33461 medium 2 62500
R1day M.californicum ATCC33461 low 2 520
R3day M.californicum ATCC33461 high 2 5150000
R3day M.californicum ATCC33461 medium 2 65000
R3day M.californicum ATCC33461 low 2 580
R5day M.californicum ATCC33461 high 2 5100000
R5day M.californicum ATCC33461 medium 2 49000
R5day M.californicum ATCC33461 low 2 535
Fresh M.californicum UCD8 high 2 385000
Fresh M.californicum UCD8 medium 2 5500
Fresh M.californicum UCD8 low 2 35
R1day M.californicum UCD8 high 2 500000
R1day M.californicum UCD8 medium 2 9000
R1day M.californicum UCD8 low 2 55
R3day M.californicum UCD8 high 2 255000
113
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M.californicum UCD8 medium 2 1500
R3day M.californicum UCD8 low 2 55
R5day M.californicum UCD8 high 2 265000
R5day M.californicum UCD8 medium 2 4000
R5day M.californicum UCD8 low 2 45
Fresh M.canadense ATCC29418 high 2 19500000
Fresh M.canadense ATCC29418 medium 2 202500
Fresh M.canadense ATCC29418 low 2 2565
R1day M.canadense ATCC29418 high 2 20650000
R1day M.canadense ATCC29418 medium 2 182000
R1day M.canadense ATCC29418 low 2 2710
R3day M.canadense ATCC29418 high 2 19350000
R3day M.canadense ATCC29418 medium 2 183500
R3day M.canadense ATCC29418 low 2 2825
R5day M.canadense ATCC29418 high 2 10800000
R5day M.canadense ATCC29418 medium 2 179000
R5day M.canadense ATCC29418 low 2 2315
Fresh M.canadense CU21113 high 2 10050000
Fresh M.canadense CU21113 medium 2 116500
Fresh M.canadense CU21113 low 2 1230
R1day M.canadense CU21113 high 2 7500000
R1day M.canadense CU21113 medium 2 124500
R1day M.canadense CU21113 low 2 1145
R3day M.canadense CU21113 high 2 6200000
114
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M.canadense CU21113 medium 2 91500
R3day M.canadense CU21113 low 2 900
R5day M.canadense CU21113 high 2 9250000
R5day M.canadense CU21113 medium 2 122000
R5day M.canadense CU21113 low 2 785
Fresh M.bovigenitalium ATCC19852 high 2 138000
Fresh M.bovigenitalium ATCC19852 medium 2 500
Fresh M.bovigenitalium ATCC19852 low 2 15
R1day M.bovigenitalium ATCC19852 high 2 150500
R1day M.bovigenitalium ATCC19852 medium 2 1000
R1day M.bovigenitalium ATCC19852 low 2 10
R3day M.bovigenitalium ATCC19852 high 2 72000
R3day M.bovigenitalium ATCC19852 medium 2 1000
R3day M.bovigenitalium ATCC19852 low 2 5
R5day M.bovigenitalium ATCC19852 high 2 90000
R5day M.bovigenitalium ATCC19852 medium 2 2500
R5day M.bovigenitalium ATCC19852 low 2 5
Fresh M. bovis ATCC25523 high 2 9900000
Fresh M. bovis ATCC25523 medium 2 161000
Fresh M. bovis ATCC25523 low 2 1070
R1day M. bovis ATCC25523 high 2 13650000
R1day M. bovis ATCC25523 medium 2 94000
R1day M. bovis ATCC25523 low 2 1365
R3day M. bovis ATCC25523 high 2 14350000
115
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M. bovis ATCC25523 medium 2 136500
R3day M. bovis ATCC25523 low 2 1015
R5day M. bovis ATCC25523 high 2 11000000
R5day M. bovis ATCC25523 medium 2 101000
R5day M. bovis ATCC25523 low 2 940
Fresh M. bovis ATCC27368 high 2 9000000
Fresh M. bovis ATCC27368 medium 2 167500
Fresh M. bovis ATCC27368 low 2 2090
R1day M. bovis ATCC27368 high 2 12350000
R1day M. bovis ATCC27368 medium 2 124000
R1day M. bovis ATCC27368 low 2 1325
R3day M. bovis ATCC27368 high 2 10600000
R3day M. bovis ATCC27368 medium 2 127000
R3day M. bovis ATCC27368 low 2 1265
R5day M. bovis ATCC27368 high 2 10150000
R5day M. bovis ATCC27368 medium 2 93000
R5day M. bovis ATCC27368 low 2 1100
Fresh M.bovigenitalium ATCC14173 high 2 6950000
Fresh M.bovigenitalium ATCC14173 medium 2 79500
Fresh M.bovigenitalium ATCC14173 low 2 945
R1day M.bovigenitalium ATCC14173 high 2 9150000
R1day M.bovigenitalium ATCC14173 medium 2 80500
R1day M.bovigenitalium ATCC14173 low 2 1035
R3day M.bovigenitalium ATCC14173 high 2 10400000
116
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M.bovigenitalium ATCC14173 medium 2 88500
R3day M.bovigenitalium ATCC14173 low 2 1095
R5day M.bovigenitalium ATCC14173 high 2 7750000
R5day M.bovigenitalium ATCC14173 medium 2 68000
R5day M.bovigenitalium ATCC14173 low 2 880
Fresh M. alkalescens CU21146 high 2 550000
Fresh M. alkalescens CU21146 medium 2 2000
Fresh M. alkalescens CU21146 low 2 20
R1day M. alkalescens CU21146 high 2 430000
R1day M. alkalescens CU21146 medium 2 5500
R1day M. alkalescens CU21146 low 2 35
R3day M. alkalescens CU21146 high 2 345000
R3day M. alkalescens CU21146 medium 2 4500
R3day M. alkalescens CU21146 low 2 70
R5day M. alkalescens CU21146 high 2 351000
R5day M. alkalescens CU21146 medium 2 3000
R5day M. alkalescens CU21146 low 2 35
Fresh M. alkalescens CU22261 high 2 7750000
Fresh M. alkalescens CU22261 medium 2 98000
Fresh M. alkalescens CU22261 low 2 1125
R1day M. alkalescens CU22261 high 2 8050000
R1day M. alkalescens CU22261 medium 2 118000
R1day M. alkalescens CU22261 low 2 1130
R3day M. alkalescens CU22261 high 2 8850000
117
Treatment Organism Strain Starting Concentration Replication CFU/ml
R3day M. alkalescens CU22261 medium 2 105500
R3day M. alkalescens CU22261 low 2 1280
R5day M. alkalescens CU22261 high 2 9050000
R5day M. alkalescens CU22261 medium 2 92000
R5day M. alkalescens CU22261 low 2 1265
A.2: Chapter 3 (Freezing experiment)
Treatment Organism Strain Starting Concentration Replication CFU/ml
Fresh M. alkalescens CU22261 high 1 18150000
Fresh M. alkalescens CU22261 medium 1 214500
Fresh M. alkalescens CU22261 low 1 2135
Fresh M.bovigenitalium ATCC14173 high 1 3850000
Fresh M.bovigenitalium ATCC14173 medium 1 36000
Fresh M.bovigenitalium ATCC14173 low 1 810
Fresh M. bovis ATCC25025 high 1 1810000
Fresh M. bovis ATCC25025 medium 1 20000
Fresh M. bovis ATCC25025 low 1 190
Fresh M.californicum ATCC33461 high 1 14350000
Fresh M.californicum ATCC33461 medium 1 51000
Fresh M.californicum ATCC33461 low 1 605
Fresh M.canadense ATCC29418 high 1 5300000
Fresh M.canadense ATCC29418 medium 1 52500
Fresh M.canadense ATCC29418 low 1 365
118
Treatment Organism Strain Starting Concentration Replication CFU/ml
0%gly M. alkalescens CU22261 high 1 9100000
0%gly M. alkalescens CU22261 medium 1 66000
0%gly M. alkalescens CU22261 low 1 750
0%gly M.bovigenitalium ATCC14173 high 1 1010000
0%gly M.bovigenitalium ATCC14173 medium 1 11000
0%gly M.bovigenitalium ATCC14173 low 1 385
0%gly M. bovis ATCC25025 high 1 740000
0%gly M. bovis ATCC25025 medium 1 3000
0%gly M. bovis ATCC25025 low 1 90
0%gly M.californicum ATCC33461 high 1 1010000
0%gly M.californicum ATCC33461 medium 1 17000
0%gly M.californicum ATCC33461 low 1 285
0%gly M.canadense ATCC29418 high 1 990000
0%gly M.canadense ATCC29418 medium 1 42000
0%gly M.canadense ATCC29418 low 1 100
10%gly M. alkalescens CU22261 high 1 10833333
10%gly M. alkalescens CU22261 medium 1 185000
10%gly M. alkalescens CU22261 low 1 1078
10%gly M.bovigenitalium ATCC14173 high 1 2477778
10%gly M.bovigenitalium ATCC14173 medium 1 36111
10%gly M.bovigenitalium ATCC14173 low 1 644
10%gly M. bovis ATCC25025 high 1 1044444
10%gly M. bovis ATCC25025 medium 1 13333
10%gly M. bovis ATCC25025 low 1 183
119
Treatment Organism Strain Starting Concentration Replication CFU/ml
10%gly M.californicum ATCC33461 high 1 3000000
10%gly M.californicum ATCC33461 medium 1 46667
10%gly M.californicum ATCC33461 low 1 522
10%gly M.canadense ATCC29418 high 1 4666667
10%gly M.canadense ATCC29418 medium 1 31667
10%gly M.canadense ATCC29418 low 1 333
30%gly M. alkalescens CU22261 high 1 10785714
30%gly M. alkalescens CU22261 medium 1 138571
30%gly M. alkalescens CU22261 low 1 1150
30%gly M.bovigenitalium ATCC14173 high 1 1628571
30%gly M.bovigenitalium ATCC14173 medium 1 21429
30%gly M.bovigenitalium ATCC14173 low 1 543
30%gly M. bovis ATCC25025 high 1 585714
30%gly M. bovis ATCC25025 medium 1 8571
30%gly M. bovis ATCC25025 low 1 571
30%gly M.californicum ATCC33461 high 1 2378571
30%gly M.californicum ATCC33461 medium 1 62143
30%gly M.californicum ATCC33461 low 1 407
30%gly M.canadense ATCC29418 high 1 2007143
30%gly M.canadense ATCC29418 medium 1 32143
30%gly M.canadense ATCC29418 low 1 300
50%gly M. alkalescens CU22261 high 1 8500000
50%gly M. alkalescens CU22261 medium 1 112000
50%gly M. alkalescens CU22261 low 1 650
120
Treatment Organism Strain Starting Concentration Replication CFU/ml
50%gly M.bovigenitalium ATCC14173 high 1 580000
50%gly M.bovigenitalium ATCC14173 medium 1 12000
50%gly M.bovigenitalium ATCC14173 low 1 240
50%gly M. bovis ATCC25025 high 1 268000
50%gly M. bovis ATCC25025 medium 1 1000
50%gly M. bovis ATCC25025 low 1 100
50%gly M.californicum ATCC33461 high 1 1350000
50%gly M.californicum ATCC33461 medium 1 34000
50%gly M.californicum ATCC33461 low 1 160
50%gly M.canadense ATCC29418 high 1 850000
50%gly M.canadense ATCC29418 medium 1 19000
50%gly M.canadense ATCC29418 low 1 280
Fresh M. alkalescens CU21146 high 1 12050000
Fresh M. alkalescens CU21146 medium 1 205500
Fresh M. alkalescens CU21146 low 1 1300
Fresh M.bovigenitalium ATCC19852 high 1 340000
Fresh M.bovigenitalium ATCC19852 medium 1 3000
Fresh M.bovigenitalium ATCC19852 low 1 100
Fresh M. bovis ATCC25523 high 1 2215000
Fresh M. bovis ATCC25523 medium 1 24500
Fresh M. bovis ATCC25523 low 1 185
Fresh M.californicum UCD8 high 1 48500
Fresh M.californicum UCD8 medium 1 10000
Fresh M.californicum UCD8 low 1 195
121
Treatment Organism Strain Starting Concentration Replication CFU/ml
fresh M.canadense CU21113 high 1 172500
fresh M.canadense CU21113 medium 1 2000
fresh M.canadense CU21113 low 1 20
0%gly M. alkalescens CU21146 high 1 9250000
0%gly M. alkalescens CU21146 medium 1 111500
0%gly M. alkalescens CU21146 low 1 865
0%gly M.bovigenitalium ATCC19852 high 1 24000
0%gly M.bovigenitalium ATCC19852 medium 1 50
0%gly M.bovigenitalium ATCC19852 low 1 0
0%gly M. bovis ATCC25523 high 1 3750000
0%gly M. bovis ATCC25523 medium 1 46500
0%gly M. bovis ATCC25523 low 1 530
0%gly M.californicum UCD8 high 1 1620000
0%gly M.californicum UCD8 medium 1 19500
0%gly M.californicum UCD8 low 1 335
0%gly M.canadense CU21113 high 1 1540000
0%gly M.canadense CU21113 medium 1 23000
0%gly M.canadense CU21113 low 1 215
10%gly M. alkalescens CU21146 high 1 13277778
10%gly M. alkalescens CU21146 medium 1 91111
10%gly M. alkalescens CU21146 low 1 1561
10%gly M.bovigenitalium ATCC19852 high 1 82778
10%gly M.bovigenitalium ATCC19852 medium 1 556
10%gly M.bovigenitalium ATCC19852 low 1 0
122
Treatment Organism Strain Starting Concentration Replication CFU/ml
10%gly M. bovis ATCC25523 high 1 4222222
10%gly M. bovis ATCC25523 medium 1 70556
10%gly M. bovis ATCC25523 low 1 628
10%gly M.californicum UCD8 high 1 1616667
10%gly M.californicum UCD8 medium 1 16111
10%gly M.californicum UCD8 low 1 222
10%gly M.canadense CU21113 high 1 3555556
10%gly M.canadense CU21113 medium 1 40000
10%gly M.canadense CU21113 low 1 317
30%gly M. alkalescens CU21146 high 1 4857143
30%gly M. alkalescens CU21146 medium 1 182857
30%gly M. alkalescens CU21146 low 1 857
30%gly M.bovigenitalium ATCC19852 high 1 12143
30%gly M.bovigenitalium ATCC19852 medium 1 0
30%gly M.bovigenitalium ATCC19852 low 1 14
30%gly M. bovis ATCC25523 high 1 842857
30%gly M. bovis ATCC25523 medium 1 102857
30%gly M. bovis ATCC25523 low 1 643
30%gly M.californicum UCD8 high 1 578571
30%gly M.californicum UCD8 medium 1 12143
30%gly M.californicum UCD8 low 1 271
30%gly M.canadense CU21113 high 1 3214286
30%gly M.canadense CU21113 medium 1 92857
30%gly M.canadense CU21113 low 1 286
123
Treatment Organism Strain Starting Concentration Replication CFU/ml
50%gly M. alkalescens CU21146 high 1 6600000
50%gly M. alkalescens CU21146 medium 1 67000
50%gly M. alkalescens CU21146 low 1 1130
50%gly M.bovigenitalium ATCC19852 high 1 0
50%gly M.bovigenitalium ATCC19852 medium 1 0
50%gly M.bovigenitalium ATCC19852 low 1 0
50%gly M. bovis ATCC25523 high 1 88000
50%gly M. bovis ATCC25523 medium 1 6000
50%gly M. bovis ATCC25523 low 1 620
50%gly M.californicum UCD8 high 1 70000
50%gly M.californicum UCD8 medium 1 10000
50%gly M.californicum UCD8 low 1 300
50%gly M.canadense CU21113 high 1 540000
50%gly M.canadense CU21113 medium 1 0
50%gly M.canadense CU21113 low 1 250
Fresh M. alkalescens CU22261 high 2 17333333
Fresh M. alkalescens CU22261 medium 2 212778
Fresh M. alkalescens CU22261 low 2 1972
Fresh M.bovigenitalium ATCC14173 high 2 3111111
Fresh M.bovigenitalium ATCC14173 medium 2 77222
Fresh M.bovigenitalium ATCC14173 low 2 778
Fresh M. bovis ATCC25025 high 2 5000000
Fresh M. bovis ATCC25025 medium 2 117222
Fresh M. bovis ATCC25025 low 2 1189
124
Treatment Organism Strain Starting Concentration Replication CFU/ml
Fresh M.californicum ATCC33461 high 2 5555556
Fresh M.californicum ATCC33461 medium 2 70000
Fresh M.californicum ATCC33461 low 2 1000
Fresh M.canadense ATCC29418 high 2 4833333
Fresh M.canadense ATCC29418 medium 2 65556
Fresh M.canadense ATCC29418 low 2 933
0%gly M. alkalescens CU22261 high 2 86111
0%gly M. alkalescens CU22261 medium 2 5556
0%gly M. alkalescens CU22261 low 2 6
0%gly M.bovigenitalium ATCC14173 high 2 1788889
0%gly M.bovigenitalium ATCC14173 medium 2 59444
0%gly M.bovigenitalium ATCC14173 low 2 350
0%gly M. bovis ATCC25025 high 2 16111
0%gly M. bovis ATCC25025 medium 2 0
0%gly M. bovis ATCC25025 low 2 0
0%gly M.californicum ATCC33461 high 2 141111
0%gly M.californicum ATCC33461 medium 2 5556
0%gly M.californicum ATCC33461 low 2 22
0%gly M.canadense ATCC29418 high 2 0
0%gly M.canadense ATCC29418 medium 2 0
0%gly M.canadense ATCC29418 low 2 0
10%gly M. alkalescens CU22261 high 2 31111
10%gly M. alkalescens CU22261 medium 2 1111
10%gly M. alkalescens CU22261 low 2 0
125
Treatment Organism Strain Starting Concentration Replication CFU/ml
10%gly M.bovigenitalium ATCC14173 high 2 2516667
10%gly M.bovigenitalium ATCC14173 medium 2 63889
10%gly M.bovigenitalium ATCC14173 low 2 706
10%gly M. bovis ATCC25025 high 2 644444
10%gly M. bovis ATCC25025 medium 2 17778
10%gly M. bovis ATCC25025 low 2 106
10%gly M.californicum ATCC33461 high 2 255556
10%gly M.californicum ATCC33461 medium 2 3333
10%gly M.californicum ATCC33461 low 2 61
10%gly M.canadense ATCC29418 high 2 67222
10%gly M.canadense ATCC29418 medium 2 3889
10%gly M.canadense ATCC29418 low 2 11
30%gly M. alkalescens CU22261 high 2 22857
30%gly M. alkalescens CU22261 medium 2 1429
30%gly M. alkalescens CU22261 low 2 14
30%gly M.bovigenitalium ATCC14173 high 2 714286
30%gly M.bovigenitalium ATCC14173 medium 2 3571
30%gly M.bovigenitalium ATCC14173 low 2 543
30%gly M. bovis ATCC25025 high 2 321429
30%gly M. bovis ATCC25025 medium 2 8571
30%gly M. bovis ATCC25025 low 2 143
30%gly M.californicum ATCC33461 high 2 557143
30%gly M.californicum ATCC33461 medium 2 5000
30%gly M.californicum ATCC33461 low 2 179
126
Treatment Organism Strain Starting Concentration Replication CFU/ml
30%gly M.canadense ATCC29418 high 2 22857
30%gly M.canadense ATCC29418 medium 2 1429
30%gly M.canadense ATCC29418 low 2 43
50%gly M. alkalescens CU22261 high 2 58000
50%gly M. alkalescens CU22261 medium 2 3000
50%gly M. alkalescens CU22261 low 2 310
50%gly M.bovigenitalium ATCC14173 high 2 182000
50%gly M.bovigenitalium ATCC14173 medium 2 5000
50%gly M.bovigenitalium ATCC14173 low 2 0
50%gly M. bovis ATCC25025 high 2 171000
50%gly M. bovis ATCC25025 medium 2 3000
50%gly M. bovis ATCC25025 low 2 370
50%gly M.californicum ATCC33461 high 2 0
50%gly M.californicum ATCC33461 medium 2 2000
50%gly M.californicum ATCC33461 low 2 570
50%gly M.canadense ATCC29418 high 2 50000
50%gly M.canadense ATCC29418 medium 2 0
50%gly M.canadense ATCC29418 low 2 0
Fresh M. alkalescens CU21146 high 2 16055556
Fresh M. alkalescens CU21146 medium 2 101111
Fresh M. alkalescens CU21146 low 2 1400
Fresh M.bovigenitalium ATCC19852 high 2 361111
Fresh M.bovigenitalium ATCC19852 medium 2 6111
Fresh M.bovigenitalium ATCC19852 low 2 39
127
Treatment Organism Strain Starting Concentration Replication CFU/ml
Fresh M. bovis ATCC25523 high 2 2555556
Fresh M. bovis ATCC25523 medium 2 55556
Fresh M. bovis ATCC25523 low 2 572
Fresh M.californicum UCD8 high 2 4666667
Fresh M.californicum UCD8 medium 2 35000
Fresh M.californicum UCD8 low 2 544
Fresh M.canadense CU21113 high 2 2733333
Fresh M.canadense CU21113 medium 2 182778
Fresh M.canadense CU21113 low 2 161
0%gly M. alkalescens CU21146 high 2 5444444
0%gly M. alkalescens CU21146 medium 2 66667
0%gly M. alkalescens CU21146 low 2 556
0%gly M.bovigenitalium ATCC19852 high 2 134444
0%gly M.bovigenitalium ATCC19852 medium 2 556
0%gly M.bovigenitalium ATCC19852 low 2 0
0%gly M. bovis ATCC25523 high 2 1627778
0%gly M. bovis ATCC25523 medium 2 38889
0%gly M. bovis ATCC25523 low 2 250
0%gly M.californicum UCD8 high 2 1983333
0%gly M.californicum UCD8 medium 2 33333
0%gly M.californicum UCD8 low 2 244
0%gly M.canadense CU21113 high 2 1266667
0%gly M.canadense CU21113 medium 2 22778
0%gly M.canadense CU21113 low 2 33
128
Treatment Organism Strain Starting Concentration Replication CFU/ml
10%gly M. alkalescens CU21146 high 2 10833333
10%gly M. alkalescens CU21146 medium 2 109444
10%gly M. alkalescens CU21146 low 2 1456
10%gly M.bovigenitalium ATCC19852 high 2 335556
10%gly M.bovigenitalium ATCC19852 medium 2 3333
10%gly M.bovigenitalium ATCC19852 low 2 6
10%gly M. bovis ATCC25523 high 2 2277778
10%gly M. bovis ATCC25523 medium 2 14444
10%gly M. bovis ATCC25523 low 2 517
10%gly M.californicum UCD8 high 2 1705556
10%gly M.californicum UCD8 medium 2 35000
10%gly M.californicum UCD8 low 2 306
10%gly M.canadense CU21113 high 2 1216667
10%gly M.canadense CU21113 medium 2 10556
10%gly M.canadense CU21113 low 2 44
30%gly M. alkalescens CU21146 high 2 5928571
30%gly M. alkalescens CU21146 medium 2 81429
30%gly M. alkalescens CU21146 low 2 964
30%gly M.bovigenitalium ATCC19852 high 2 62857
30%gly M.bovigenitalium ATCC19852 medium 2 714
30%gly M.bovigenitalium ATCC19852 low 2 7
30%gly M. bovis ATCC25523 high 2 1957143
30%gly M. bovis ATCC25523 medium 2 15714
30%gly M. bovis ATCC25523 low 2 336
129
Treatment Organism Strain Starting Concentration Replication CFU/ml
30%gly M.californicum UCD8 high 2 1692857
30%gly M.californicum UCD8 medium 2 24286
30%gly M.californicum UCD8 low 2 379
30%gly M.canadense CU21113 high 2 2250000
30%gly M.canadense CU21113 medium 2 36429
30%gly M.canadense CU21113 low 2 193
50%gly M. alkalescens CU21146 high 2 6100000
50%gly M. alkalescens CU21146 medium 2 47000
50%gly M. alkalescens CU21146 low 2 520
50%gly M.bovigenitalium ATCC19852 high 2 3000
50%gly M.bovigenitalium ATCC19852 medium 2 0
50%gly M.bovigenitalium ATCC19852 low 2 0
50%gly M. bovis ATCC25523 high 2 1110000
50%gly M. bovis ATCC25523 medium 2 19000
50%gly M. bovis ATCC25523 low 2 380
50%gly M.californicum UCD8 high 2 1240000
50%gly M.californicum UCD8 medium 2 73000
50%gly M.californicum UCD8 low 2 480
50%gly M.canadense CU21113 high 2 2380000
50%gly M.canadense CU21113 medium 2 20000
50%gly M.canadense CU21113 low 2 210
130
A.3: Chapter 4 and 5
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v1 M. bovis + - M M. bovis M. bovis
v2 M. bovis + - M M. bovis M. bovis
v3 M. bovis + - M M. bovis M. bovis
v4 M. bovis + - M M. bovis M. bovis
v5 M. bovis + - M M. bovis M. bovis
v6 M. bovis + - M M. bovis M. bovis
v7 M. bovis + - M M. bovis M. bovis
v8 M. bovis + - M M. bovis M. bovis
v9 M. bovis + - M M. bovis M. bovis
v10 M. bovis + - M M. bovis M. bovis
v11 M. bovis + - M M. bovis M. bovis
v12 M. bovis + - M M. bovis M. bovis
v13 M. bovis + - M M. bovis M. bovis
v14 M. bovis + - M M. bovis M. bovis
v15 M. bovis + - M M. bovis M. bovis
v16 M. bovis + - M M. bovis M. bovis
v17 M. bovis + - M M. bovis M. bovis
v18 M. bovis + - M M. bovis M. bovis
v19 M. bovis + - M M. bovis M. bovis
v20 M. bovis + - M M. bovis M. bovis
v21 M. bovis + - M M. bovis M. bovis
v22 M. bovis + - M M. bovis M. bovis
v23 M. bovis + - M M. bovis M. bovis
131
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v24 M. bovis + - M M. bovis M. bovis
v25 M. bovis + - M M. bovis M. bovis
v26 M. bovis + - M M. bovis M. bovis
v27 M. bovis + - M M. bovis M. bovis
v28 M. bovis + - M M. bovis M. bovis
v29 M. bovis + - M M. bovis M. bovis
v30 M. bovis + - M M. bovis M. bovis
v31 M. bovis + - M M. bovis M. bovis
v32 M. bovis + - M M. bovis M. bovis
v33 M. bovis + - M M. bovis M. bovis
v34 M. bovis + - M M. bovis M. bovis
v35 M. bovis + - M M. bovis M. bovis
v36 M. bovis + - M M. bovis M. bovis
v37 M. bovis + - M M. bovis M. bovis
v38 M. bovis + - M M. bovis M. bovis
v39 M. bovis + - M M. bovis M. bovis
v40 M. bovis + - M M. bovis M. bovis
v41 M. bovis + - M M. bovis M. bovis
v42 M. bovis + - M M. bovis M. bovis
v43 M. bovis + - M M. bovis M. bovis
v44 M. bovis + - M M. bovis M. bovis
v45 M. bovis + - M M. bovis M. bovis
v46 M. bovis + - M M. bovis M. bovis
v47 M. bovis + - M M. bovis M. bovis
132
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v48 M. bovis + - M M. bovis M. bovis
v49 M. bovis + - M M. bovis M. bovis
v50 M. bovis + - M M. bovis M. bovis
v51 M. bovis + - M M. bovis M. bovis
v52 M. bovis + - M M. bovis M. bovis
v53 M. bovis + - M M. bovis M. bovis
v54 M. bovis + - M M. bovis M. bovis
v55 M. bovis + - M M. bovis M. bovis
v56 M. bovis + - M M. bovis M. bovis
v57 M. bovis + - M M. bovis M. bovis
v58 M. bovis + - M M. bovis M. bovis
v59 M. bovis + - M M. bovis M. bovis
v60 M. bovis + - M M. bovis M. bovis
v61 M. bovis + - M M. bovis M. bovis
v62 M. bovis + - M M. bovis M. bovis
v63 M. bovis + - M M. bovis M. bovis
v64 M. bovis + - M M. bovis M. bovis
v65 M. bovis + - M M. bovis M. bovis
v66 M. bovis + - M M. bovis M. bovis
v67 M. bovis + - M M. bovis M. bovis
v68 M. bovis + - M M. bovis M. bovis
v69 M. bovis + - M M. bovis M. bovis
v70 M. bovis + - M M. bovis M. bovis
v71 M. bovis + - M M. bovis M. bovis
133
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v72 M. bovis + - M M. bovis M. bovis
v73 M. bovis + - M M. bovis M. bovis
v74 M. bovis + - M M. bovis M. bovis
v75 M. bovis + - M M. bovis M. bovis
v76 M. bovis + - M M. bovis M. bovis
v77 M. bovis + - M M. bovis M. bovis
v78 M. bovis + - M M. bovis M. bovis
v79 M. bovis + - M M. bovis M. bovis
v80 M. bovis + - M M. bovis M. bovis
v81 M. bovis + - M M. bovis M. bovis
v82 M. bovis + - M M. bovis M. bovis
v83 M. bovis + - M M. bovis M. bovis
v84 M. bovis + - M M. bovis M. bovis
v85 M. bovis + - M M. bovis M. bovis
v86 M. bovis + - M M. bovis M. bovis
v87 M. bovis + - M M. bovis M. bovis
v88 M. bovis + - M M. bovis M. bovis
v89 M. bovis + - M M. bovis M. bovis
v90 M. bovis + - M M. bovis M. bovis
v91 M. bovis + - M M. bovis M. bovis
v92 M. bovis + - M M. bovis M. bovis
v93 M. bovis + - M M. bovis M. bovis
v94 M. bovis + - M M. bovis M. bovis
v95 M. bovis + - M M. bovis M. bovis
134
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v96 M. bovis + - M M. bovis M. bovis
v97 M. bovis + - M M. bovis M. bovis
v98 M. bovis + - M M. bovis M. bovis
v99 M. bovis + - M M. bovis M. bovis
v100 M. bovis + - M M. bovis M. bovis
v101 M. bovis + - M M. bovis M. bovis
v102 M. bovis + - M M. bovis M. bovis
v103 M. bovis + - M M. bovis M. bovis
v104 M. bovis + - M M. bovis M. bovis
v105 M. bovis + - M M. bovis M. bovis
v106 M. bovis + - M M. bovis M. bovis
v107 M. bovis + - M M. bovis M. bovis
v108 M. bovis + - M M. bovis M. bovis
v109 M. bovis + - M M. bovis M. bovis
v110 M. bovis + - M M. bovis M. bovis
v111 M. bovis + - M M. bovis M. bovis
v112 M. bovis + - M M. bovis M. bovis
v113 M. bovis + - M M. bovis M. bovis
v114 M. bovis + - M M. bovis M. bovis
v115 M. bovis + - M M. bovis M. bovis
v116 M. bovis + - M M. bovis M. bovis
v117 M. bovis + - M M. bovis M. bovis
v118 M. bovis + - M M. bovis M. bovis
v119 M. bovis + - M M. bovis M. bovis
135
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v120 M. bovis + - M M. bovis M. bovis
v121 M. bovis + - M M. bovis M. bovis
v122 M. bovis + - M M. bovis M. bovis
v123 M. bovis + - M M. bovis M. bovis
v124 M. bovis + - M M. bovis M. bovis
v125 M. bovis + - M M. bovis M. bovis
v126 M. bovis + - M M. bovis M. bovis
v127 M. bovis + - M M. bovis M. bovis
v128 M. bovis + - M M. bovis M. bovis
v129 M. bovis + - M M. bovis M. bovis
v130 M. bovis + - M M. bovis M. bovis
v131 M. bovis + - M M. bovis M. bovis
v132 M. bovis + - M M. bovis M. bovis
v133 M. bovis + - M M. bovis M. bovis
v134 M. bovis + - M M. bovis M. bovis
v135 M. bovis + - M M. bovis M. bovis
v136 M. bovis + - M M. bovis M. bovis
v137 M. bovis + - M M. bovis M. bovis
v138 M. bovis + - M M. bovis M. bovis
v139 M. bovis + - M M. bovis M. bovis
v140 M. bovis + - M M. bovis M. bovis
v141 M. bovis + - M M. bovis M. bovis
v142 M. bovis + - M M. bovis M. bovis
v143 M. bovis + - M M. bovis M. bovis
136
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v144 M. bovis + - M M. bovis M. bovis
v145 M. bovis + - M M. bovis M. bovis
v146 M. bovis + - M M. bovis M. bovis
v147 M. bovis + - M M. bovis M. bovis
v148 M. bovis + - M M. bovis M. bovis
v149 M. bovis + - M M. bovis M. bovis
v150 M. bovis + - M M. bovis M. bovis
v151 M. bovis + - M M. bovis M. bovis
v152 M. bovis + - M M. bovis M. bovis
v153 M. bovis + - M M. bovis M. bovis
v154 M. bovis + - M M. bovis M. bovis
v155 M. bovis + - M M. bovis M. bovis
v156 M. bovis + - M M. bovis M. bovis
v157 M. bovis + - M M. bovis M. bovis
v158 M. bovis + - M M. bovis M. bovis
v159 M. bovis + - M M. bovis M. bovis
v160 M. bovis + - M M. bovis M. bovis
v161 M. bovis + - M M. bovis M. bovis
v162 M. bovis + - M M. bovis M. bovis
v163 M. bovis + - M M. bovis M. bovis
v164 M. bovis + - M M. bovis M. bovis
v165 M. bovis + - M M. bovis M. bovis
v166 M. bovis + - M M. bovis M. bovis
v167 M. bovis + - M M. bovis M. bovis
137
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v170 M. bovis + - M M. bovis M. bovis
v171 M. bovis + - M M. bovis M. bovis
v172 M. bovis + - M M. bovis M. bovis
v173 M. bovis + - M M. bovis M. bovis
v174 M. bovis + - M M. bovis M. bovis
v175 M. bovis + - M M. bovis M. bovis
v176 M. bovis + - M M. bovis M. bovis
v177 M. bovis + - M M. bovis M. bovis
v178 M. bovis + - M M. bovis M. bovis
v179 M. bovis + - M M. bovis M. bovis
v180 M. bovis + - M M. bovis M. bovis
v181 M. bovis + - M M. bovis M. bovis
v182 M. bovis + - M M. bovis M. bovis
v183 M. bovis + - M M. bovis M. bovis
v184 M. bovis + - M M. bovis M. bovis
v185 M. bovis + - M M. bovis M. bovis
v186 M. bovis + - M M. bovis M. bovis
v187 M. bovis + - M M. bovis M. bovis
v188 M. bovis + - M M. bovis M. bovis
v189 M. bovis + - M M. bovis M. bovis
v190 M. bovis + - M M. bovis M. bovis
v191 M. bovis + - M M. bovis M. bovis
v192 M. bovis + - M M. bovis M. bovis
v193 M. bovis + - M M. bovis M. bovis
138
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v194 M. bovis + - M M. bovis M. bovis
v195 M. bovis + - M M. bovis M. bovis
v196 M. bovis + - M M. bovis M. bovis
v197 M. bovis + - M M. bovis M. bovis
v198 M. bovis + - M M. bovis M. bovis
v199 M. bovis + - M M. bovis M. bovis
v200 M. bovis + - M M. bovis M. bovis
v201 M. bovis + - M M. bovis M. bovis
v202 M. bovis + - M M. bovis M. bovis
v203 M. bovis + - M M. bovis M. bovis
v204 M. bovis + - M M. bovis M. bovis
v205 M. bovis + - M M. bovis M. bovis
v206 M. bovis + - M M. bovis M. bovis
v207 M. bovis + - M M. bovis M. bovis
v208 M. bovis + - M M. bovis M. bovis
v209 M. bovis + - M M. bovis M. bovis
v210 M. bovis + - M M. bovis M. bovis
v211 M. bovis + - M M. bovis M. bovis
v212 M. bovis + - M M. bovis M. bovis
v213 M. bovis + - M M. bovis M. bovis
v214 M. bovis + - M M. bovis M. bovis
v215 M. bovis + - M M. bovis M. bovis
v216 M. bovis + - M M. bovis M. bovis
v217 M. bovis + - M M. bovis M. bovis
139
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
v218 M. bovis + - M M. bovis M. bovis
v219 M. bovis + - M M. bovis M. bovis
v220 M. bovis + - M M. bovis M. bovis
v221 M. bovis + - M M. bovis M. bovis
v222 M. bovis + - M M. bovis M. bovis
v223 M. bovis + - M M. bovis M. bovis
v224 M. bovis + - M M. bovis M. bovis
v225 M. bovis + - M M. bovis M. bovis
v226 M. bovis + - M M. bovis M. bovis
v227 M. bovis + - M M. bovis M. bovis
v228 M. bovis + - M M. bovis M. bovis
v229 M. bovis + - M M. bovis M. bovis
v230 M. bovis + - M M. bovis M. bovis
v231 M. bovis + - M M. bovis M. bovis
v232 M. bovis + - M M. bovis M. bovis
v233 M. bovis + - M M. bovis M. bovis
O1 M.californicum +/- - M M.californicum M.californicum
O2 M.californicum +/- - M M.californicum M.californicum
O3 M.californicum +/- - M M.californicum M.californicum
O4 M.californicum +/- - M M.californicum M.californicum
O5 M.californicum + - M M.californicum M.californicum
O6 M.californicum + - M M.californicum M.californicum
O7 M.californicum +/- - M M.californicum M.californicum
O8 M.californicum +/- - M M.californicum M.californicum
140
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
O9 M.californicum + - M M.californicum M.californicum
O10 M.californicum + - M M.californicum M.californicum
O11 M.bovigenitalium + - M M.bovigenitalium M.californicum
O12 M.alkalescens + - M Other species Other species
O13 A.axanthum - + A Other species Other species
O14 M.bovigenitalium + - M M.bovigenitalium M.bovigenitalium
O15 M.californicum +/- - M M.californicum M.californicum
O16 M.californicum +/- - M M.californicum M.californicum
O17 M.bovigenitalium + - M M.bovigenitalium M.californicum
O18 M.yeatsii - - M Other species Other species
O19 M.cottewii - - M Other species Other species
O20 M.yeatsii - - M Other species Other species
O21 M.bovigenitalium + - M M.bovigenitalium M.bovigenitalium
O22 M.bovis + - M Other species Other species
O23 M.bovirhinis +/- - M Other species Other species
O24 M. arginini +/- - M Other species Other species
O25 A. axanthum - + A Other species Other species
O26 M. alkalescens +/- - M Other species Other species
O27 M.arginini + - M Other species Other species
O28 M.californicum +/- - M M.californicum M.californicum
O29 M.californicum +/- - M M.californicum M.californicum
O30 M.californicum + - M M.californicum M.californicum
O31 M.californicum +/- - M M.californicum M.californicum
O32 M.californicum +/- - M M.californicum M.californicum
141
Sample 16S sequencing Digitonin Nisin PCR Real-time PCR PCR-RFLP
O33 M.arginini +/- - M Other species Other species
O34 M.bovigenitalium + - M M.bovigenitalium M.bovigenitalium
O35 M.alkalescens + - M Other species Other species
O36 M. agalactiae + - M Other species Other species
O37 M. agalactiae + - M Other species Other species
O38 M. agalactiae + - M Other species Other species
O39 M. agalactiae + - M Other species Other species
O40 M.californicum +/- - M M.californicum M.californicum
O41 M.californicum + - M M.californicum M.californicum
O42 M.californicum + - M M.californicum M.californicum
O43 M.californicum +/- - M M.californicum M.californicum
O44 M.californicum +/- - M M.californicum M.californicum
O45 M.bovigenitalium + - M M.bovigenitalium M.bovigenitalium
O46 M.alkalescens + - M Other species Other species
O47 M.arginini +/- - M Other species Other species
O48 M.felis +/- - M Other species Other species
O51 M.arginini +/- - M Other species Other species
O53 M. leachii +/- - M Other species Other species
O54 M.californicum + - M M.californicum M.californicum
142
B. METHODS
B.1: Cloning and filtration techniques for Mycoplasmas (adapted from Tully, 1983)
1. Defrost frozen isolates at room temperature.
2. Transfer 100 µl of defrosted cultured tube to 5 ml of new sterile PPLO broth
3. Incubate the culture tube at 37 °C with 10 % CO 2 for 4 to 5 days
4. Pass the culture broth through 0.22 and 0.45 µm syringe filter
5. Make 10-fold serial dilution of the pass-through broth from 10 -1 to 10 -6 with new sterile
PPLO broth
6. Pour and spread 200 µl of each diluted solution on the surface of mycoplasma agar plate
7. Incubate the plate at 37 °C with 10 % CO 2 for 7 to 10 days or until mycoplasma colonies
can be observed
8. Read the plates under stereomicroscope and choose the plate of a dilution at which less
than 10 colonies presented
9. Punch out a single colony of mycoplasma from selected agar plate and put into a new
sterile PPLO broth
10. Repeat step 3 to 8 at least two times (a total of 3 times of filtering)
11. The cultured broth from the third filtering contains a pure clone
143
B.2: DNA extraction and purification using PureLink™ Genomic DNA Kits (adapted from
PureLink™Genomic DNA Kits for purification of genomic DNA user manual)
Before Starting
1. Add 96-100% ethanol to PureLink™ Genomic Wash Buffer 1 and PureLink™ Genomic
Wash Buffer 2 according to instructions on each label. Mix well. Mark on the labels that
ethanol is added. Store both wash buffers with ethanol at room temperature.
2. Prepare a master Buffer/ethanol Mix by mixing 200 µl Lysis/Binding Buffer and 200 µl
96-100% ethanol for each sample.
3. Set a water bath at 55 °C.
Preparing Lysates
1. Transfer 2 ml of cultured PPLO broth into a sterile 2-ml microcentrifuge tube.
2. Centrifuge the microcentrifuge tube at 5,000 x g for 25-30 minutes at room temperature.
3. Resuspend the cell pellet in 180 µl PureLink™ Genomic Digestion Buffer. Add 20 µl
Proteinase K (supplied with the kit) to lyse the cells. Mix well by brief vortexing.
4. Incubate the tube at 55 °C for 45 minutes.
5. Add 20 µl RNase A (supplied with the kit) to the lysate, mix well by brief vortexing, and
incubate at room temperature for 2 minutes.
6. Add 400 µl the master Buffer/ethanol mix and mix well by vortexing to obtain a
homogenous solution.
Binding DNA
1. Remove a PureLink™ Spin Column in a Collection Tube from the package.
144
2. Load the lysate with Lysis/Binding Buffer and ethanol prepared as described to the
PureLink™ Spin Column.
3. Centrifuge the column at 10,000 x g for 1 minute at room temperature.
4. Discard the collection tube and place the spin column into a new collection tube.
5. Preceed to Washing DNA
Washing DNA
1. Wash the column with 500 µl Wash Buffer 1 prepared with ethanol
2. Centrifuge the column at 10,000 x g for 1 minute at room temperature. Discard the
collection tube and place column into a mew collection tube.
3. Wash the column with 500 µl of Wash Buffer 2 prepared with ethanol
4. Centrifuge the column at maximum speed for 3 minutes at room temperature. Discard the
collection tube.
5. Proceed to Eluting DNA.
Eluting DNA
1. Place the spin column in a sterile 2-ml microcentrifuge tube.
2. Elute the DNA with 50-75 µl of PureLink™ Genomic Elution Buffer.
3. Incubate the column at room temperature for 1 minute.
4. Centrifuge the column at room temperature for 1 minute.
5. Use the purified genomic DNA for the desired downstream application. Store the purified
genomic DNA at 4 °C for short-term or -20 °C for long-term storage.
145
B.3: PCR to amplify 16S-23S rRNA intergenic spacer region of Mycoplasma species and
Acholeplasma species (adapted from Tang et al., 2000)
1. Reaction setup as follow;
10 x PCR buffer 5 µl per sample
10 mM deoxynucleotide triphosphate 0.5 µl per sample
50 mM MgCl2 2 µl per sample
10 µM F2 Primer 2 µl per sample
10 µM R2 Primer 2 µl per sample
10 µM R34 Primer2 µl per sample
Taq polymerase 0.2 µl per sample
DNase-free Water 31.3 µl per sample
Mix well by brief vortexing.
2. Dispense 45 µl of the solution into each PCR tube.
3. Add 5 µl of DNA template into the solution.
4. Place the PCR tube in the PCR cycler machine. Set the thermal profile as follow;
Initial denaturation at 94 °C for 30 seconds
35 cycles of
-denaturation at 94 °C for 30 seconds
-primer annealing at 55 °C for 2 minutes
-extension at 72 °C for 2 minutes
Final extension at 72 °C for 5 minutes
Holding at 4 °C for ∞
146
B.4: Restricted Fragment Length Polymorphism (RFLP)
1. Prepare the reaction mix as follow;
ASEI restriction enzyme 1 µl per sample
10 x buffer 3 2 µl per sample
DNase-free water 2 µl per sample
Mix well by brief vortexing.
2. Dispense 5 µl of the mixture into each PCR tube.
3. Add 15 µl of PCR product of each sample into the mixture.
4. Incubate the tube at 37 °C for 5 to 18 hours (depending on the amount of PCR products)
B.5: PCR to amplify 16S rRNA gene using universal primers (adapted from Stakenborg et al., 2005)
1. Reaction setup as follow;
10 x PCR buffer 5 µl per sample
10 mM deoxynucleotide triphosphate 10 µl per sample
50 mM MgCl2 1.5 µl per sample
10 µM pH Primer 1 µl per sample
10 µM pA Primer 1 µl per sample
Taq polymerase 0.6 µl per sample
DNase-free Water 38.9 µl per sample
Mix well by brief vortexing.
5. Dispense 49 µl of the solution into each PCR tube.
6. Add 1 µl of DNA template into the solution.
147
7. Place the PCR tube in the PCR thermocycler machine. Set the thermal profile as follow;
Initial denaturation at 95 °C for 3 minutes
30 cycles of
-denaturation at 94 °C for 20 seconds
-primer annealing at 57 °C for 40 seconds
-extension at 72 °C for 2 minutes
Holding at 4 °C for ∞
B.6: Gel Electrophoresis
1. Make 2% agarose gel by dissolve the agarose gel powder into 0.5x TBE buffer
2. Melt agarose gel powder using microwave oven
3. Add 6 to 10 µl of 10 mg/ml Ethidium Bromide into agarose gel
4. Pour the agarose gel onto the taped gel tray with comb in place.
5. Allow the gel to be solidified.
6. Carefully remove the comb out of the gel and immerse the gel tray in electrophoresis
apparatus.
7. On a strip of Parafilm, place a small drop of tracking dye (~1 µl), one for each sample
including the negative control.
8. Load 5 µl of the 100 bp ladder in the first and last wells of the gel.
9. Load 5 µl of PCR products or 10 µl of digested PCR products which are already mixed
with tracking dye into each well.
10. Run the gel for 1 hour and 30 minutes at 114 volts
11. Remove gel tray from apparatus and take photograph of it.
148
B.7: Real-time PCR using QuantiTect® Probe PCR reaction kit for Applied Biosystem
StepOne Plus real-time PCR machine
1. Thaw 2x QuantiTect Probe PCR Master Mix, template DNA, primer and probe solutions,
and RNase-free water. Mix the individual solutions.
2. Reaction setup as follow;
2x QuantiTect Probe PCR Master Mix 12.5 µl per sample
10 µM PrimerA 1 µl per sample
10 µM PrimerB 1 µl per sample
10 µM Probe 0.5 µl per sample
RNase-free water 5 µl per sample
3. Mix the reaction mix thoroughly, and dispense 20 µl of the reaction mix into PCR tubes
or plates.
4. Add 5 µl of template DNA to the individual PCR tubes or wells containing the reaction
mix.
5. Program the real-time cycler condition as followed;
PCR initial activation step at 95 °C for 15 min
45 cycles of
- Denaturation at 94 °C for 15 seconds
- Combined annealing/extension at 60 °C for 60 seconds
B.8: Digitonin disc diffusion assay (adapted from Tully, 1983)
1. Preparing digitonin stock solution by adding 75 mg of digitonin to 5 ml of 95% ethanol in
a screw-capped tube.
149
2. Gently heat the solution by immersing the tube in boiling water until digitonin powder is
completely dissolved.
3. Store the stock solution at 4 °C until use.
4. Make digitonin discs by adding 25 µl of the digitonin stock solution to each 6 mm paper
disc.
5. Allow the digitonin discs to be dried overnight and stored at 4 °C until use.
6. Defrost frozen isolates at room temperature.
7. Transfer 100 µl of defrosted cultured tube to 5 ml of new sterile PPLO broth
8. Incubate the culture tube at 37 °C with 10 % CO 2 for 4 to 5 days
9. Pour and spread 200 µl of each diluted solution on the surface of modified Hayflick’s
agar plates. Allow the surface to dry.
10. Place a digitonin disc on the surface of agar.
11. Incubate the plate at 37 °C with 10 % CO 2 for 7 to 10 days.
12. Measure the zone of inhibition from the edge of the disc to the edge of the clear zone
(mm) around the disc under the stereomicroscope.
13. Interpret the results as follow;
- inhibition zones of >5 mm = positive (+)
- inhibition zones of 3-5 mm = ambiguous result (+/-)
- inhibition zones of <3 mm = negative (-)
B.9: Nisin disc diffusion assay
1. Store nisin stock solution (5.16 mg/ml) at 5-7 °C. This stock solution can be used up to
24 months.
150
2. Make a 10-fold dilution of nisin from stock solution with 10 mM citrate pH 3.5.
3. Make nisin discs by adding 20 µl of the nisin stock solution and the 10-fold nisin solution
to each 6 mm paper disc. Each disc will contain 103.2 µg and 10.32 µg of nisin for the
undiluted and diluted solution, respectively.
4. Allow the nisin discs to be dried overnight and stored at 4 °C until use.
5. Defrost frozen isolates at room temperature.
6. Transfer 100 µl of defrosted cultured tube to 5 ml of new sterile PPLO broth
7. Incubate the culture tube at 37 °C with 10 % CO 2 for 4 to 5 days
8. Pour and spread 200 µl of each diluted solution on the surface of modified Hayflick’s
agar plates. Allow the surface to dry.
9. Place undiluted and diluted nisin discs on the surface of agar.
10. Incubate the plate at 37 °C with 10 % CO 2 for 7 to 10 days.
11. Measure the zone of inhibition from the edge of the disc to the edge of the clear zone
(mm) around the disc under the stereomicroscope.
12. Interpret the results as follow;
- Presence of inhibition zones = positive (+)
- Absence of inhibition zones = negative (-)
151
C. COPY RIGHTS RELEASES
ELSEVIER LICENSE TERMS AND CONDITIONS
Nov 04, 2010
This is a License Agreement between Sukolrat Boonyayatra ("You") and Elsevier ("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.
Supplier Elsevier Limited The Boulevard,Langford Lane Kidlington,Oxford,OX5 1GB,UK
Registered Company 1982084 Number
Customer name Sukolrat Boonyayatra
Customer address 1620 NW Bella Vista Dr.
Pullman, WA 99163
License number 2526310541781
License date Oct 12, 2010
Licensed content Elsevier publisher
Licensed content Veterinary Microbiology publication
Licensed content title Effects of storage methods on the recovery of Mycoplasma
152
species from milk samples
Licensed content author S. Boonyayatra, L.K. Fox, T.E. Besser, A. Sawant, J.M. Gay
Licensed content date 29 July 2010
Licensed content volume 144 number
Licensed content issue 1-2 number
Number of pages 4
Type of Use reuse in a thesis/dissertation
Intended publisher of new other work
Portion full article
Format both print and electronic
Are you the author of this Yes Elsevier article?
Will you be translating? No
Order reference number
Title of your Diagnosis of Mycoplasma mastitis: Validation and thesis/dissertation Development
Expected completion date Dec 2010
Estimated size (number of 120 pages)
Elsevier VAT number GB 494 6272 12
Terms and Conditions
153
INTRODUCTION 1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at http://myaccount.copyright.com ).
GENERAL TERMS 2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated. 3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows: “Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier.” 4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given. 5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [email protected]) 6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee. 7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and
154
conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials. 9. Warranties: Publisher makes no representations or warranties with respect to the licensed material. 10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license. 11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission. 12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control. 14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.
LIMITED LICENSE The following terms and conditions apply only to specific license types: 15. Translation : This permission is granted for non-exclusive world English rights only unless your license was granted for translation rights. If you licensed translation rights you
155
may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all languages. 16. Website : The following terms and conditions apply to electronic reserve and author websites: Electronic reserve : If licensed material is to be posted to website, the web site is to be password-protected and made available only to bona fide students registered on a relevant course if: This license was made in connection with a course, This permission is granted for 1 year only. You may obtain a license for future website posting, All content posted to the web site must maintain the copyright information line on the bottom of each image, A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at http://www.elsevier.com , and Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 17. Author website for journals with the following additional clauses: All content posted to the web site must maintain the copyright information line on the bottom of each image, and he permission granted is limited to the personal version of your paper. You are not allowed to download and post the published electronic version of your article (whether PDF or HTML, proof or final version), nor may you scan the printed edition to create an electronic version, A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx , As part of our normal production process, you will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This number provides the electronic link to the published article and should be included in the posting of your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any posting. Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 18. Author website for books with the following additional clauses: Authors are permitted to place a brief summary of their work online only. A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com All content posted to the web site must maintain the copyright information line on the bottom of each image You are not allowed to download and post the published electronic version of your
156
chapter, nor may you scan the printed edition to create an electronic version. Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 19. Website (regular and for author): A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx . or for books to the Elsevier homepage at http://www.elsevier.com 20. Thesis/Dissertation : If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. 21. Other Conditions : v1.6
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.
If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number RLNK10864195. Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.
Make Payment To: Copyright Clearance Center
Dept 001 P.O. Box 843006 Boston, MA 02284-3006
If you find copyrighted material related to this license will not be used and wish to cancel, please contact us referencing this license number 2526310541781 and noting the reason for cancellation.
Questions? [email protected] or +1-877-622-5543 (toll free in the US) or +1-978-646-2777.
157
ELSEVIER LICENSE TERMS AND CONDITIONS
Nov 04, 2010
This is a License Agreement between Sukolrat Boonyayatra ("You") and Elsevier ("Elsevier") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.
Supplier Elsevier Limited The Boulevard,Langford Lane Kidlington,Oxford,OX5 1GB,UK
Registered Company 1982084 Number
Customer name Sukolrat Boonyayatra
Customer address 1620 NW Bella Vista Dr.
Pullman, WA 99163
License number 2523310014473
License date Oct 06, 2010
Licensed content Elsevier publisher
Licensed content International Journal of Food Microbiology publication
Licensed content title Mode of action of lipid II-targeting lantibiotics
Licensed content author R. Bauer, L.M.T. Dicks
158
Licensed content date 25 May 2005
Licensed content volume 101 number
Licensed content issue 2 number
Number of pages 16
Type of Use reuse in a thesis/dissertation
Portion figures/tables/illustrations
Number of 2 figures/tables/illustrations
Format both print and electronic
Are you the author of this No Elsevier article?
Will you be translating? No
Order reference number
Title of your Diagnosis of Mycoplasma mastitis: Validation and thesis/dissertation Development
Expected completion date Dec 2010
Estimated size (number of 120 pages)
Elsevier VAT number GB 494 6272 12
Terms and Conditions
INTRODUCTION
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with completing this licensing transaction, you agree that the following terms
159
and conditions apply to this transaction (along with the Billing and Payment terms and conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are available at any time at http://myaccount.copyright.com ).
GENERAL TERMS 2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the terms and conditions indicated. 3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement to another source, permission must also be sought from that source. If such permission is not obtained then that material may not be included in your publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in a reference list at the end of your publication, as follows: “Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with permission from Elsevier.” 4. Reproduction of this material is confined to the purpose and/or media for which permission is hereby given. 5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/ or any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please contact Elsevier at [email protected]) 6. If the permission fee for the requested use of our material is waived in this instance, please be advised that your future requests for Elsevier materials may attract a fee. 7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no license is finally effective unless and until full payment is received from you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms and conditions, the license is automatically revoked and shall
160
be void as if never granted. Use of materials as described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright in the materials. 9. Warranties: Publisher makes no representations or warranties with respect to the licensed material. 10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their respective officers, directors, employees and agents, from and against any and all claims arising out of your use of the licensed material other than as specifically authorized pursuant to this license. 11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or transferred by you to any other person without publisher's written permission. 12. No Amendment Except in Writing: This license may not be amended except in a writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated herein), comprise the entire agreement between you and publisher (and CCC) concerning this licensing transaction. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and conditions shall control. 14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice of such denial will be made using the contact information provided by you. Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied permissions.
LIMITED LICENSE The following terms and conditions apply only to specific license types: 15. Translation : This permission is granted for non-exclusive world English rights only unless your license was granted for translation rights. If you licensed translation rights you may only translate this content into the languages you requested. A professional translator must perform all translations and reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 or 2 figures then permission is granted for non-exclusive world rights in all languages.
161
16. Website : The following terms and conditions apply to electronic reserve and author websites: Electronic reserve : If licensed material is to be posted to website, the web site is to be password-protected and made available only to bona fide students registered on a relevant course if: This license was made in connection with a course, This permission is granted for 1 year only. You may obtain a license for future website posting, All content posted to the web site must maintain the copyright information line on the bottom of each image, A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at http://www.elsevier.com , and Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 17. Author website for journals with the following additional clauses: All content posted to the web site must maintain the copyright information line on the bottom of each image, and he permission granted is limited to the personal version of your paper. You are not allowed to download and post the published electronic version of your article (whether PDF or HTML, proof or final version), nor may you scan the printed edition to create an electronic version, A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx , As part of our normal production process, you will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect (www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This number provides the electronic link to the published article and should be included in the posting of your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any posting. Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 18. Author website for books with the following additional clauses: Authors are permitted to place a brief summary of their work online only. A hyper-text must be included to the Elsevier homepage at http://www.elsevier.com All content posted to the web site must maintain the copyright information line on the bottom of each image You are not allowed to download and post the published electronic version of your chapter, nor may you scan the printed edition to create an electronic version. Central Storage: This license does not include permission for a scanned version of the material to be stored in a central repository such as that provided by Heron/XanEdu.
162
19. Website (regular and for author): A hyper-text must be included to the Homepage of the journal from which you are licensing at http://www.sciencedirect.com/science/journal/xxxxx . or for books to the Elsevier homepage at http://www.elsevier.com 20. Thesis/Dissertation : If your license is for use in a thesis/dissertation your thesis may be submitted to your institution in either print or electronic form. Should your thesis be published commercially, please reapply for permission. These requirements include permission for the Library and Archives of Canada to supply single copies, on demand, of the complete thesis and include permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be published commercially, please reapply for permission. 21. Other Conditions : v1.6
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.
If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number RLNK10861808. Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.
Make Payment To: Copyright Clearance Center Dept 001 P.O. Box 843006 Boston, MA 02284-3006
If you find copyrighted material related to this license will not be used and wish to cancel, please contact us referencing this license number 2523310014473 and noting the reason for cancellation.
Questions? [email protected] or +1-877-622-5543 (toll free in the US) or +1-978-646-2777.
163
JOHN WILEY AND SONS LICENSE TERMS AND CONDITIONS
Nov 04, 2010
This is a License Agreement between Sukolrat Boonyayatra ("You") and John Wiley and Sons ("John Wiley and Sons") provided by Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and conditions provided by John Wiley and Sons, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see information listed at the bottom of this form.
License Number 2523320935036
License date Oct 06, 2010
Licensed content publisher John Wiley and Sons
Licensed content FEMS Microbiology Reviews publication
Licensed content title Lantibiotics: structure, biosynthesis and mode of action
Licensed content author Olivia McAuliffe,R.Paul Ross,Colin Hill
Licensed content date May 1, 2001
Start page 285
End page 308
Type of use Dissertation/Thesis
Requestor type University/Academic
Format Print and electronic
Portion Figure/table
164
Number of figures/tables 2
Original Wiley figure/table Figure2 and Figure4 number(s)
Will you be translating? No
Order reference number
Total 0.00 USD
Terms and Conditions
TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc. or one if its group companies (each a “Wiley Company”) or a society for whom a Wiley Company has exclusive publishing rights in relation to a particular journal (collectively “WILEY”). By clicking “accept” in connection with completing this licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the billing and payment terms and conditions established by the Copyright Clearance Center Inc., (“CCC’s Billing and Payment terms and conditions”), at the time that you opened your Rightslink account (these are available at any time at http://myaccount.copyright.com ).
Terms and Conditions
1. The materials you have requested permission to reproduce (the "Materials") are protected by copyright.
2. You are hereby granted a personal, non-exclusive, non-sublicensable, non-transferable, worldwide, limited license to reproduce the Materials for the purpose specified in the licensing process. This license is for a one-time use only with a maximum distribution equal to the number that you identified in the licensing process. Any form of republication granted by this licence must be completed within two years of the date of the grant of this licence (although copies prepared before may be distributed thereafter). Any electronic posting of the Materials is limited to one year from the date permission is granted and is on the condition that a link is placed to the journal homepage on Wiley’s online journals publication platform at www.interscience.wiley.com . The Materials shall not be used in any other manner or for any other purpose. Permission is granted subject to an appropriate acknowledgement given to the author, title of the material/book/journal and the publisher and on the understanding that nowhere in the text is a previously published source acknowledged for all or part of this Material. Any third party material is expressly excluded from this permission.
165
3. With respect to the Materials, all rights are reserved. No part of the Materials may be copied, modified, adapted, translated, reproduced, transferred or distributed, in any form or by any means, and no derivative works may be made based on the Materials without the prior permission of the respective copyright owner. You may not alter, remove or suppress in any manner any copyright, trademark or other notices displayed by the Materials. You may not license, rent, sell, loan, lease, pledge, offer as security, transfer or assign the Materials, or any of the rights granted to you hereunder to any other person.
4. The Materials and all of the intellectual property rights therein shall at all times remain the exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) or their respective licensors, and your interest therein is only that of having possession of and the right to reproduce the Materials pursuant to Section 2 herein during the continuance of this Agreement. You agree that you own no right, title or interest in or to the Materials or any of the intellectual property rights therein. You shall have no rights hereunder other than the license as provided for above in Section 2. No right, license or interest to any trademark, trade name, service mark or other branding ("Marks") of WILEY or its licensors is granted hereunder, and you agree that you shall not assert any such right, license or interest with respect thereto.
5. WILEY DOES NOT MAKE ANY WARRANTY OR REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND WAIVED BY YOU.
6. WILEY shall have the right to terminate this Agreement immediately upon breach of this Agreement by you.
7. You shall indemnify, defend and hold harmless WILEY, its directors, officers, agents and employees, from and against any actual or threatened claims, demands, causes of action or proceedings arising from any breach of this Agreement by you.
8. IN NO EVENT SHALL WILEY BE LIABLE TO YOU OR ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING
166
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED HEREIN.
9. Should any provision of this Agreement be held by a court of competent jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as nearly as possible the same economic effect as the original provision, and the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.
10. The failure of either party to enforce any term or condition of this Agreement shall not constitute a waiver of either party's right to enforce each and every term and condition of this Agreement. No breach under this agreement shall be deemed waived or excused by either party unless such waiver or consent is in writing signed by the party granting such waiver or consent. The waiver by or consent of a party to a breach of any provision of this Agreement shall not operate or be construed as a waiver of or consent to any other or subsequent breach by such other party.
11. This Agreement may not be assigned (including by operation of law or otherwise) by you without WILEY's prior written consent.
12. These terms and conditions together with CCC’s Billing and Payment terms and conditions (which are incorporated herein) form the entire agreement between you and WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all prior agreements and representations of the par ties, oral or written. This Agreement may not be amended except in a writing signed by both parties. This Agreement shall be binding upon and inure to the benefit of the parties' successors, legal representatives, and authorized assigns.
13. In the event of any conflict between your obligations established by these terms and conditions and those established by CCC’s Billing and Payment terms and conditions, these terms and conditions shall prevail.
14. WILEY expressly reserves all rights not specifically granted in the combination of (i) the license details provided by you and accepted in the course of this licensing transaction, (ii) these terms and conditions and (iii) CCC’s Billing and Payment terms and conditions.
15. This Agreement shall be governed by and construed in accordance with the laws of England and you agree to submit to the exclusive jurisdiction of the English courts.
16. Other Terms and Conditions:
BY CLICKING ON THE "I ACCEPT" BUTTON, YOU ACKNOWLEDGE THAT YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING TO ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS AGREEMENT.
167
V1.2
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license for your reference. No payment is required.
If you would like to pay for this license now, please remit this license along with your payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be invoiced within 48 hours of the license date. Payment should be in the form of a check or money order referencing your account number and this invoice number RLNK10861822. Once you receive your invoice for this order, you may pay your invoice by credit card. Please follow instructions provided at that time.
Make Payment To: Copyright Clearance Center
Dept 001 P.O. Box 843006 Boston, MA 02284-3006
If you find copyrighted material related to this license will not be used and wish to cancel, please contact us referencing this license number 2523320935036 and noting the reason for cancellation.
Questions? [email protected] or +1-877-622-5543 (toll free in the US) or +1-978-646-2777.
168
169